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Abstract
Breast cancer is the most commonly diagnosed cancer and the second leading
cause of cancer death in women. Although recent improvements in the preven-
tion, early detection, and treatment of breast cancer have led to a significant
decrease in the mortality rate, the identification of an optimal therapeutic strat-
egy for each patient remains a difficult task because of the heterogeneous nature
of the disease. Clinical heterogeneity of breast cancer is in part explained by the
vast genetic and molecular heterogeneity of this disease, which is now emerging
from large-scale screening studies using “-omics” technologies (e.g. microarray
gene expression profiling, next-generation sequencing). This genetic and molecu-
lar heterogeneity likely contributes significantly to therapy response and clinical
outcome. The recent advances in our understanding of the molecular nature of
breast cancer due, in particular, to the explosion of high-throughput technolo-
gies, is driving a shift away from the “one-dose-fits-all” paradigm in healthcare,
to the new “Personalized Cancer Care” paradigm. The aim of “Personalized
Cancer Care” is to select the optimal course of clinical intervention for individ-
ual patients, maximizing the likelihood of effective treatment and reducing the
probability of adverse drug reactions, according to the molecular features of the
patient. In light to this medical scenario, the aim of this project is to identify
novel molecular mechanisms that are altered in breast cancer through the devel-
opment of a computational pipeline, in order to propose putative biomarkers and
druggable target genes for the personalized management of patients. Through
the application of a Systems Biology approach to reverse engineer Gene Regula-
tory Networks (GRNs) from gene expression data, we built GRNs around “hub”
genes transcriptionally correlating with clinical-pathological features associated
with breast tumor expression profiles. The relevance of the GRNs as putative
cancer-related mechanisms was reinforced by the occurrence of mutational events
related to breast cancer in the “hub” genes, as well as in the neighbor genes.
ii
Moreover, for some networks, we observed mutually exclusive mutational pat-
terns in the neighbors genes, thus supporting their predicted role as oncogenic
mechanisms. Strikingly, a substantial fraction of GRNs were overexpressed in
triple negative breast cancer patients who acquired resistance to therapy, sug-
gesting the involvement of these networks in mechanisms of chemoresistance. In
conclusion, our approach allowed us to identify cancer molecular mechanisms
frequently altered in breast cancer and in chemorefractory tumors, which may
suggest novel cancer biomarkers and potential drug targets for the development
of more effective therapeutic strategies in metastatic breast cancer patients.
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Cancer is a multifactorial disease characterized at a macroscopic level by un-
controlled and limitless cell proliferation, self-sufficiency in growth signals, and
the ability to invade tissues, spread to distant organs (metastasize) and form
new blood vessels for nutrient supply to cancer cells (angiogenesis; Figure 1.1)
([1],[2]). With 1,665,540 new cases and 585,720 deaths estimated in the United
States, alone, in 2014 ([3]) cancer remains one of the main causes of death world-
wide. Therefore, the identification of innovative cancer biomarkers, as well as
more effective strategies for detection and treatment of cancer, is paramount.
Figure 1.1: The hallmarks of cancer.
Schematic representation of the hallmarks of cancer. Recent advances in cancer biology
have improved our comprehension of cancer-related mechanisms required to sustain the




There are over 100 different types of cancer classified by the type of cell that is
initially affected. Cancer types can be grouped in five main categories according
to the histological type and the primary site:
• Carcinoma is a type of cancer that originates from epithelial cells lining
the inner or outer surfaces of the body. Many histological subtypes of car-
cinoma have been characterized including basal cell carcinoma, adenosqua-
mous carcinoma, transitional cell carcinoma and squamous cell carcinoma.
• Sarcoma is a type of cancer originating in blood vessels, nerves and ten-
dons, muscles, cartilage, bone, fat, connective tissue.
• Lymphoma and myeloma originate in the lymph system (lymph nodes
and lymphatic vessels) and in general involve cells of the immune system.
• Leukemia is a type of cancer that originates in blood-forming tissue (bone
marrow) allowing the formation of abnormal blood cells that will be released
in the blood.
• Central nervous system cancers are cancers originating in brain tissues.
1.1.2 Cancer development
Cancer development may be caused by environmental factors, harmful life habits,
and genetic inheritance. The accumulation of mutations in the DNA due to ex-
ogenous and endogenous DNA-damaging agents and the resulting genomic insta-
bility are at the basis of neoplastic transformation ([4]). More recently, a role
for epigenetic alterations was also proposed as an addictive factor that may in-
duce neoplastic transformation ([5],[6],[7],[8]). Genes that hold the potential to
promote neoplastic transformation are called oncogenes, while those that oppose
transformation are named tumor suppressor genes. Mutations or epigenetic al-
terations may cause overexpression or reduction/ablation of an oncogene or a
tumor suppressor, respectively, thereby contributing to neoplastic transforma-
tion [9],[10],[11]). In addition, many cancer-related mutations cause activation or
inactivation of specific signaling proteins, resulting in hyper-activation of signal-
ing pathways that promote proliferation, migration or invasion, and ultimately
neoplastic transformation ([12],[13],[14]).
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1.1.3 Cancer stem cells
An emerging field in cancer biology is related to the identification and charac-
terization of cancer stem cells ([15],[16]). Cancer stem cells are thought to be
the engine of the tumor since they are the only cells within the tumor that are
able to regenerate tumors in vivo. Cancer stem cells possess self-renewal and
differentiation capabilities similar to those of normal adult stem cells ([17],[18]).
The elucidation of the mechanisms that control such stem cell properties would
shed light on the disrupted pathways responsible for cancer stem cell generation
and tumor growth.
The first evidence of the existence of cancer stem cells came from the study of
leukemia; it was shown that only a small fraction of leukemia cells proliferated
extensively in vivo and in vitro ([15]). The involvement of cancer stem cells
in tumorigenesis is further sustained by their distinctive trait to be the only
long-lived cell population. This feature makes them preferential targets of ini-
tial oncogenic mutations because of their long exposure to genotoxic stresses. In
addition, two further observations support the cancer stem cell theory: the first
refers to tumor heterogeneity; the second concerns the number of cells required
for tumor growth. In the first case, although cancer cells originate from a single
transformed cell they display different phenotypic traits that were present in the
original normal tissue from which they derive ([19]). In the second case, the can-
cer stem cell hypothesis is supported by evidence showing that only cells with a
high capability of self-renewal, like the cancer stem cells, are able to sustain the
intensive proliferation of a tumor.
1.1.4 Cancer metastasis
Cancer cells may invade and colonize other tissues and organs through the lym-
phatic system and/or blood. This metastatic process is initially triggered by
stochastic events that allow the dispersion of cancer cells into the circulation,
and is dependent on the ability of a small fraction of cells to survive in distant
organs, giving rise to metastases ([20]). The ability of cancer cells to invade dis-
tant organ sites is tumor-specific, although in some cases different tumor types
are able to colonize the same organ site (Table 1.1).
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Table 1.1: Metastatic relapse sites for solid tumors.
Tumor typet Principal sites of metastasis
Breast Bone, lungs, liver, brain
Lung adenocarcinoma Brain, bones, adrenal gland, liver
Skin melanoma Lungs, brain, skin, liver
Colorectal Liver, lungs




In the case of metastatic invasion through the lymphatic system, cancer cells
travel through the lymph system and they may end up in lymph nodes giving
rise to a metastatic lymph node tumor. In order to spread to new parts of the
body through the lymphatic system, cancer cells have to break away from the
original tumor and attach themselves to the outside wall of a lymph vessel. Then,
the cells move through the vessel wall to flow with the lymph to a new lymph
node. The progression of the tumor towards metastasis through the blood vessels
can be summarized by the following steps (Figure A.1):
• the local invasion: the cancer cells locally infiltrate through the basement
membrane into the surrounding/adjacent tissue.
• the intravasion, also called “endothelial transmigration”, of tumor cells
into vessels: the cancer cells invade the blood or lymphatic vessels through
the basal membrane.
• the hematogenous survival and translocation: the cancer cells are able
to survive in the circulatory system and disseminate through the blood-
stream to microvessels of distant tissues. The intravasion together with
the hematogenous survival constitute the “hematogenous dissemination”
process.
• the extravasion: cancer cells exit from the bloodstream.
• the colonization: cancer cells colonize distant organs. The cells adapt
to the foreign microenvironment of distant site and start proliferating and
forming macroscopic secondary tumors in competent organs.
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Although the molecular mechanisms at the basis of the metastatic ability of
cancer cells are not fully characterized, the functional activity of some genes is
associated to the initiation and progression of metastasis. The metastasis initi-
ation genes promote cell motility, epithelial-to-mesenchymal transition (EMT),
extracellular matrix degradation and angiogenesis. The key genes that, for ex-
ample, promote EMT (local tumor invasion) through changes in cell adhesion
and migratory properties of tumor cells include the Snail (SNAI1 and SNAI2)
([22],[23]), Zeb (ZEB1 and ZEB2) ([24],[25]) and basic helix-loop-helix (bHLH:
E47 and TWIST) ([26]) transcription factor families that contribute to the acti-
vation of a plethora of genes involved in the above mentioned EMT pathway.




Breast cancer is the most common cancer diagnosed worldwide in women (sec-
ond most common cancer overall) with 232,670 new cases and 40,000 deaths
estimated in the US in 2014 ([27]). The incidence and overall mortality rates
are higher in high-income countries respect to low and middle-income countries
mainly because of an increasing adoption of cancer-causing behaviors, like for
example overweight/obesity, a sedentary lifestyle and smoking. Although the
incidence and the overall mortality rates are lower in low and middle-income
countries the fatality rates from breast cancer still remain high mainly because
of a scarcity of adequate facilities for detection and diagnosis, as well as poor
access to primary treatment ([28],[29],[30]). Breast cancer originates from the ep-
ithelial and myoepithelial cells lining the ductal or lobular part of the mammary
gland, and it occurs almost entirely in women, although there are rare cases of
breast cancer in men. The majority of breast cancers originate in cells lining
the ducts: tubes that carry the milk from the lobules to the nipple. Thus, these
cancers are named ductal carcinomas. Tumors originating from cells lining the
lobules are instead named lobular carcinomas (Figure 1.3). Ductal and lobular
carcinomas can be further classified as invasive or in situ carcinoma depending
on whether the cancer has spread into the surrounding tissues or to distant sites
(i.e., invasive ductal carcinoma, IDC, or invasive lobular carcinoma, ILC), or
whether it has remained localized at the site of origin (i.e., ductal carcinoma in
situ, DCIS, or lobular carcinoma in situ, LCIS). IDC accounts for 80% of inva-
sive breast cancers while ILC accounts for 10% of invasive breast tumors ([31]).
Generally, in situ carcinomas are classified as early stage (stage 0) tumors and if
untreated may become invasive and metastatic breast tumors.
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Collecting ducts Lobules 
Fatty connective tissue 
Figure 1.3: Breast cancer sites of origin.
Breast cancers may arise from the cells lining the milk lobules (glands) or from the cells
lining the milk ducts within the breast lobes. In the first case they are called lobular
carcinomas while in the second case they are called ductal carcinomas. Both types of
tumours are further classified as invasive or in situ carcinoma according to the site of
invasion. Taken from ([31]).
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1.2.1 Breast cancer is an heterogeneous disease
Breast carcinoma is a highly heterogeneous disease with multiple tumor sub-
types characterized by different histological and molecular features, which likely
impact on therapy response and clinical outcome ([32],[33],[34]). Despite recent
improvements in prevention, early detection, and treatment of breast cancer have
led to a significant decrease in the mortality rate ([27]), the identification of an
optimal therapeutic strategy for each patient remains a difficult task because
of the heterogeneous nature of the disease. Originally, breast cancer diagnosis
and subtype classification was based on specific histological and morphological
features (histological heterogeneity) that allow the classification of the disease
in 20 major tumor types and 18 minor subtypes ([35]). The recent advances
in microarray gene expression profiling, next-generation sequencing (NGS), and
high-throughput proteomics, is now allowing a more in-depth molecular char-
acterization of breast cancer at a genomic and proteomic level. This has led
to the identification of novel breast cancer subtypes ([36],[37],[38],[39]), and an
improvement in the diagnostic and prognostic evaluation of breast cancer pa-
tients ([40],[41]). In addition, recent NGS studies of breast tumors revealed a
certain level of intra-tumor heterogeneity ([42],[43]). In particular, Navin and
colleagues ([43]), through single-nucleus DNA sequencing, identified the presence
of intra-tumor distinct clonal subpopulations characterized by distinct genomic
alterations. In some cases, an almost identical profile was found in metastatic
tumor cells (i.e. synchronous metastatic lesions) respect to specific clonal sub-
populations in primary tumours. Indeed, Ding and colleagues ([42]) showed that
in basal-like breast tumors, metastatic lesions arise from sub-populations of can-
cer cells in the primary tumor with a specific repertoire of mutations, which were
suggested to be drivers for cancer progression. However, despite these recent ad-
vances in the characterization of the genomic profiles of breast cancer, the molec-
ular mechanisms involved in disease onset and progression remain mostly unclear.
Further studies are thus necessary to better characterize these breast cancer path-
ways and to identify reliable cancer biomarkers for improving therapeutic inter-
vention and survival of breast cancer patients ([37],[38],[44],[45],[46],[47],[48]).
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1.2.2 Molecular classification of breast cancer
Breast cancer can be classified into three main groups based on the expression
of different breast cancer markers, which are detected by immunohistochemistry
(IHC) or fluorescence in situ hybridization (FISH) assays:
• The hormone receptor positive group: these tumors express the ER
and/or PgR and account for 68% of breast cancers.
• The Her2 positive group: these tumors overexpress the Her2 receptor
at the protein level (detected by IHC), or carry an amplification of the
Her2 gene (detected by FISH). They do not express ER and/or PgR. The
frequency of occurrence is 11% in the female breast cancer population.
• The triple negative group: there tumors lack expression of all three
receptors, ER, PgR and Her2, and account for 19% of female breast cancers.
The hormone receptor positive group can be further divided into two additional
subtypes, according to the expression of the proliferation marker, Ki-67, and
Her2 receptor:
• The Luminal A subtype: these tumors express the ER and/or PgR, but
not Her2, and poorly express the Ki-67 proliferation marker. These tumors
account for 44% of female breast cancers.
• The Luminal B subtype: these tumors express the ER and/or PgR, and
Her2, and highly express the Ki-67 proliferation marker. The frequency of
occurrence is 24% in female breast cancer population.
The Luminal A subtype is the only breast cancer subtype that has a good prog-
nosis, high survival rates and low risk of recurrence ([49],[50],[51]). The low level
of aggressiveness of these tumors is attributed to their low rate of proliferation
and their positivity for ER expression, which allows the use of endocrine therapy
(also referred to as hormone therapy): a systemic therapy that blocks tumor cell
growth ([52]). In contrast, the Luminal B subtype is highly proliferative and
poorly-differentiated, and displays features associated with poor prognosis, such
as: i) large tumor size; ii) high tumor grade; iii) the presence of tumor cells
in the lymph nodes. The Her2-positive and triple negative subtypes are highly
metastatic and exhibit the worse clinical outcome, although more effective ther-
apies are available for the former ([49],[53],[54],[55],[56]).
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1.2.3 Breast cancer treatment
Breast cancer is generally treated locally through surgery and/or radiation
therapy, or systemically using chemotherapeutic agents or hormone therapy.
Chemotherapy may be given in a neoadjuvant regimen to reduce tumor burden
before surgery, or in an adjuvant regimen after surgery to reduce the risk of
recurrence. Recently, it has been documented that chemotherapy treatments
including taxane (i.e., paclitaxel, Taxol and docetaxel, Taxotere) and anthra-
cycline (i.e., doxorubicin, Adriamycin and epirubicin, Ellence) in a neoadjuvant
setting is an effective strategy to increase overall survival in patients with lo-
cally advanced breast cancer ([57],[58]). Other chemotherapeutic agents for
breast cancer treatment include: Cyclophosphamide (Cytoxan), Capecitabine
(Xeloda) and fluorouracil (5 FU), methotrexate (Rheumatrex, Trexall), lapa-
tinib (Tykerb). Chemotherapy drugs are usually given in 2-4 week cycles, but
some may be used on a weekly basis. They can be also given in combinations
with two or more drugs. The hormone therapy drugs frequently used in clin-
ical practice to treat early, locally advanced or metastatic ER positive breast
cancers are: i) tamoxifen (Nolvadex), a selective ER modulator (SERM) that
binds to the receptor and prevents its activation by the ligand, estrogen, thereby
inhibiting tumor cell growth; ii) the aromatase inhibitors that act by blocking
the biosynthesis of estrogen, thus, reducing the availability of estrogen to cancer
cells ([52]). Patients diagnosed with Her2-positive tumors or with triple nega-
tive breast tumors are frequently unresponsive to standard chemotherapy. The
use of the hormone therapy is not an option since these tumors do not express
ER or PgR. For Her2-positive tumors, a molecularly targeted therapy is avail-
able based on monoclonal antibodies targeting the extracellular portion of the
Her2/neu receptor (i.e. Trastuzumab or Herceptin). Patients with metastatic
breast cancer (late-stage), who were treated with Trastuzumab displayed an
increase in overall survival of 20 to 25 months ([59]), while in patients with
Her2-positive non metastatic cancer (early-stage) Trastuzumab reduce the ab-
solute risk of relapse after the surgery of 9.5% and the absolute risk of death
of 3%([60]). Triple negative tumors are typically treated with the combination
of surgery radiation therapy and chemotherapy. They cannot be treated with
hormone therapy or Trastuzumab (Herceptin) because they are ER-negative and
Her2-negative. Target therapies are not available for these tumours because the
genes that are linked to this breast cancer subtype are still not well understood.
Although new treatments are being studied ([61]), more effective treatments are
urgently required for this group of breast cancer patients characterized to have
low five-year survival rate.
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1.2.4 Personalized Breast Cancer Care
Although metastatic breast cancer still remains an aggressive and incurable dis-
ease, early stage breast cancer is curable in most patients. Indeed, the decrease
in the mortality rate observed worldwide in the last 10 years ([27]) is, in part,
due to the diffusion of preventive mammography screening programs that allow
the detection of non-metastatic, early-stage disease that is curable by surgery
([62],[63]). In addition, our increased understanding of breast cancer biology
over recent years has led to the development of more effective, molecularly tar-
geted treatments like for example those making use of Lapatinib (Tykerb) and
Trastuzumab (Herceptin) for Her2-positive tumours, Tamoxifen ER-positive tu-
mours, that have helped to reduce the mortality of certain breast cancer sub-
types ([64]). The deeply understanding of breast cancer due, in particular, to
the explosion of “-omics” technologies, is driving a shift away from the “one-dose-
fits-all” paradigm to a new paradigm in healthcare, the so-called “Personalized
Cancer Care” or “Personalized Medicine”. Personalized medicine aims to select
the optimal course of clinical intervention for individual patients, maximizing
the likelihood of effective treatment and reducing the probability of adverse drug
reactions. The major determinant in the success of personalized medicine is the
identification of predictive and prognostic molecular biomarkers that reflect the
variability of breast cancer patients in terms of therapy response and clinical out-
come, respectively. The availability of such cancer biomarkers would allow the
stratification of patients in terms of risk of disease recurrence and responsiveness
to specific therapies, thereby overcoming the problems of undertreatment and
overtreatment of cancer. For instance, biomarkers that identify more aggressive
tumors can help avoid undertreatment, since such tumors can be treated with
more aggressive therapies. Whereas, biomarkers that are predictive of therapy
response, will help to prevent overtreatment of patients who would otherwise re-
ceive little benefit from the treatment, whilst being exposed to potentially adverse
side-effects ([65],[66],[67],[68],[69]).
1.2.5 Prognostic and predictive biomarkers in breast cancer care
As defined in Clark et al.,([70]) prognostic biomarkers are biological molecules
whose modulation, in terms of quantity or function, correlates with prognosis
([71],[72],[73]). These biomarkers can be used in clinical practice to stratify can-
cer patients and identify the optimal treatment regimens. Predictive biomarkers,
instead, correlate with treatment response and are used to predict whether or
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not a patient is likely to respond to a specific treatment. Predictive biomarkers
may overlap with prognostic biomarkers. For instance, the prognostic biomarkers
that are routinely used in the clinic for breast cancer, i.e., Her2 and ER/PgR, are
also predictive biomarkers. The levels of ER/PgR are used to predict response to
endocrine therapy, with high ER/PgR expressing tumors being more responsive
than low ER/PgR expressing tumor ([48],[74],[75],[76]). Likewise, Her2 overex-
pression, as well as being a risk factor for metastatic disease, is also an indicator
of responsiveness to targeted therapy with the anti-Her2 monoclonal antibod-
ies, Trastuzumab and Herceptin ([77],[78]). Cancer genomics is producing a
wealth of gene signatures with prognostic and predictive potential. However,
only few of them are commercially available and currently employed in clinical
practice ([79]): the Oncotype DX signature ([48]) and the MammaPrint signature
([45]). MammaPrint is a 70-gene expression assay that stratifies patients accord-
ing to high and low risk of distant recurrence, using marker genes associated
with proliferation, angiogenesis, stromal invasion and metastases ([45]). It has
been shown that this signature is able to predict relapse better than traditional
clinicopathological features ([45],[80]). The Oncotype DX classifies patients into
two groups: i) those with a low or intermediate-risk of recurrence who benefit
significantly from Tamoxifen treatment; ii) those with a high risk of recurrence
who may benefit from chemotherapy. The genes in the Oncotype DX signature
that have a high predictive value include proliferation genes, such as those en-
coding cyclin B1 (CCNB1), Ki67, Myb-related protein B (MyBL2), survivin, and
serine/threonine protein kinases (STKs), as well as genes encoding the ER and
PgR ([81]). Apart from these two examples of prognostic and predictive gene
signatures that are currently in clinical use, numerous other signatures have not
made it to the clinic. The major reasons why many gene signatures have not
been developed into clinical tools are: their poor overlap in terms of common
genes, the lack of validation in independent studies and limited improvement
in the predictive value with respect to that provided by standard clinicopatho-
logic parameters([79],[82],[83],[84],[85]). Historically, prognostic gene signatures
were derived using microarray gene expression profiles. Such profiles allow the
identification of the transcriptional variations amongst breast tumors that corre-
late with clinical outcome and therapy response. Despite the potential of such
genomics technologies, the poor overlap between the currently available signa-
tures is mainly due to: i) the large number of the differentially expressed genes
that correlate with prognosis; ii) the high tumor genetic heterogeneity added
to the intrinsic genetic heterogeneity of individuals of different ethnicities; iii)
Introduction 13
the different data analysis techniques; iv) poor experimental design and insuffi-
cent sample size ([86]). An alternative strategy towards the discovery of more
powerful prognostic and predictive tools is the definition of molecular biomark-
ers according to disease-related pathways, such as signal transduction pathways
directly implicated in disease phenotypes.
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1.3 The Systems Biology approach to cancer research:
Cancer Systems Biology (CSB)
Systems Biology is a field of biological research ([87]). The major goal of Sys-
tems Biology is to discover the general properties that govern biological sys-
tems at system-level through the characterization of the functional relationships
among biological molecules. Systems Biology integrates multi-scale types of high-
throughput biological data (i.e. genomic, transcriptomic, metabolic, proteomic
data) and uses mathematical modeling and simulations to understand the bio-
logical complexity. A second aim of Systems Biology, when applied to the human
health, is to investigate the impact of perturbations on the biological systems and
to determine whether these perturbations are linked to a specific disease, and
could thus be relevant to the development of novel therapeutic strategies ([88]).
The application of System Biology to cancer research is called Cancer Systems
Biology (CSB). CSB aims to unveil biological properties of cancer cellular sys-
tems through the characterization of molecular mechanisms involved in cancer
(ranging from genome-wide regulatory and signalling networks to more detailed
kinetic models of key biological reactions) to finally identify molecular therapeu-
tic targets. Traditional approaches to the study of complex diseases like cancer,
were based on the gene-centric analysis of constituent parts of the system under
study ([89],[90]) and their functional involvement in the pathology. Although this
has been a successful approach that has led to the discovery of genes (and mech-
anisms) involved in tumorigenesis, such as MYC, TP53, ERBB2, and EGFR, it
is unable to fully and comprehensively capture the complex nature of biologi-
cal systems ([91],[92],[93],[94]) and in particular of highly perturbed systems like
cancer cells. CSB aims to gain insights into such complexity using unbiased and
genome-wide high-throughput “-omics” data. The deconvolution of the structure
and topological properties of the molecular mechanisms actively involved in can-
cer will increase the understanding of tumor initiation and progression, unveil
mechanisms of action of anticancer drugs, and contribute to the elucidation of
mechanisms of resistance to pharmacological treatments towards more effective
therapeutic strategies. The ineffectiveness of some lifesaving pharmacological
treatments making use of anti-cancer drugs, with a failure rate of approxima-
tively 95% ([95]), is, in fact, mainly due to the ability of cancer cells to find
alternative mechanisms to escape the effect of anti-cancer molecules ([96],[97]).
In light of the flexible behavior of cancer cells it is of crucial importance to shed
light on the complex mechanisms governing cancer disease in order to increase
the probability of success of pharmacological therapies. A typical approach in
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CSB, is the inference of mechanisms of gene expression regulation (i.e. Gene Reg-
ulatory Networks (GRNs)) that are altered in cancer and that contribute to the
major hallmarks of the disease like the sustained cell proliferation, escape from
apoptosis and invasiveness. GRNs are collections of genes and regulators, con-
nected by physical and/or regulatory interactions. Some examples of GRNs are:
transcription factor (TF)-target genes network, microRNA-target genes network,
and networks deriving from the combinatorial activity of regulators like TFs,
microRNA, RNA binding proteins and their target genes. GRNs, and more in
general biological mechanisms and systems, are represented by graph diagrams,
i.e. networks, in which the functional relationships between the components are
represented by edges connecting nodes, i.e. biological molecules (see “Graph
Theoretical Models (GTMs)”, Subsection 1.4.4).
1.3.1 The Systems Biology pipeline to model cancer systems and
computational approaches to Systems Biology and Cancer
Systems Biology
The Systems Biology approach to cancer research involves:
1. The massive profiling of the tumor genome, transcriptome, proteome,
epigenome and metabolome (DNA/RNA sequencing, microarray gene ex-
pression profiling, proteome screening), to qualitatively and quantitatively
map the molecular profile of cancer cells.
2. The integration of multi-omics data layers to produce a comprehensive
molecular landscape.
3. The modelling of the system through realistic models (e.g. models of gene
expression regulation, GRNs), to infer the dynamical properties and key
features of the system.
4. The experimental validation of the reliability of the predicted models and
their biological relevance.
5. The identification of candidate molecular targets for disease therapy ac-
cording to the structure and topological properties of biologically relevant
models.
Computational approaches to Systems Biology, also applied to CSB, can be di-
vided into two major categories: data mining and simulation-based approaches.
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Computational approaches that focuses on data mining aim to extract hidden
patterns from high-throughput experimental data (knowledge discovery), while
simulation-based approaches test hypothesis from in silico experiments, produc-
ing predictions to be tested in vitro and in vivo wet lab experiments ([98]).
Data-mining approaches make use of sophisticated machine learning algorithms
that are able to deal with high-dimensional data. In contrast, simulation-based
analysis methods predict the dynamics of systems and experimentally tests the
validity of such predictions in the wet lab. This approach is relies on the interplay
between computationally predicted models and experimental observation.
1.3.2 Bioinformatics tools used in Systems Biology and in Cancer
Systems Biology
Systems Biology and CSB strongly depend on software tools and resources to
achieve the goals of novel biological discovery and design of more effective drugs.
Over the last years, we have witnessed the explosion of a plethora of computa-
tional tools for Systems Biology and CSB (summarized in Figure 1.4).
Figure 1.4: Softwares and computational resources commonly used in Systems Bi-
ology and in CSB. Taken from ([99]).
Introduction 17
Computational tools for Systems Biology and CSB can be divided into different
categories:
• tools for data knowledge management (e.g., MAGE-TAB, ISA-TAB,
Taverna) and in particular for the acquisition and storage of data ([100]).
These are of crucial importance especially in the current big-data era. A
critical challenge that faces the development of such tools concerns the
definition of standard formats and identifiers to facilitate data exchange
between different sources.
• tools for data-driven network inference (e.g., R, MATLAB and Banjo)
from high-throughput static and time-course data, which are able to infer
causal relationships among biomolecules ([101],[102]).
• tools to build molecular interaction maps from curated data(e.g.,
CellDesigner, PathVISIO). This is an alternative strategy to network in-
ference from data and it is based on the integration of different sources
of curated data ([103]). Networks generated using this approach do not
necessarily carry information on the causality of the relationships between
the molecular entities.
• tools for in silico simulation (e.g., MATLAB, COBRA, SenSB). These
tools are frequently use to model dynamic networks ([104]). This task is
not addressed by data-driven network inference methods nor from networks
built from curated data because of the static nature of such inferred mecha-
nisms. Dynamic simulations are often made on networks from curated data
because of the stoichiometry and the mechanistic information they carry.
• tools for multi-scale physiological modeling (e.g., JSim, PhysioDe-
signer, GENESIS). These tools allow the development of models describing
the association between genetic polymorphisms and network dynamics as-
sociated with such polymorphisms that are responsible for physiological
traits and diseases ([105]).
In light of such diversity in the tools used in systems biology, it is clear that the
emergence of analytical platforms and bioinformatics tools is at the core of the
development and application of systems biology.
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1.4 Data-driven Gene Regulatory Network Inference
1.4.1 Gene expression regulatory mechanisms of
eukaryotic cellular systems
The functional activities of a cell originate from information that is encoded in
the DNA. However, cell behavior depends ultimately on regulatory mechanisms
that influence gene expression at the transcriptional, post-transcriptional, trans-
lational, and post-translational level. Regulation of gene expression depends
on the cell’s functional state and may be also influenced by the environment.
Moreover, gene expression levels are mainly determined at the transcriptional
level by the activity of thousands of TFs and cofactors, chromatin modification
(i.e. DNA methylation), and histone modification (Figure 1.5). Instead, at the
post-transcriptional level, RNA editing and non-coding RNAs (i.e. microRNAs,
miRNAs; long intergenic non-coding RNAs, lincRNAs) are key regulators of gene
expression ([106],[107],[108],[109]). The control of gene expression programs is an
essential and vital process for living organisms and its alteration is often asso-
ciated with diseases, such as cancer ([110],[111],[112],[113]). DNA mutations in
CIS-regulatory elements (i.e. enhancers, promoters) or TRANS-regulatory ele-
ments (i.e. TFs, co-factors), as well as in chromatin modifiers, can have profound
effects on gene expression patterns, with relative pathological consequences. In-
deed, the association between mutations in these regulatory elements and cancer
has been extensively demonstrated ([114],[115],[116],[117]). For example: i) aber-
rant overexpression of the TAL1 TF in T cell acute lymphoblastic leukemia leads
to an increase in its transcriptional activity and activation of oncogenic pathways
([118],[119]); ii) amplification and overexpression of c-Myc, which controls tran-
scription of genes involved in cell proliferation, cell growth, differentiation and
apoptosis, leads to the activation of molecular pathways that are involved in can-
cer ([120]); iii) loss of RB gene function leads to a pro-tumorigenic activation of
the E2F TF activity ([121]).
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Figure 1.5: Mechanisms of transcriptional regulation.
The full set of mechanisms of transcriptional regulation is reported.
Binding of transcription factors to enhancer sequences and to coactivators.
RNA polymerase II (RNA Pol II) binds to TF coactivator complexes at the transcrip-
tional start sites. The loop formed between the enhancer sequences and the start site
at genomic level is stabilized by cofactors (e.g. mediator complex and cohesin) and is
necessary for transcription.
B. Initiation of the transcriptional activity by RNA Pol II. The initiation site is
the starting point for RNA polymerase II activity. Pause control factors stop RNA Pol
II activity approximately 10 base pairs downstream of the initiation site.
C. Elongation of the mRNA molecule after removal of the pause control fac-
tors. Different elongation factors and cofactors allow the RNA Pol II to proceed and
elongate the mRNA molecule.
D. Accessibility to the DNA molecule. ATP-dependent remodeling complexes act
on the nucleosome allowing the transcriptional complex access to DNA regions to be
transcribed.
E. Histone components of nucleosomes are modified by proteins. This modifi-
cation influences transcriptional activity and can be summarized into five types of modifi-
cations: acetylation (Ac), methylation (Me), phosphorylation (P), sumoylation (Su) and
ubiquitination (Ub). The modifications are added by proteins called writers and they
are removed by proteins called erasers. Readers proteins are able to bind DNA via these
modifications.
F. Patterns of transcriptional activity determine the histone modifications.
Patterns of histone modifications relative to actively transcribed genes are reported as
examples: the histone H3 lysine 27 acetylation (H3K27Ac), histone H3 lysine 4 trimethy-




1.4.2 Gene Regulatory Networks Inference from microarray gene
expression data: limitations and challenges
Recently, the application of Systems Biology approaches to cancer “-omics” data
has resulted in the identification of Gene Regulatory Networks (GRNs) repre-
senting molecular mechanisms involved in cancer. The inference of GRNs is of
crucial importance to explain the homeostasis of a cell and, most importantly, to
understand the effect of genomic alterations on the disruption of these regulatory
networks which results in the onset and progression of diseases. Although many
regulatory molecular mechanisms have been already well characterized at the bio-
chemical and biophysical level, the availability of “-omics” data is now allowing a
more comprehensive data-driven characterization of them as well as of, more gen-
erally, complex cellular systems ([123], [124],[125],[126],[127],[128]). Microarray
gene expression profiles represented the commonly and widely used “-omic” data
source for Gene Regulatory Network Inference (GRNi) at mRNA level. The in-
ference of regulatory mechanisms that control the mRNA levels of a cell is based
on the assumption that the functional relationship between expressed molecules
generates statistical relations in the observed data. This simplification allows
the application of mathematical and statistical techniques to network inference
in an unbiased way, i.e. without priori knowledge on the functional relationships
between the expressed genes. Specifically, if groups of genes are expressed in a
cell at the same time, there is a possible functional relationship between these
genes, that might be explained by statistical correlations. Different statistical
frameworks have been successfully applied to infer networks of interacting genes
from microarray gene expression data ([129],[130],[131],[132],[133]). Despite the
great contribution of powerful statistical methods to the inference of regulatory
mechanisms from microarray gene expression data, some technical issues limits
the reliability of the inferred networks. In particular the available data sets lack
the quantitative and statistical power to infer GRNs, i.e. the number of possible
inferred interactions greatly exceeds the number of independent measurements.
This is the “underdetermination” problem, also called “the curse of dimensional-
ity” problem. To gain the statistical power necessary to generate data-driven ac-
curate maps of regulatory mechanisms, hundreds of biological samples are needed.
Consequently, it is difficult to derive reliable regulatory network models from the
available data, even for small size networks according to data requirements for
statistical significance. An innovative strategy to decipher GRNs was introduced
by Segal et al. ([134],[135],[136]) and is based on the definition of modules of
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co-expressed genes that constitute the building blocks of the GRN. The princi-
ple behind this approach is that genes that are grouped together into modules
share a common regulatory program. Grouping together functionally regulated
genes strongly reduces the complexity of the system that has to be modeled, and
further increases the statistical power needed for regulatory network inference.
Another crucial factor that affects the inference of gene regulatory networks from
microarray data and in general network inference biology is the lack of bench-
marking studies for biological data. Benchmarking studies are powerful tools that
allow the identification of the best mathematical and statistical framework for
finding true and realistic relationships between genes. Consequently, the evalua-
tion of the accuracy of the methods for regulatory network inference is measured
through simulated data that even if they represent the only possible way for the
validation of the methods they do not capture the true variability of biologi-
cal systems. To address all these problems, collaborative efforts have been made
worldwide through public initiatives, such as the Dialogue of Reverse Engineering
Assessments and Methods (DREAM) ([137],[138],[139],[140]) and Sage Bionet-
works (http://sagebase.org/). The aim of such projects is to catalyze world-
wide efforts towards the standardization and rigorous assessment of methods for
cellular network inference and quantitative model building in systems biology.
In particular, the DREAM project (http://www.the-dream-project.org/) is
a promising initiative that through a yearly competition allows algorithm de-
velopers to present their own methods for network inference and it provides an
unbiased assessment of these methods. From the recent DREAM competitions,
it has emerged that different algorithms for reverse engineering cellular networks,
highly complement each other ([141]), and that a community-based, consensus-
driven, reverse-engineering approach can lead to high quality network inference.
The reason why integration of reverse engineering algorithms is superior to the
selection of the best performing algorithm from a pool of proposed methods, is
mainly due to the compensatory effect of using multiple algorithms to balance
the strengths and weaknesses of each single algorithm. In conclusion, in spite
of the theoretical and technical limitations of network inference methods and
strategies, network biology offers an unprecedented opportunity to interpret and
reinterpret experimental findings in a global view, to unveil novel interactions
and molecular regulatory processes.
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1.4.3 Co-expression networks and transcription-regulatory
networks
Two types of GRNs can be inferred from high-throughput gene expression data:
co-expression networks and transcription-regulatory networks (Figure 1.6) [142].
In co-expression networks, nodes represent genes and edges represent connec-
tions between genes. Genes are connected to one another if they share similar
expression patterns under various biological conditions. The degree of similarity
between two genes can be formalized using statistical weights. Co-expression net-
works allow the identification of highly connected subgraphs, also called “cliques”,
corresponding to modules of genes having the same transcriptional profile. In
transcription-regulatory networks, networks are represented as bipartite graphs,
in which it is possible to identify a set of nodes representing transcription fac-
tors and a set of nodes representing target genes (i.e., modules of genes under
the control of transcription factors). While in co-expression networks the rela-
tionships between genes are undirected for large scale networks, in the case of
transcription-regulatory networks the edges are often directed reflecting a causal
relationship between genes determined by the transcription factor regulatory pro-
gram. Causal relationships in transcription-regulatory networks indicate that the
observed transcriptional correlation in a module of co-expressed genes, is caused
by the expression and regulation of a transcription factor on nodes representing
target genes. When a set of genes is under the control of multiple transcription
factors, a transcriptional program is defined.
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Figure 1.6: Co-expression networks and transcriptional-regulatory net-
works.
The two types of GRNs are reported: a) co-expression networks in which genes show-
ing the same transcriptional pattern are grouped together forming modules of genes;
b) transcription-regulatory networks in which regulators (i.e., transcription factors) and
their target genes are distinguishable. Adapted from [142].
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1.4.4 Model Gene Regulatory Networks
Microarray technology have produced a plethora of gene expression data at
mRNA level ([143]), providing an unprecedented opportunity to decipher the
functional regulatory mechanisms (GRNs) that control gene expression in a
cell. Specifically, microarray technology allows a quantitative and simultaneous
measure of the transcriptome and relative fluctuations upon a genetic perturba-
tion ([144]), drug-induced perturbations ([145],[146]) or according to a disease
state. Whereas direct experimental investigation of the functional relationship
between genes is labor-intensive and time-consuming, computational analysis of
gene expression profiles, through the use of statistical inference algorithms, offers
a reliable alternative to explore the structure of GRNs that control molecular
mechanisms in the cell. In recent years there has been an explosion in the num-
ber of computational and mathematical methods to model complex GRNs from
different sources of data. Here, the generally used methods to model GRNs are
reported. The mRNA cellular levels measured through the microarray technol-
ogy represent the data source to model regulatory networks.
Graph Theoretical Models (GTMs)
Graph Theoretical Models (GTMs) belong to the group of qualitative network
models together with the Boolean Network models, that will be discussed later,
because they do not yield any quantitative prediction of gene expression in the
system. GTMs are the most frequently used models to explore the structure
of regulatory networks from gene expression data ([147],[148]). GTMs are used
to decipher the topological structure of biological regulatory networks and are
well suited for networks graphical representation or for the representation of the
dynamical evolution of the networks (i.e. the topological evolution of biological
networks according to the time, cellular context and conditions). In a graph
structure, the network G(N,E) is made up of genes as nodes N = {1, 2, ..., n}
connected by thousands of edges E = {(i, j)|i, j ∈ N} which represent the rela-
tionships between the genes (Figure 1.7). The types of the relationships between
the genes range from physical-interactions, i.e. the protein-protein interaction
networks (PPI networks) and the DNA-protein interaction networks, to gene
expression correlations for co-expression networks. Graphs can be directed (ori-
ented) or undirected (unoriented). In the first case the gene node from which
the edge starts is the precursor of the node towards the edge is directed and are
represented usually by arrows. Directed graph from microarray gene expression
data, can be built, for example using time-series data, because using temporal
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information associated with gene expression profiles allows the inference of the
causality of the connections ([149]). In the case of undirected graphs it is not
possible to assign a direction, i.e. causal relationship to the edges connecting
the network nodes. A graph of such type is also called “unoriented graph” in
contrast with the first case in which the graph is called “oriented graph”. Since
undirected graphs do not imply a direct causality between the nodes the network
can be built by using static (i.e. stationary) gene expression measurements. Fi-
nally, in both directed and undirected graphs, the edges can be weighted, where
the weights indicate the strength of the connections.
Figure 1.7: A typical representation of a biological network with nodes and edges.
A representation of a typical biological network is reported with circles representing the
genes (nodes) and blue lines (edges) representing the relationships between genes. The
size of the circles varies according to the number of connections each gene establishes




Besides GTMs, another model that is used to explore the structure of regula-
tory networks from gene expression data is based on Bayesian networks, which
combine probability and graph theory, i.e. they are a class of graphical proba-
bilistic models. A Bayesian network consists of an annotated Directed Acyclic
Graph (DAG) where the nodes xiX are random variables representing genes’
expression values and the edges indicate the probabilistic dependencies between
the nodes. The relationships between the connected nodes are specified by a
conditional probability distribution ([150],[129]) for each node given its par-
ents: P (xi|Parents(xi)). A Bayesian network implicitly encodes the Markov
Assumption where each gene (child node) is conditionally independent from
each non-descendants given the parents nodes (genes) of the network. Besides
the set of dependencies (children nodes depend on parent nodes) a Bayesian
network implies a set of independencies too. The Bayesian networks allow to
infer causalities between genes but at the same time they need an additional
level of information with respect to the GTMs, that is the prior knowledge on
the conditional relationships between the genes. In addition, Bayesian networks
need the discretization of gene expression measures into a few values, gener-
ally -1 for the underexpression, 0 for no expression and +1 for overexpression.
Although Bayesian networks are a valuable tool to infer functional relation-
ships between genes and expression values, the available data suffer from the
dimensionality curse (i.e. number of genes, n  number of experiments, m) so
that gene expression data are insufficient for the accurate gene network inference.
Boolean networks
The explosion of computational and mathematical methods to model complex
GRNs is the result of recent progress in molecular biology and the explosion of
genome-wide technologies. However a pioneering work in modeling GRNs dates
back to 1960s by Stuart Kauffman and colleagues. In their work they considered
an idealized random gene network because of the absence of experimental data
([151]). In this modeling attempt Kauffman defined genes as equivalent entities
able to receive inputs from a variable number of K neighbors. According to the
inputs that each gene receives it can be in only one of two states: the ON (1)
or OFF (0). A Boolean function that governs the ON/OFF state of each gene
is a statement that uses logical operators AND, OR and NOT. The output is
1 if the statement is true and 0 if it is false. A Boolean network is a directed
graph G(X,E) where the nodes xi ∈ X are boolean variables (e.g. mRNA mea-
surements). At any given time, the state of each node represents the state of
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the network. Although the dynamic properties of Boolean networks, and the
reproducibility and the possibility of a finite number of states that make them
attractive to model GRNs of living systems, the strong discretization of gene
expression values into only two states (up and down) limits the representation
of the realistic regulatory mechanisms where expression values are continuous.
Another drawback concerns the high computing times (NP-complete problem,
[152]) required to build biological networks. As a consequence it performs well
for networks with a limited number of nodes and a small in degree value (i.e.
with low levels of node connectivity). Finally, the network states are synchronous
while realistic biological states of a network are generally asynchronous.
Differential Equations (DEs)
Differential Equations (DE) are used to quantitatively model complex systems.
DEs describe gene expression changes as a function of the expression of the other
genes and environmental factors. They are well suited to model the non-linear
dynamic behaviour of GRNs in a quantitative manner through a continuous and
deterministic modelling formalism. DEs are highly flexible models that allow
to describe even complex relations among components. The general form of
equations for the modelling of gene expression dynamics that apply Ordinary
Differential Equations (ODEs) is:
dx
dt
= f(x, p, u, t)
where x(t) = (x1(t), ...., xn(t)) is the gene expression vector of the genes 1,...., n
at time t, f is the function that describes the rate of change of the state vari-
able xi according to the parameter set p and the external perturbations u. In
network inference the function f and parameters p are derived from measured x,
u and t. The identification of the model structure (f) and model parameters (p)
requires specifications of the function f and constraints like prior knowledge, ap-
proximations and simplifications because without constraints there are multiple
solutions to ODEs system. One of the possible constraints is for example the prior
assumption of the linearity or non-linearity of the f function. Generally, regula-
tory processes are characterized by complex and non-linear dynamics. However,
many GRNs are modeled by using linear models because of the complexity to
model non-linear f function ([153]). Other variants of DEs include stochastic
differential equations that consider the stochasticity of gene expression occurring
especially for low cellular levels of TFs molecules ([154]).
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1.4.5 Reverse engineering Gene Regulatory Networks from
“genome-wide” expression data
Different approaches have been proposed for Gene Regulatory Network infer-
ence (GRNi) using “genome-wide” expression data, and a consensus on the best
strategy to adopt to optimize and standardize analyses is still lacking. The
heterogeneity of methodologies proposed for GRNi is strictly dependent on the
variability of biological systems, which determines the adoption of different the-
oretical assumptions for statistical inference. However, all GRNi methods are
based on the common biological assumption that mRNA measurements, can pre-
dict protein activities, and, thus, the function of regulatory mechanisms. The
key concept at the basis of the gene regulatory network inference (GRNi) is that
tightly co-expressed genes, i.e., genes having the same transcriptional pattern,
may be functionally related. Different types of functional relationships may exist
for co-expressed genes. For example, co-expressed genes may be part of the same
protein complex, or may be indirectly involved in the same pathway, or they
may share similar regulatory DNA sequence motifs (i.e. transcriptional regula-
tory sites) that allow genes to respond similarly to developmental or environ-
mental changes. Traditionally, groups of co-expressed genes have been identified
by using clustering algorithms ([155]). Gene expression clustering is still the
widely used tool to analyze and visualize gene expression data. Genes sharing
a similar gene expression profile are clustered together to highlight a possible
functional relationship that can be direct or indirect ([156]). The degree of simi-
larity of the expression profiles between different genes is often measured through
distance metrics. One of the most frequently used metric is the Pearson correla-
tion coefficient. Other measures of association are: the Euclidean distance, the
Spearman rank correlation coefficient, the partial correlation coefficient and the
Mutual Rank. The most frequently used clustering methods are: the Hierar-
chical Clustering (HCL) ([156]), the k-means ([157]), the Self Organizing Map
(SOM) ([158]), the Principal Component Analysis (PCA) ([159]) and the Expec-
tation Maximization algorithm ([134],[160]). The major limitation of clustering
methods concerns the best number of clusters needed to partition the gene ex-
pression data. Usually, the number of clusters is not known in advance. One
frequently used strategy regarding, for example, the k-means method, to over-
come this limitation is to iteratively try different numbers of clusters (k) and then
choose the k number that best fits the data. In addiction, another limitation of
genome-wide clustering of expression profiles concerns the biological interpreta-
tion of clusters of genes. Indeed the clustering method groups together genes
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that exhibit similar transcriptional responses, under different cellular conditions;
however it cannot distinguish direct pair-wise transcriptional interactions from
non-direct transcriptional interactions, because most of the similarity measures
used by this method are linear. Despite the limitations of the cluster analysis in
identifying the functional relationships between genes, it allows the user to hy-
pothesize functions of unknown genes based on genes with known functions in the
same cluster ([161],[162]). Moreover, the clustering of gene expression patterns,
although not suitable for network inference of functionally related genes, allows
the identification of signatures of co-differentially expressed genes according to a
cell’s phenotype ([45],[163],[164]). To overcome the intrinsic limitations relating
to the identification of functional relationships based on cluster analysis, model
networks methods are frequently applied to infer causal relationships among genes
from their activity profile (See Subsection 1.4.4). Although graphical models for
network inference are powerful probabilistic tools to infer conditional relation-
ships between genes, they are affected by some limitations:
• they are based on the assumption of parametric probability distribution.
• they are powerful only with small lists of genes. For largest lists of genes
(∼10,000 genes) many observations are required to reliably estimate the
conditional dependencies between genes, which are not available from gene
expression profiling studies.
• The set of models that can be inferred from multidimensional data (like
microarray gene expression data) grows superexponentially, thus, only a
subset of them can be reasonably tested considering the computational
power of a well-equipped research lab.
• they are based on the assumption of conditional independence that may
generate unrealistic models.
To overcome such limitations, methods based on Mutual Information (MI) for
GRNi were recently proposed. MI captures non-linear dependence relationships
between quantitative variables, in addition to positive and negative correlations
([165],[166]). Specifically, it computes the differential entropy between differen-
tially expressed genes. For two random variables it computes:
Iij = S(Xi) + S(Xj)− S(Xi, Xj)
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where S(t) is the entropy of an arbitrary variable (t). For a discrete variable,
the entropy is computed as follows:




where: p(ti) is the probability of each discrete state (value) of the variable. Like
many other correlation metrics, the MI measures the statistical dependency be-
tween two variables. The advantage of using MI is that it remains invariant
after re-parametrization, unlike, for example, the Pearson correlation measure.
In addition, using linear correlation metrics (such as Pearson correlation) the
correlation coefficient might be 0 even for clearly dependent variables (non-linear
relationships), while the MI is always different from 0 for statistically dependent
variables ([167]). The first attempt to build networks by using MI was by Butte
and Kohane (RELNET, RELevance NETworks; [168]). In this approach, genes
are connected with edges only if they correlate with an MI score above a threshold
established by using a permutation test. In such a way, the genes that interact
indirectly will still have high values of MI scores. Recently, in the ARACNE (Al-
gorithm for the Reconstruction of Accurate Cellular Networks) algorithm ([133])
to overcome the problem of indirect interactions, the Data Processing Inequality
(DPI) measure was introduced. Briefly it states that if g1 and g3 interact only
through a third gene g2, then:
I(g1, g3) ≤ min[I(g1, g2); I(g2, g3)]
The MI score calculated between g1 and g3 will result from an indirect interaction.
The advantage of DPI is that it allows the identification of indirect interactions
between genes, even if they have high MI scores (i.e. significant MI scores). The
ARACNE algorithm starts assigning pairwise connections to genes according to
the computed MI score. Before assigning connections, a threshold of significance
of the computed MI score is established. Then, the algorithm compares all the
possible triplets and removes the edge with the smallest value representing the
indirect interaction. The major advantage of the ARACNE algorithm (based on
MI and DPI measures) with respect to graph models, is that it does not assume
any restraints on the network model, even if the interaction network is greatly
simplified to the unrealistic pair-wise interactions while biological interactions
are multivariate and of a higher order. Other approaches have been proposed to
discriminate between direct and indirect interactions. The Context Likelihood
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of Relatedness (CLR) ([169])) algorithm, for example, modifies the MI score
according to the empirical distribution of all MI values while the Minimum Re-
dundancy Network (MRNET) ([170]) algorithm uses a feature selection method
based on a maximum relevance/minimum redundancy criterion. All of them are
based on robust and well defined mathematical and statistical formulations and
are commonly used to infer reliable GRNs from high-throughput gene expression
data.
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1.5 Rationale of the project
Breast cancer is a complex disease. Although most breast cancer cases are cur-
able, with a 5-year survival rate of 96% for localized (i.e. early stage) dis-
ease and 77% for regional disease, metastatic breast cancer is still incurable
with a 5-year survival rate of ∼23% (SEER Cancer Statistics Review (CSR),
http://seer.cancer.gov/publications/csr.html). The curability of early-
detected and locally-recurrent non-metastatic disease is mainly due to effective
treatment regimens involving surgical resection and therapeutic interventions
(i.e., radiation therapy and pharmacological treatment), while for metastatic dis-
ease, pharmacological treatment is often the only option to control the growth
of the tumor. Despite a steady decrease in the breast cancer mortality rate
observed over the last decades, attributable to early detection and more effec-
tive treatment strategies employing predictive and prognostic biomarkers and
targeted therapies, breast cancer remains the leading cause of cancer death in
women worldwide ([27]). The high level of intra- and inter-tumor molecular
heterogeneity of breast cancers is one of the main determinants of the failure of
current therapeutic strategies that follow the “one-dose-fits-all” paradigm ([171]).
In particular, the lack of knowledge, on the molecular mechanisms that underlie
disease progression, on a patient-by-patient basis, represents a major hurdle to
development of more effective personalized therapies for breast cancer. In this
study, we developed a bioinformatic approach to identify altered transcriptional
regulatory networks using a “pathway-centric” approach in order to get more in-
sights in the biology of breast cancer. Our computational pipeline exploited the
huge amount of publicly available “genome-wide” transcriptional (steady-state)
data on breast cancer, and identified, through the application of sophisticated
computational algorithms used in Systems Biology for the reverse engineering
the Gene Regulatory Networks (GRNs), a set of GRNs that correlate, at the
gene expression level, with clinical-pathological parameters of breast cancer pa-
tients (i.e. tumor grade, stage, estrogen status, prognosis, response to therapy).
Specifically, we:
• identified modules of genes (i.e. Cancer Modules (CMs)) that transcription-
ally correlated with several clinical-pathological parameters starting from
oncogenic gene-signatures.
• Built cancer-related GRNs by assuming each gene in CMs, i.e. each CM-
gene, as the “hub” gene (i.e. the highly interconnected gene) of the network.
Probabilistic dependencies were inferred from the mRNA levels of the hub
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gene and of the expressed genes in cancer cells, generating networks that
indirectly represent much more sophisticated molecular and biochemical
mechanisms of gene expression regulation.
• Performed the mutational annotation of the of the inferred GRNs in order
to gain insights into the oncogenic role of the networks in breast cancer
biology.
• Predicted candidate transcriptional Master Regulator (MR) genes of GRNs
by performing an in-deep network deconvolution analysis.
• Described the transcriptional state of each network in breast cancer patients
defining an active/inactive state according to the expression regulation of
the gene neighbours with respect to the hub gene.
• Further investigated the transcriptional correlation of the active networks
with chemotherapy response in Triple Negative Breast Cancer (TNBC) pa-
tients.
Using this approach we hypothesize that an in-depth characterization of the
transcriptional regulatory networks that are associated with breast cancer, will
allow the identification of novel predictive and prognostic biomarkers for high-
resolution patient stratification, as well as the identification of new molecular
targets for the development of more effective pharmacological treatments.
Chapter 2
Materials & Methods
2.1 Cancer Modules (CMs) identification
2.1.1 Oncogenic gene signatures selection
We retrieved a total of 23 transcriptional gene sets representing different onco-
genic events form the Molecular Signatures Database (MSigDB) and other previ-
ously published studies (Table 2.1). Most of the gene signatures were downloaded
from C2 curated gene sets (MSIGdb v.3.0; [172]), with the following exceptions
(Table 2.2): VEGF signature ([173]); EGFR signature ([174]); Chromosomal In-













Table 2.1: MSigDB Gene sets details.
Gene Sets Name Cancer gene(s) Genes Sample type Organ(s) and Tissue(s) Organism(s)
(Up/Down) Up Down Total
M14590 ZEB1 - - 29 Cell Lines Breast H.sapiens
M7062/M6189 HIF1A/HIF2A 41 104 146 Cell Lines Breast H.sapiens
M7160/M12455 TGFB1 106 35 141 Cell Lines Pancreas H.sapiens
M16229/M11403 TP53 48 16 64 Cell Lines Lung H.sapiens
M3456 MYC - - 176 Cell Lines Blood H.sapiens
M17742/M1217 TERT 128 71 199 Tissue Sample Breast H.sapiens
M16737/M3464 BRCA1 33 38 71 Tissue Sample Breast H.sapiens
M2706/M2704 E2F3 238 34 272 Tissue Sample Breast, Ovary, Lung H.sapiens
M2714/M2713 SRC 8 53 61 Tissue Sample Breast, Ovary, Lung H.sapiens
M2703/M2702 BCAT 11 73 84 Tissue Sample Breast, Ovary, Lung H.sapiens
M12029 HRAS - - 321 Tissue Sample Breast, Ovary, Lung H.sapiens
M2776/M6315 KRAS/PTEN 228 429 657 Tissue Sample Lung M.Musculus
M9118/M9362 KRAS 196 141 337 Tissue Sample Lung M.Musculus
M366-M3102/M8901-M1219 ERBB2 306 163 469 Tissue Sample Breast M.Musculus
M18438/M15346 E2F1 63 65 128 Tissue Sample Liver H.sapiens/M.Musculus
M4420/M5636 MYC/E2F1 57 66 123 Tissue Sample Liver H.sapiens/M.Musculus
M3432/M17372 MYC/TGFA 61 66 127 Tissue Sample Liver H.sapiens/M.Musculus
The description of the 17 gene sets retrieved from MSigDB is reported. Specifically are reported: the MSigDB systematic gene set name (Gene Sets Name).
For each gene set two systematic gene set names are reported if the genes are divided into Up-regulated and Down-regulated genes, otherwise only one
systematic name is reported; the relative official gene symbol (Cancer gene(s)) of the gene(s) on which the experimental perturbation was applied to generate
the transcriptional signature; the number of genes in each gene sets (Genes) divided in up-regulated genes (Up) and down-regulated genes (Down) together
with the total amount of genes in the signature (Total); the experimental source of sample (Sample type); the sample type organ and tissue of origin (Organ(s)











Table 2.2: Literature derived gene sets details.
Cancer gene(s) Genes Sample type Organ(s) and Tissue(s) Organism(s)
Up Down Total
VEGF - - 58 Tissue Sample Blood Vessels H.sapiens
EGFR - - 487 Cell Lines Breast H.sapiens
CIN - - 70 Tissue Sample Breast, Ovary, Lung H.sapiens
E1A 473 16 348 Cell Lines Breast M.Musculus
JAP/TAZ - - 93 Cell Lines Breast H.sapiens/M.Musculus
JAG1/NOTCH 250 206 456 Cell Lines Breast H.sapiens/M.Musculus
The description of the 6 gene sets retrieved from the literature is reported. Specifically are reported: the official gene symbol (Cancer gene(s)) of the gene(s)
on which the experimental perturbation was applied to generate the transcriptional signature; the number of genes in each gene sets (Genes) divided in
up-regulated genes (Up) and down-regulated genes (Down) together with the total amount of genes in the signature (Total); the experimental source of
sample (Sample type); the sample type organ and tissue of origin (Organ(s) and Tissue(s)) and the sample type organism of origin (Organism(s)).
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2.1.2 Microarray gene expression datasets selection, quality
control and normalization
Breast cancer microarray data sets (Discovery and Validation sets) and the as-
sociated clinical information were downloaded from Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/) database. We retrieved microar-
ray data from 9 independent cohorts of patients with breast cancer. The cohorts
were subdivided in a Discovery set (5 cohorts of patients) and a Validation set
(4 cohorts of patients) (see Table 2.3). We then applied the following quality
control procedure on .CEL files to identify flawed arrays, using Relative Log Ex-
pression (RLE) values and Normalized Unscaled Standard Error (NUSE) values
([179],[180]):
• We computed the median value and the IQR of both the NUSE and the
RLE statistics for each array. This gave four values for each chip: MNUSE ,
MRLE , IQRNUSE and IQRRLE .
• We compared each of these values with a corresponding cutoff value. If any
value exceeded the cutoff, the chip was tagged as “dubious”.
• We calculated IQRs of MNUSE , MRLE , IQRNUSE and IQRRLE across the
arrays. This gave four values: IQRMNUSE , IQRMRLE , IQRIQRNUSE and
IQRIQRRLE .
• If any of these IQR values was greater than q3 + 1.5IQR or less than q1 -
1.5IQR where q1 and q3 are the first and the third quartile of the distribu-
tion, we considered such values as outliers and flagged the corresponding
array as “rejected”.
• We made diagnostic plots for both the dubious and the rejected arrays for
a successive visual analysis.
Cutoff values were chosen heuristically, with a preference for overestimating the
number of poor quality chips rather than failing to identify a compromised chip.
The four cutoff values are shown in Table 2.4. Arrays identified as defective were
removed from the dataset before normalization. Further details on the number
of microarrays flagged as: dubious, rejected and accepted for each dataset are
reported in the next Subsection 2.1.3. After the filtering, a total amount of 1019
transcriptional profiles for the full collection of the Discovery datasets and 916
for the Validation datasets were retained. The quality control procedure was
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implemented using the R (version 2.15.1) language for statistical computing and











Table 2.3: The datasets used in the breast cancer microarray screening.
datasets Year Samples Platform used GEO acc. Reference
raw filtered
Discovery datasets
Ivshina 2006 289 239 Aymetrix HG-U133A GSE4922 ([183])
Pawitan 2005 159 149 Aymetrix HG-U133A GSE1456 ([46])
TRANSBIG 2007 198 189 Aymetrix HG-U133A GSE7390 ([185])
Wang 2005 286 286 Aymetrix HG-U133A GSE2034 ([186])
EORTC 10994BIG 00-01 clinical trial 2007 161 156 Hu-X3P GSE6861 ([187])
Validation datasets
Minn 2005 121 115 Aymetrix HG-U133A GSE2603 ([188])
Sotiriou(KIU) 2006 64 63 Aymetrix HG-U133A GSE2990 ([189])
Hatzis 2011 508 437 Aymetrix HG-U133A GSE25066 ([190])
Kao 2011 301 301 Affymetrix HG-U133 Plus 2.0 Array GSE20685 ([191])
The year of publication, number of samples before and after the filtering (in parenthesis), the microarray gene expression platform selected, the relative GEO
accession number and pubblication.
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After the quality control procedure, for each dataset the accepted microarrays
were normalized using the RMA algorithm ([181]) with default parameters ex-
cept for the GSE2034 dataset. In this case Affymetrix MAS5.0 algorithm was
used (see “The Wang dataset” in Subsection 2.1.3.4). Microarray gene expres-
sion normalization was performed using the R (version 2.15.1) library affy of
the Bioconductor suite. For each normalized gene expression dataset a gene-
level annotation of the Affymetrix probe sets was performed using the probeset-
gene mapping tables provided at NetAffx, the official gene-level annotation of
Affymetrix probesets ([182]).
Table 2.4: Cutoff chosen in the quality control procedure.
MNUSE MRLE IQRNUSE IQRRLE
1.10 0.2 0.10 1.0
The chosen cutoff values for the four quantities defined in step 1 of the quality control
procedure.
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2.1.3 Gene Expression datasets
2.1.3.1 The Ivshina dataset
The Ivshina et al. dataset included gene expression data from two cohorts of
patients with primary invasive breast cancer, referred to as the Uppsala and
Singapore cohorts ([183]). Affymetrix HG-U133A and HG-U133B microarrays
were used for the expression profile, for a total of 578 arrays. We restricted
the analysis on HG-U133A microarrays (i.e. 289 arrays) because the HG-U133B
arrays were not available for all the other breast cancer data sets we selected
originally. Samples from the Singapore cohort (40 samples) were also excluded
from analysis due to the lack of clinical information. After the quality control
analysis, 14 arrays were flagged as “dubious” of which 7 were removed after
visual inspection and 3 were rejected. The clinical parameters we considered for
subsequent analysis were:
• Elston (NGS) histologic Tumor Grade.
• Estrogen Receptor (ER) status.
• Disease-Free Survival (DFS).
• Disease-Free Survival in Lymph Node negative (N-) ER+ patients (N- ER+
DFS).
The number of patients per clinical information is reported in Table 2.5
Table 2.5: Ivshina dataset clinical information detail.
Tumor Grade ER status N- ER+ DFS DFS
G1 (66) ER+ (204) Relapse (33) Recurrence or Death (85)
G2 (121) ER- (34) Non-Relapse or Censored (33) Censored (157)
G3 (55) - - -
The number of patients (in parenthesis) relative to the following clinical information: the
Tumor Grade (Grade 1 [G1], Grade 2 [G2], Grade 3 [G3]), the ER status (ER+, ER-), the
Disease-Free Survival in Lymph Node negative (N-) ER+ patients (Relapse, Non-relapse
or Censored), the Disease-Free Survival (Recurrence or Death, Censored).
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2.1.3.2 The Pawitan dataset
The Pawitan dataset consists of 159 patients with primary invasive breast cancer
operated at the Karolinska Hospital from January 1994 to December 1996 ([46]).
We applied the quality control procedure to the dataset: 10 arrays were fagged as
“dubious” of which 9 were excluded after visual inspection and one as “rejected”.
The clinical information (see Table 2.6) we considered for subsequent analysis
refers to:
• Elston (NGS) Tumor Grade.
• Breast Cancer Relapse.
• Death due to Breast Cancer.
Table 2.6: Pawitan dataset clinical information detail.
Tumor Grade Breast Cancer Relapse Death due to Breast Cancer
G1 (28) Relapse (38) Dead from Breast Cancer (27)
G2 (58) Non-relapse or Censored (112) Alive or Censored (123)
G3 (61) - -
The number of patients (in parenthesis) relative to the following clinical information: the
Tumor Grade (Grade 1 [G1], Grade 2 [G2], Grade 3 [G3]), the Breast Cancer Relapse
(Relapse, Non-relapse or Censored) and Death due to Breast Cancer (Dead from Breast
Cancer, Alive or Censored).
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2.1.3.3 The TRANSBIG dataset
TRANSBIG is an international network that was launched in 2004 to promote
the scientific collaboration in translational research ([184]). It comprises 39 world
class institutions in 21 countries. The dataset stored in the GEO data base
with accession ID GSE7390 contains 198 expression profiles of primary lymph
node negative untreated breast cancer patients. A complete description of the
dataset can be found in (Buyse 2006) and ([185]). We applied our quality control
procedure, which led to the exclusion of 9 arrays from the dataset, leaving 189
for the successive analysis. We also checked for the presence of batch effects by
plotting an array-wise boxplot using the raw data. No obvious batch effects were
observed (see Figure 2.1).
Figure 2.1: Batch effect inspection of TRANSBIG dataset.
Different colors indicate the different hospitals that provided patient samples.
The available clinical data for the TRANSBIG dataset includes information on:
• Elston (NGS) Tumor Grade.
• Estrogen Receptor (ER) status.
• Relapse due to Distant Metastasis (event of time to distant metastasis
[E.TDM]).
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• Disease-Free Survival in Lymph Node negative (N-) ER+ patients (Relapse
in N- ER+).
• Overall Survival (OS).
Overall Survival was defined as time from diagnosis to death from any cause. See
Table 2.7 for the number of patients with associated relative clinical information
we considered for subsequent analysis.
Table 2.7: TRANSBIG dataset clinical information detail.
Tumor Grade ER status E.TDM Relapse in N- ER+ OS
G1 (27) ER+ (128) Relapse (51) Relapse (28) Dead (56)
G2 (80) ER- (61) Non-Relapse (138) Non-Relapse (100) Alive (133)
G3 (80) - - - -
The number of patients (in parenthesis) relative to the following clinical information: the
Tumor Grade (Grade 1 [G1], Grade 2 [G2], Grade 3 [G3]), the ER status (ER+, ER-), the
Relapse due to Distant Metastasis (Relapse, Non-Relapse), the Relapse in Lymph Node
negative (N-) ER+ patients (Relapse, Non-Relapse), the Overall Survival (Dead, Alive).
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2.1.3.4 The Wang dataset
The Wang dataset ([186]) consists of 286 samples from LN-patients. This dataset
presents some technical issues. First, the raw data were not available on GEO
database. Thus no quality control procedure was possible. Second, the clinical
information was limited to:
• The ER status.
• The occurrence of the Relapse in Lymph Node negative (N-) ER+ patients
(Relapse in N- ER+).
• The occurrence of the relapse.
See Table 2.8 for the number of patients with associated relative clinical infor-
mation we considered for subsequent analysis.
Table 2.8: Wang dataset clinical information detail.
ER status Relapse in N- ER+ Relapse
ER+ (209) Relapse (80) Relapse (107)
ER- (77) Non-Relapse (129) Non-Relapse(179)
The number of patients (in parenthesis) relative to the following clinical information: the
ER status (ER+, ER-), the occurrence of the relapse in Lymph Node negative (N-) ER+
patients (Relapse, Non-Relapse), the occurrence of Relapse (Relapse, Non-Relapse).
Another technical issue concerned the gene expression arrays normalization. As
a matter of fact the available gene expression matrix was normalized by using
MAS5 algorithm, while we used RMA to normalize all the other datasets. To
evaluate the effect of a different normalization method on gene expression data,
we renormalized our previously collected gene expression datasets with the MAS5
method, repeated the analyses, and compared the results with those obtained
with the RMA normalized data. We found that the lists of significantly regulated
probe sets were almost identical with similar p-values and fold changes. The
addiction of this dataset in our analysis allowed us to have three datasets with
information on ER status (not available in the Pawitan and EORTIC datasets).
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2.1.3.5 The EORTC 10994BIG 00-01 dataset
The EORTIC dataset is composed by 161 arrays and is part of EORTC
10994 phase III breast cancer clinical trial comparing non-taxane regimen (5-
fluorouracil, cyclophosphamide, epirubicin) with a taxane regimen (epirubicin,
docetaxel) in women with estrogen receptor negative breast cancer ([187]). The
gene expression was measured using Affymetrix Hu-X3P chip containing the
whole exome. After the quality control procedure 5 arrays were flagged as du-
bious and retained after visual inspection while the remaining 156 arrays were
classified as good quality arrays. Finally we retained 156 arrays for subsequent
analysis. The clinical information we considered were:




2.1.3.6 The Minn dataset
The Minn dataset ([188]) is composed by an initial set of 121 expression profiles.
22 expression profiles were of breast cancer cell lines and 99 were of primary
breast tumors. We performed the quality control procedure only on the 99 sam-
ples of primary breast tumors. The expression profiles of the cell lines were
removed because no clinical information is possible for cell lines. After quality
control 4 arrays were flagged as dubious and removed after visual inspection and
2 arrays were flagged as rejected. 93 arrays were retained as good quality arrays
for GSEA analysis. Gene expression analysis was performed using HG-U133A
GeneChip (Affymetrix). The clinical information we considered for GSEA anal-
ysis were (see Table 2.9):
• Estrogen Receptor (ER) status
• Relapse due to Metastatic Event
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Table 2.9: Minn dataset clinical information detail.
ER status Relapse due to Metastatic Event
ER+ (52) Relapse (26)
ER- (41) Non-Relapse (52)
The number of patients (in parenthesis) relative to the following clinical information: the
ER status (ER+, ER-), the occurrence of relapse due to the Metastatic Event (Relapse,
Non-Relapse).
2.1.3.7 The Sotiriou dataset
The Sotiriou dataset contains information on 189 patients with primary operable
invasive breast cancer. The frozen tumor specimens were obtained from two
institutes: the John Radcliffe Hospital (Oxford, UK) and the Uppsala University
Hospital (Uppsala, Sweden). RNA samples from Oxford (101 total samples)
were processed at the Jules Bordet Institute in Brussels, Belgium ([189]). For
the Uppsala samples (88 in total), RNA was extracted at the Karolinska Institute
and processed at the Genome Institute of Singapore. Some of the patients were
treated with tamoxifen while others were not. Table 2.10 shows the partition of
the samples with respect to the institute of origin and treatment.
Table 2.10: Sotiriou dataset institutes of origin.
Origin (label) Samples Treatment
Uppsala (KIT) 24 YES
Oxford (OXFT) 40 YES
Uppsala (KIU) 64 NO
Oxford (OXFU) 61 NO
Partition of the samples in the Sotiriou dataset with respect to the institute of the origin
and the treatment.
Gene expression analysis was performed with Affymetrix Human Genome U133A
microarray platform. We performed the quality control procedure on the Sotiriou
dataset, which led to the exclusion of 5 arrays, leaving 184 for the successive anal-
ysis. The fact that the samples were from different institutes and had undergone
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different manipulations was a reason of concern. We checked for the presence
of batch effects by analyzing the distribution of the measured signal before and
after the normalization procedure (raw and normalized signal). Unfortunately
even after the normalization, the difference between the Oxford and the Uppsala
data sets was still present: the Uppsala and the Oxford samples form two per-
fectly separated groups. Specifically the OXFT and the OXFU form two separate
groups while there is no difference between the KIT and the KIU groups. We,
therefore, concluded that it was inappropriate to treat the data as a single data
set. Thus, we analyzed only the arrays from the Uppsala group that had passed
the initial quality control and specifically the 63 (on 64 total) samples from the
KIU group. We excluded the samples of the KIT group because of the clinical
information were not available. The clinical information we considered for GSEA
analysis were (see Table 2.11):
• Elston (NGS) Tumor Grade.
• Estrogen Receptor (ER) status.
• Relapse Free Survival [RFS].
Table 2.11: Sotiriou dataset clinical information detail.
Tumor Grade ER status RFS
G1(26) ER+ (53) Relapse (11)
G2(27) ER- (10) Non-Relapse (52)
G3(9) - -
The number of patients (in parenthesis) relative to the following clinical information: the
Tumor Grade (Grade 1 [G1], Grade 2 [G2], Grade 3 [G3]), the ER status (ER+, ER-),
the occurrence of Relapse (Relapse, Non-Relapse).
Materials & Methods 49
2.1.3.8 The Hatzis dataset
The Hatzis dataset ([190]) is composed by 508 total patients with newly diag-
nosed ERBB2 (Her2 or Her2/neu) negative invasive breast cancer treated with
taxane and anthracycline (and endocrine therapy for estrogen receptor positive
patients) in neoadjuvant and adjuvant regime in a multicentric study. They are
divided into the Discovery and Validation set. The Discovery set comprises 310
patients while the Validation set comprises 198 patients. All gene expression
microarrays were profiled in the Department of Pathology at the M. D. Ander-
son Cancer Center (MDACC), Houston, Texas with Affymetrix Human Genome
U133A microarray platform. We performed the quality control on the full set
of patients: the discovery and the validation set. Three chips were classified as
bad quality chips and they were rejected while 68 were classified as doubt chips.
We decided to reject all the dubious chips because this dataset was used to vali-
date the cancer modules identified through the GSEA analysis. This allowed us
to avoid the effects of technical artifacts on the validation step of our pipeline.
Finally we retained 437 arrays for subsequent analysis. The clinical information
we considered were (see Table 2.12):
• Elston (NGS) Tumor Grade.
• Estrogen Receptor (ER) status.
• Distant Relapse Free Survival [DRFS].
The Distant Relapse Free Survival was defined as “the interval from initial diag-
nostic biopsy until diagnosis of distant metastasis or death from breast cancer,
non breast cancer or unknown causes”.
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Table 2.12: Hatzis dataset clinical information detail.
Tumor Grade ER status DRFS
G1(30) ER+ (245) Relapse (100)
G2(146) ER- (186) Non-Relapse (128)
G3(224) - -
The number of patients (in parenthesis) relative to the following clinical information: the
Tumor Grade (Grade 1 [G1], Grade 2 [G2], Grade 3 [G3]), the ER status (ER+, ER-),
the Distant Relapse Free Survival [DRFS] (Relapse, Non-Relapse).
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2.1.3.9 The Kao dataset
The Kao dataset ([191]) is composed by 327 total patients. 312 breast cancer
patients were diagnosed and treated between 1991 and 2004 at the Koo Founda-
tion Sun-Yat-Sen Cancer Center (KFSYSCC) while 15 lobular breast carcinoma
samples were collected between 1999 and 2004 at the KFSYSCC. All patients
received radiotherapy, adjuvant chemotherapy, and/or hormonal therapy if indi-
cated, after the surgical resection of the tumor. Patients with locally advanced
disease received the neoadjuvant chemotherapy too. Gene expression analysis
was performed with Affymetrix Human Genome U133 Plus 2.0 platform. After
the quality control analysis, 26 arrays were classified as doubt chips and were
removed. Finally we retained 301 good quality chips. The clinical information
we considered were (see Table 2.13):
• Relapse (Metastatic Event).
• Survival.
Table 2.13: Kao dataset clinical information detail.
Relapse (Metastatic Event) Survival
Relapse (74) Dead (74)
Non-Relapse (227) Alive (227)
The number of patients (in parenthesis) relative to the following clinical information:
the Relapse due to a metastatic Event (Relapse, Non-Relapse), and the Survival (Dead,
Alive).
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2.1.4 Gene Set Enrichment Analysis
Gene Set Enrichment Analysis (GSEA) was performed using the R-GSEA pro-
gram (GSEA-P-R.1.0). The Signal2Noise (S2N) metric was used for gene rank-
ing according to the gene expression regulation across the phenotype labels. The
statistical significance of the Enrichment Score (ES) was assessed through an em-
pirical phenotype-based procedure consisting of 1,000 permutations of the Phe-
notype Labels (PhLs). In addition, we randomly selected a set of 20 lists of genes
by using, as universe, the 4,697 unique genes derived from all the collected 23
signatures. These random gene lists were used as an additional control for the
significance of our results (see Results, Subsection 3.1.1). The initially collected
23 oncogenic gene signatures and the 20 randomly generated gene sets represent
our a priori defined set of genes S while each gene expression cohort previously
retrieved, preprocessed, normalized and annotated for gene symbols represents
the Expression datasets. All the remaining parameters were as by default.
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2.2 GRN inference analysis on Cancer Modules genes
(CM-genes)
Network inference on cancer module genes (CM-genes) was performed using
ARACNE algorithm ([133],[131]). CUDA-MI ([192]) and WGCNA ([193])
algorithms were used to benchmark the pairwise interactions inferred using
ARACNE. The Loi et al. breast cancer dataset ([194]) was used for Gene
Regulatory Network inference (GRNi). This dataset was an independent tran-
scrptional dataset with respect to those previously used for the GSEA analysis
in order to avoid data overfitting, and it was large enough (≥ 100 samples)
to account for ARACNE network inference analysis requirements ([133]). Mi-
croarray gene expression profiles (Affymetrix HG-U133A array 2.0 array) were
retrieved from GEO database, (http://www.ncbi.nlm.nih.gov/geo/) at the
following accession number: GSE6532. We applied the quality control procedure
previously described (see Subsection 2.1.2) retaining 327 microarrays classified
as good quality microarrays for subsequent analysis. No “doubt chips” or “re-
jected chips” were flagged. Microarray chips were normalized by using MAS5
algorithm (Affymetrix 2002) because, as demonstrated by Lim et al. ([195]) it
provides the most faithful cellular network reconstruction (i.e. with a reduced
fraction of False Positive (FP) inferred interactions) respect to the normalization
performed with RMA, GCRMA and Li-Wong ([196]) representing the frequently
used normalization methods for microarray data. The normalized data were log2
transformed and Affymetrix probesets were annotated to Unique Gene Symbols
(see Subsection 2.1.2). Gene expression relative to 13,211 unique gene symbols
and 1,258 not annotated probe sets was finally considered for network infer-
ence analysis. For each network inferred around each single CM-gene by using
ARACNE, CUDA-MI and WGCNA algorithms, the first 100 best correlating
genes (neighbors) having the highest measured correlation score with respect to
the hub gene (CM-gene) were considered. The concordance analysis was per-
formed to measure the extent of the overlap of the inferred networks by using
the three independent algorithms. The Cohen test (R, version 2.15.1) was used
to test significance of the concordance analysis results.
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2.2.1 GRN inference analysis using ARACNE
The adaptive partitioning algorithm was used for gene expression values dis-
cretization. The statistical p-value for mutual information (MI) threshold was
set to 1e-7, while the data processing inequality (DPI) tolerance was set to 0.1
(default settings). One thousand bootstrap iterations were performed to assess
the statistical significance of the inferred transcriptional pairwise gene interac-
tions. The p-value threshold to construct the consensus network after bootstrap
analysis was set to 1e-6. A total of 1,516 genes (i.e. representative of the 7 major
Cancer Modules) out of 1,652 total genes in Cancer Modules were used as marker
list (hubs) for network inference. We further reduced the gene list to 1516 genes
because the FANCD2 gene was not represented on the Affymetrix HG-U133A 2.0
chip but it is represented on the Affymetrix HG-U133B 2.0 array. The analysis
was performed on a Linux cluster of 12 nodes with a total of 288 hyperthreaded
cores and 1.2 TB RAM memory.
2.2.2 GRN inference analysis using CUDA-MI
The number of bins for gene expression data discretization and the order of spline
functions were set to 10 and 3, respectively. The algorithm was run on a NVIDIA
Tesla C3050 GPU machine.
2.2.3 GRN inference analysis using WGCNA
Soft thresholding power estimate for scale-free topology approximation was set
to 8. The resulting adjacency matrix was used. WCGNA R package was used to
infer GRNs.
Materials & Methods 55
2.3 Cancer Modules (CMs) somatic mutation
annotation
CM-genes were annotated for the presence of somatic mutations using the Cat-
alogue Of Somatic Mutations in Cancer (COSMIC http://cancer.sanger.ac.
uk/cancergenome/projects/cosmic/) and The Cancer Genome Atlas (TCGA
http://cancergenome.nih.gov/) repositories. All the statistical tests were per-
formed using the R (version 2.15.1) library stats.
2.3.1 Cancer Modules (CMs) somatic mutation annotation:
COSMIC
Only the breast cancer mutations relative to primary tumors annotated in the
Cancer Gene Census of COSMIC v61 database were considered for the annotation
for a total of 5,416 mutations (238 genes). The following criteria were applied in
order to further identify a subset of candidate mutations for the annotation:
• Available PubMed ID.
• Available genomic position.
• Validation of the mutation as somatic mutation.
• Mutation identified in primary tumors (i.e. tumor origin).
From the initial set of 5,416 breast cancer mutations in Cancer Gene Census,
1,781 final somatic mutations were retained for a total amount of 238 unique
genes. The final set of mutated genes was used for the annotation of 1,652 genes
composing the Cancer Modules. To check for the statistical significance of the
enrichment of mutated genes in Cancer Modules, a set of 1,000 random lists of
1,652 genes length was generated through sampling with replacement using 19,639
genes as starting universe (i.e. all the genes annotated in the original microarray
platforms used for CMs identification: Affymetrix HG-U133A and HuX3P chip).
A Shapiro-Wilk test to check for the normality of the distribution of annotated
mutated genes in random lists was performed with a p-value < 0.05 (2.2e-16).
The enrichment of mutated genes in CMs was evaluated by performing a propor-
tion test between the total amount of mutated genes of each random list and the
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total amount of mutated genes in the Cancer Modules. A Benjamini-Hochberg
multiple testing correction was applied on the full set of comparisons. Only the
comparisons showing an FDR< 0.01 were considered statistically significant.
2.3.2 Cancer Modules (CMs) somatic mutation annotation:
TCGA
The mutational annotation was performed by using the breast invasive car-
cinoma [BRCA] dataset (CGA Network, 2012, http://www.cbioportal.org/
public-portal/). A total amount of 7,136 unique mutated genes on 463 total
complete tumors (available data relative to: mRNA, miRNA, methylation, CNA,
whole exome-sequencing) were used for the mutational annotation. The statisti-
cal analysis pipeline to check for a the significance of the enrichment of mutated
genes in Cancer Modules was as previously described for COSMIC mutational
annotation (see Subsection 2.3.1).
2.3.3 Mutational annotation of GRNs and mutual mxclusivity
analysis
Mutual exclusivity analysis was performed on the gene neighbors of the GRNs
found to be mutated according to the mutational annotation performed us-
ing TCGA [BRCA] data (CGA Network, 2012, http://www.cbioportal.org/
public-portal/). Mutational data relative to only complete tumors (available
data relative to: mRNA, miRNA, methylation, CNA, whole-exome sequencing)
were used, for a total amount of 463 tumor samples matching the selection criteria
and 7,136 unique mutated genes. For the generation of the 1,000 random gene
lists we used the genes represented on the Affymetrix HG-U133A platform as
universe prior to random lists generation because the networks from CM-genes
were inferred from Affymetrix HG-U133A transcriptional profiles (see Subsec-
tion 2.2.1). This allowed us to be consistent with the network inference analysis
we performed, avoiding the effect of the overrepresentation of genes in the ran-
dom set due to a different universe of genes. We firstly annotated the 22.215
Affymetrix HG-U133A probe sets to 14,469 unique gene symbols that were sub-
sequently mapped on the TCGA dataset gene symbol annotation. This was done
in order to remove the discrepancies of gene names annotation between two dif-
ferent sources of data. Finally, the universe was composed by a curated list of
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13,397 genes. Both, random lists and the inferred networks were annotated for
the presence of mutated genes. Multiple mutations per gene were considered only
once to avoid the bias of different frequency of mutation per gene. We performed
a two-tailed proportion test (with 95% CI) followed by a BH correction for mul-
tiple testing in order to investigate for a statistically significant enrichment (i.e.
in terms of number of genes) of mutually exclusive mutated genes in the inferred
GRNs respect to the random gene lists. Specifically we compared the number
of genes having a mutually exclusive pattern in each GRN with the number of
genes with a mutually exclusive pattern in each one of the 1,000 gene lists. The
statistical tests were performed using R version 2.15.1. Only the comparisons
showing an FDR< 0.01 were considered statistically significant.
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2.4 The Concordance analysis
The occurrence of gene expression patterns defining the transcriptional activity
(activation/inhibition) of the inferred GRNs and MR-gene networks was deter-
mined by a scoring strategy. By using this approach, it was possible to deter-
mine the concordance of the GRNs in terms of the gene expression regulation
of the gene neighbors. The concordance (i.e. the transcriptional activity of
the networks) was evaluated on the transcriptional profiles of 997 breast tumors
(Metabric study Discovery set [36]). The pre-processed gene expression matrix
was used. The Illumina Human WG-v3 probes were annotated to human gene
symbols by using HUGO gene name annotation. The absolute intensities ex-
pressed on a logaritmic scale were transformed to obtain a log ratio of the gene
expression measures by subtracting raw-wise (gene-wise) the median expression
from the measurement in each sample. For further details on the scoring strategy
see Results, Subsection 3.5.1.
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2.5 Gene set analysis of transcriptionally active net-
works in Triple Negative Breast Cancer (TNBC)
patients
The gene expression dataset for the enrichment analysis was retrieved form
GEO at the following accession ID GSE25066 ( http://www.ncbi.nlm.nih.gov/
geo/). It contains a discovery and a validation cohort of patients. In both co-
horts, patients were treated with neoadjuvant taxane-anthracycline chemotherapy
(NACT). The gene expression profiles refer to human breast tissues before any
systemic therapy. For our analysis both cohorts of patients were considered (508
total patients) to increase statistical power. Raw data were downloaded and pre-
processed (see Subsection 2.1.2 for the quality control procedure, normalization
and gene symbol annotation). After the quality control procedure we retained 437
total expression profiles. The gene expression matrix was raw-wise (gene-wise)
centered on the median gene expression value across all samples by subtracting
for each gene and for each patient the median gene expression value from the
log2 normalized expression measures. The gene set analysis was performed by
using two independent computational methods: the GSEA ([197]) and the GSA
([198]). GSEA analysis was run by using the R-GSEA program (GSEA-P-R.1.0)
and the GSA analysis by using the R software package GSA. The analysis was per-
formed on data normalized according to three different normalization procedures:
the RMA, the MAS5 normalization and the normalization reported in [190] on a
set of 152 Triple Negative Breast Cancer (TNBC) transcriptional profiles passing
the quality control procedure. TNBC patients were selected, from the associated
clinical data, according to the histopathological negativity to ER, PgR and Her2
receptors. The pathologic response following NACT was considered as clinical
variable for gene ranking. Specifically, the enrichment of the transcriptionally ac-
tive networks was evaluated respect to the pathologic complete response (pCR;
52 patients) and Residual Disease (RD; 100 patients) based on RECIST criteria.
For the GSEA analysis parameters setting see Subsection 2.1.4. For the GSA
analysis we used the maxmean method for summarizing a gene set as by default
and we performed 1,000 permutations to estimate false discovery rates.
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Results
A synthetic representation of the computational pipeline used to infer
breast cancer-related GRNs from microarray gene expression data.
To infer breast cancer-related GRNs from microarray gene expression data we
used a pathway-centric approach (Figure 3.1) in which we firstly retrieved pub-
licly available oncogenic gene sets representing collections of genes whose ex-
pression levels are modulated according to an experimentally induced genetic
perturbation on known oncogenes and tumor suppressor genes. We then investi-
gated, through the Gene Set Enrichment Analysis (GSEA), the enrichment of the
oncogenic gene sets in breast cancer microarray expression profiles from tumor
patients (Discovery set) according to a set of clinical-pathological parameters
(i.e., tumor grade, ER status, nodal status and prognosis) used as Phenotype
Labels (PhLs). We then identified, by clustering, groups of “core genes” (i.e.
Cancer gene Modules, CMs) from the enriched oncogenic gene sets whose ex-
pression significantly correlated with the pathological variables we used. We
confirmed the enrichment of the CMs according to the clinical-pathological vari-
ables we used before, by performing the GSEA analysis of CMs on an indepen-
dent set of breast cancer microarray expression profiles (Validation set). GRNs
were then inferred by assuming each gene in CMs (i.e. CM-gene) as marker
or ‘hub” gene of the network and by searching for all possible gene neighbours
among all the expressed genes in cancer cells. Networks were inferred by using
primarily ARACNE algorithm ([133]). We also performed a network inference
analysis by using two independent algorithms (CUDA-MI ([192]) and WGCNA
([193]) in order to confirm the transcriptional statistical interactions predicted by
the ARACNE algorithm. A statistical concordance analysis was then performed
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in order to compare the gene neighbours of the CM hub gene predicted by the
three independent algorithms. A mutational annotation was then performed on
CM-genes and on the GRN genes, in order to gain insights into the possible
role of the CM-genes as oncogenic gene drivers and of the inferred GRNs as
possible oncogenic mechanisms. The mutational annotation was performed by
using the mutational data from COSMIC (Census) and TCGA databases. We
then performed a mutual exclusivity analysis of the mutated genes composing the
GRNs in order to investigate the role of the breast cancer mutated genes (i.e.
the mutational landscape of breast cancer) in a network context of predicted
interacting genes. We then selected two subsets of putative biologically relevant
networks in breast cancer biology: the first set of networks contains GRNs in-
ferred from mutated CM-genes while the second set contains GRNs enriched in
mutually exclusive mutated genes. From the two sets of networks, we performed
an in deep network deconvolution analysis in order to identify the transcriptional
“hub” of the network (i.e. the transcriptional candidate regulator), to overcome
the initial bias of assuming each one of the CM-genes as the hub genes of the
network. We then inferred GRNs (MR-GRNs) from the predicted transcriptional
hub gene we called candidate Master Regulator (MR) gene of each CM-GRN. A
transcriptional analysis of the CM and MR-GRNs inferred from the two sets of
CM-networks was performed by using the Metabric breast cancer gene expres-
sion dataset in order to investigate the transcriptional profile of the networks. A
concordance scoring strategy was identified to define the transcriptional activity
of each one of the networks according to the number of gene neighbours having
the same or the opposite gene expression modulation (up or down-regulation)
with respect to the expression of the hub gene. From the concordance analysis, a
subset of CM and MR-networks was selected as transcriptionally significantly ac-
tive. Through the GSEA analysis, the enrichment of them was evaluated in gene
expression profiles from Triple Negative Breast Cancer (TNBC) patients with
Residual Disease (RD) pathological condition after neoadjuvant chemotherapy
versus patients with Pathological Complete Response (pCR) in order to propose,
for further investigation, putative mechanisms of gene expression regulation as-
sociated with the clinical condition and novel candidate biomarkers and drug
targets for therapy.
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Figure 3.1: The computational pipeline used to infer breast cancer-related GRNs
from microarray gene expression data.
Results 63
3.1 Breast Cancer gene Modules (CMs)
3.1.1 Oncogenic gene sets enrichment analysis
We characterized the expression profiles of 23 oncogenic gene sets in independent
cohorts of breast cancer patients, with the aim of identifying groups of genes (gene
modules) whose expression significantly correlated with clinical-pathological pa-
rameters (i.e., tumor grade, ER status, nodal status, and prognosis, Figure 3.2).
We preferred to use the Gene Set Enrichment Analysis (GSEA) algorithm for
this characterization, since it analyzes the expression profiles of entire gene sets,
representative of specific biological functions, rather than the expression pro-
files of individual genes. We retrieved microarray gene expression data from
5 independent cohorts of breast cancer patients (the “Discovery Set”), making
a total of 1,019 patients (Table 2.3), with complete clinical-pathological infor-
mation (Table 3.1). In the Discovery Set we performed GSEA to assess the
enrichment (ES, enrichment score) of the 23 oncogenic gene sets in breast cancer
patients stratified by tumor grade (e.g., G3 or G1), ER status (ER+ or ER-
), survival (dead or alive), and relapse (regional or distant). Importantly, the
GSEA enrichment analysis of the 23 gene sets was performed independently in
the 5 cohorts of breast cancer patients, in order to preserve cohort-dependent bi-
ological variability. Clinical-pathological characteristics of patients were defined
as “Phenotype Labels (PhLs)” and the ESs were calculated using the Weighted
Kolmogorov-Smirnov test that reflects the degree of differential expression of a
gene set according to the selected PhLs.
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Figure 3.2: Oncogenic gene sets enrichment strategy.
The in silico pipeline relative to the enrichment analysis of the 23 oncogenic gene sets on
expression profiles is reported. The transcriptional correlation of the oncogenic gene sets
(i.e. groups of genes showing a coordinate change in gene expression upon experimen-
tally induced stimuli on oncogenes and tumor suppressor genes representing the major
hallmarks of cancer) was evaluated through the GSEA algorithm on 5 breast cancer gene
expression datasets. 4 out of 5 expression profiles were performed on Affymetrix HG-
U133A platform while 1 was performed on Hu-X3P platform. The GSEA analysis was
performed by considering the following PhLs: tumor grade, ER status, survival and re-
lapse. A typical enrichment plot is reported showing the running ES of a gene sets when
comparing ER+ tumours versus ER- tumours.
The statistical significance of the computed ESs was estimated by a 1,000 time
permutation test (as by default) in which the PhLs associated with each microar-
ray expression profile were randomly shuﬄed. This allowed us to create a robust
empirical null distribution of the ES measures for the nominal p-value calculation.
Furthermore, to prevent errors in the inference of significantly enriched gene sets,
we used the False Discovery Rate (FDR) q-value, instead of the nominal p-value,
to account for the multiple testing problem. Gene sets were deemed significantly
enriched if the FDR was less than 25%. In addition, we applied a normalization
procedure on the full set of GSEA enriched gene sets (FDR < 25%), in order
to control the effect of non-homogeneous distribution of clinical-pathological pa-
rameters in the datasets (see Table 3.1). Briefly, for each gene set and for each
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clinical-pathological condition (PhL), we counted the number of patient cohorts
in which the gene set was enriched. This number was then divided by the total
number of cohorts with the relative clinical-pathological condition (PhL). The




where S represents the Normalization Score; Sxj represents, for each significantly
q-value < 25%) enriched gene set (x= 1,...23), the number of cohorts in which it
was enriched (j = 1,...5); and Nj represents the total number of cohorts in which
the clinical-pathological variable was available (Nj = 1...5 for the Discovery Set).
We then established a threshold for the selection of enriched gene sets after
the normalization procedure. To do this, we performed GSEA on a set of 20
randomly generated gene sets in the Discovery Set. After the enrichment anal-
ysis and the normalization procedure, three random gene sets appeared to be
enriched (q-value < 25%) according to tumor grade (in 1 out of the 11 cohorts,
considering each grade independently; 9%), and to ER status (in 1 out of 4
cohorts; 25%), (Table 3.2). Therefore, according to the “Normalization Score,
(S)” obtained using random gene sets, we established cut-off for selection of the
final core of significantly enriched oncogenic gene sets, which should have an
“S” above the 25%, i.e. the S relative to enrichment of random signatures in
the ER pathological condition. We found 18 gene sets with S> 25% that we
considered significantly enriched (Table 3.2). This “core set” represents 78% of
the initial set of oncogenic gene sets (18 out of 23). Specifically, the gene sets
composing the “core set” are: E1A, ZEB1, TP53, TERT, MYC/TGFA, E2F1,






Table 3.1: Breast cancer Clinical-pathological conditions and cohort-specific samples distribution relative to the Discovery set.
Clinical-pathological parameter Ivshina Pawitan TRANSBIG Wang EORTC Total
G1 66 28 27 - - 121
G2 121 58 80 - 36 295
G3 55 61 80 - 68 264
ER+ 204 - 128 209 - 541
ER- 34 - 61 77 - 172
Relapse 85* 38 51 107 - 281
Non-Relapse 157* 112 138 179 - 586
N0 ER+ Relapse 33 - 28 80 - 141
N0 ER+ Non-Relapse 33 - 100 129 - 262
Dead (Survival) 85* 27 56 - - 168
Alive (Survival) 157* 123 133 - - 413
Table reports the number of patients associated with specific clinical-pathological characteristics, used as phenotype labels (PhLs) in the GSEA analysis,
for each of the 5 cohorts (Ivshina, Pawitan, TRANSBIG, Wang, EORTC) of the Discovery Set. Clinical-pathological parameters reported include: tumor
grade (G1, G2, G3); estrogen receptor (ER) status, ER-positive (ER+) vs. ER-negative (ER-); relapse status (relapse vs. non-relapse); local/distant relapse
(node-negative (N0) ER+ relapse vs. N0 ER+ non-relapse primary tumors; survival (dead or alive). *patients were assigned to both relapse and survival





Table 3.2: Significantly enriched gene sets after the normalization procedure.
Gene set Grade(%) ER(%) Relapse(%) N0 ER+ Relapse(%) Survival(%)
E1A 77 100 40 75 100
ZEB1 - 25 - - 33
TP53 55 62 20 - 33
TERT 55 100 - - -
MYC/TGFA - 50 - - -
E2F1 9 50 - - -
MYC 86 58 40 25 67
KRAS - 25 - - 33
HRAS - 75 - - -
YAP/TAZ 55 75 - - -
HIF1A/HIF2A 63 63 40 25 67
ERBB2 36 25 20 - 33
BCAT 18 - 20 - 33
BRCA1 55 88 - - 33
CIN 82 100 60 100 68
E2F3 9 50 - - -
EGFR - 50 - - -
MYC/E2F1 64 75 20 25 33
RANDOM 12 9 - - - -
RANDOM 20 9 25 - - -
RANDOM 6 9 25 - - -
Number of cohorts per clinico-pathological parameter 11 4 5 4 3
The GSEA significantly enriched gene sets, along with associated normalization score (S, shown as a percentage), is reported for each clinical-pathological
condition. For each condition, the number of cohorts in the “Discovery Set”, for which data on the selected condition was available, is also reported. For the
clinical variable “Grade” , the G1, G2 and G3 levels were considered independently and the availability of the clinical information across the cohorts of the
“Discovery Set” was considered for each level. In red are highlighted the rejected gene sets according to the cut-off derived from the enrichment observed in
the random gene lists RANDOM 12, RANDOM 20 and RANDOM 6 (see main text). The absence of enrichment after GSEA analysis (q-value > 25%) is
reported as “-” symbol.
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3.1.2 Definition of Cancer Modules
We subsequently selected those genes in the 18 “core” gene sets that contributed
most to the enrichment of these gene sets in the PhLs analyzed. This group of
genes, identified as “core genes” by GSEA analysis is made up of 1,652 unique
genes. We summarized the enrichment results for each PhL in an N x M binary
matrix, in which the rows (N) represent the full set of 1,652 genes and the
columns (M) represent the full list of PhLs considered. We numerically indexed
the matrix with two integers: 1, indicating the gene-wise significant enrichment
in a particular PhL; 0, indicating the gene-wise non-significant enrichment in
a particular PhL. We then applied the Hierarchical Cluster Analysis (HCA) to
the binary matrix in order to cluster together the core genes according to the
relative PhLs enrichment. The cluster analysis allowed us to identify 15 groups
of core genes (clusters) enriched according to each single PhL or according to
combinations of PhLs (Figure 3.3). Of the full set of 15 gene clusters, we selected
7 “major clusters” that contained a number of genes greater than 5% of the total
(1,652 genes). By using this criterion we wanted to prioritize more “biologically”
informative clusters of genes in the specific PhLs (Figure 3.3). This subset of
clusters represents our set of “Cancer Modules (CMs)”, i.e., groups of genes whose
expression correlates with specific clinical-pathological conditions associated with
breast cancer. The number of the genes relative to each one of the 7 selected





















Phenotype Labels (PHLs) 
Figure 3.3: Definition of Cancer Modules.
The heatmap of the enrichment of the GSEA “core genes” (y-axis) belonging to the 18
enriched “core” gene sets, with respect to the PhL considered (reported on the x-axis).
The “core genes” were clustered (HCL) according to the enrichment observed in each
PhL. Red color indicates the enrichment of a core gene in the PhL considered ( x-axis).
The color bar on the right-side of the y-axis highlights the 7 CMs. From the top to the
bottom the CMs are defined as: Grade, Grade/ER, All, Relapse/Survival/Grade/ER,
Survival/Grade/ER, ER, Survival.
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The number of genes in each Cancer Module (CMs) is reported.
The composition of the CMs in terms of the enriched gene sets is reported in
Figure 3.4. The most representative gene sets per CM are:
• Grade: MYC, E1A, ERBB2.
• Grade/ER: MYC, E1A, BRCA1, TERT, TP53.
• All: YAP/TAZ, E1A, CIN, MYC.
• Relapse/Survival/Grade/ER: MYC, E1A, HIF1A/HIF2A.
• Survival/Grade/ER: BRCA1, ERBB2, E1A, MYC/E2F1, E2F1, MYC/T-
GFA.
• ER: HRAS, EGFR, HIF1A/HIF2A.


























































































Figure 3.4: Oncogenic gene set distribution across the Cancer Modules (CMs).
The most representative gene sets for each Cancer Module (CM) are reported. On the
x-axis the genes of the relative Cancer Module are reported. On the y-axis the enriched
gene sets are shown. Yellow bars indicate the fraction of the genes in each Cancer Module
relative to enriched gene set reported on the y-axis. Overlapping bars indicate that the
enriched gene sets share a fraction of genes that are in common.
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3.1.3 Independent validation of Cancer Modules
We performed an in silico validation of the CMs using GSEA on an independent
set of 4 breast cancer patient cohorts (the “Validation set”) for a total of 916
individuals (Figure 3.5; Tables 2.3 and 3.4). This in silico validation was per-
formed in order to assess the robustness of the observed CM enrichment with
respect to the PhLs in an independent set of patients (“Validation set”). As
for the Discovery Set, after a 1,000 times permutation test of PhLs, we defined
only the CMs with an FDR q-value of less than 25% as significantly enriched.
We were able to confirm 6 out of 7 CMs as significantly enriched in at least one
dataset of the “Validation Set”, (Table 3.5 and Figure 3.5). The enrichment we
observed confirmed the association, at the level of gene expression, of the genes
composing the CMs with the considered PhLs. The schematic computational
pipeline used to identify and validate CMs is reported in Appendix A in green.
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Table 3.4: Clinical-pathological characteristics of breast cancer patients belonging
to the 4 cohorts constituting the Validation Set.
Clinical-pathological condition Minn Sotiriou Hatzis Kao Total
G1 - 26 30 - 56
G2 - 27 146 - 173
G3 - 9 224 - 233
ER+ 52 53 245 - 298
ER- 41 10 186 - 196
Relapse 26 11 100 74* 211
Non-Relapse 52 52 128 227* 459
N0 ER+ Relapse - - - - -
N0 ER+ Non-Relapse - - - - -
Dead (Survival) - - - 74* 74
Alive (Survival) - - - 227* 227
Table reports the number of patients associated with specific clinical-pathological charac-
teristics, used as phenotype labels (PhLs) in the GSEA analysis, for each of the 4 cohorts
(Minn, Sotiriou, Hatzis, Kao) of the Validation Set. Clinical-pathological parameters re-
ported include: tumor grade (G1, G2, G3); estrogen receptor (ER) status, ER-positive
(ER+) vs. ER-negative (ER-); relapse status (relapse vs. non-relapse); local/distant re-
lapse (node-negative (N0) ER+ relapse vs. N0 ER+ non-relapse primary tumors; survival
(dead or alive).
*patients were assigned to both relapse and survival clinical pathological variables due to
ambiguous definition by the authors.
Table 3.5: Computational validation of Cancer Modules (CMs) enrichment.
Cancer Module ER Grade Relapse Survival
Grade - 2 - -
Grade/ER 3 2 - -
All 3 2 1 0
Relapse/Survival/Grade/ER 3 2 1 0
Survival/Grade/ER 3 2 - 1
ER 3 - - -
Survival - - - 0
Tot 3 2 4 1
Table reports the number of cohorts in which each Cancer Module (CM) shows a statis-
tically significant enrichment with respect to the total (Tot) number of cohorts, in the
Validation set, possessing the relative pathological information. The absence of a statis-
tically significant enrichment is reported as 0, while “-” indicates the absence of datasets
with the specific PhL (reported as columns).
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GSEA 
FDR : 0.029 
CANCER MODULES  
FDR : 0.002 
Grade All 




FDR : 0.046 
FDR : 0.029 
BREAST CANCER  
GENE EXPRESSION PROFILES 





Affymetrix HG-U133A  
PhLs: Grade, ER status, survival and relapse  
Figure 3.5: Validation strategy for the Cancer Modules and Enrichment Results.
The in silico validation pipeline for the 7 CMs is reported. GSEA analysis was performed
using the CMs as gene sets on 4 independent cohorts of patients, the Validation Set.
The phenotype labels (PhLs) used in the GSEA analysis are: tumor grade, ER status,
survival, relapse. Four GSEA enrichment plots are reported as representative examples
of CM validation: Grade, All, ER and Grade/ER with associated FDR q-values. (Hatzis
et al. dataset([190]), 437 patients).
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3.2 Reverse Engineering Gene Regulatory Networks
3.2.1 Reverse engineering of Gene Regulatory Networks
using ARACNE algorithm
We inferred networks of transcriptionally correlating genes starting from the full
list of genes of the 7 CMs (see the computational pipeline in Appendix A, black
section). We performed the network inference analysis in order to identify bio-
logical processes relevant to breast cancer progression that can be used for the
selection of cancer biomarkers and possible novel drug targets. Specifically, we
performed a network inference analysis by centering network growth on each of
the CM-genes (1,516 genes in total) that represent the hub/marker gene around
which the transcriptional correlations (i.e. the edges connecting two genes of
a network) were inferred. Using this strategy, we built a total of 1,516 gene
networks to be further investigated for their breast cancer relevance. The GRN
inference (GRNi) analysis (also called network deconvolution analysis) was per-
formed using the data-driven Algorithm for the Reconstruction of Accurate Cel-
lular Networks (ARACNE) ([131], [133])(see Subsection 2.2.1), which is based
on an information-theoretic method for system-wide reconstruction of complex
transcriptional networks from gene expression data. The transcriptional correla-
tion among genes was calculated through the Mutual Information (MI) measure
that estimates the amount of information one variable (gene X) contains about
another (gene Y), i.e., their mutual dependency. The total number of genes in
the full set of 1,516 GRNs was 14,293 genes and the MI measures spanned from
a minimum of 0.10 to a maximum of 1, where the higher the MI the stronger the
transcriptional correlation between two genes (i.e., the hub gene and its neigh-
bor). In order to select, for each network, the core genes that displayed the
highest degree of transcriptional correlation with the hub gene (i.e. the gene
neighbors of the hub gene with the highest MI score), we investigated the shape
of the distribution of the MI values for each inferred network. Due to the low
degree of overlap between the distributions of the MI scores across the networks
(Figure 3.6), the use of a unique MI based cut-off for the selection of the best
neighbor genes with respect to the hub gene was not feasible. We then used a
ranking strategy for the selection of the best correlating genes. For each network,
we ranked the neighbors by their MI values, from the highest to lowest, and se-
lected as best neighbors, the first 100 genes for each network with the highest
ranked MI measure. The total number of genes in the full set of 1,516 networks
was thus reduced to 11,721 unique genes.
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Figure 3.6: Distributions of Mutual Information measures.
The distributions of the Mutual Information (MI) measures of a representative subset of
the full set of 1,516 GRNs is reported. Different colours highlight the distribution of MI
measures relative to each single GRN. The distributions are clearly non-overlapping for
MI values greater than 0.2.
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3.2.2 In silico validation of the transcriptional correlations
predicted by ARACNE
To assess the robustness of the identified GRNs, in terms of their gene content and
predicted pair-wise transcriptional relationships, we performed GRNi analysis us-
ing two other independent methods: the Compute Unified Device Architecture-
Mutual Information computation (CUDA-MI) and the Weighted Correlation Net-
work Analysis (WGCNA) algorithms (see the computational pipeline in Ap-
pendix A, black section). As for the network inference analysis we performed
by using ARACNE algorithm, we assumed that each CM-gene was a hub gene
around which we could build the network of transcriptionally correlating genes.
Specifically, the CUDA-MI software implements the MI estimation using B-spline
functions proposed by Daub et al., to infer transcriptional correlations from high-
throughput gene expression data ([199]). The B-spline approach is an alternative
to the kernel-based MI estimation proposed by Margolin et al. ([133]); it propose
the use of polynomial B-spline functions to deal with the problem of assign data
points (expression values) to one bin or to the nearest one, in the discretization
(binning) phase of continuous gene expression measurements, when they are ex-
tremes of the numerical range of discrete intervals (bins). For data points near to
the border of a bin, in fact, small fluctuations due to biological or measurement
noise might shift these points to neighbouring bins affecting the resulting mutual
information, especially for datasets of small or moderate size ([199]) and gener-
ating unstable gene networks. To overcome such limitations, the gene expression
data point in the B-spline approach can be assigned simultaneously to weighted
multiple bins by a set of B-spline functions. The CUDA-MI software is based
on the Compute Unified Device Architecture (CUDA) programming model on
a graphics processing unit (GPU), in order to accelerate the B-spline function
for MI estimation in the case of large datasets. The WGCNA algorithm builds
weighted gene co-expression networks by “soft-thresholding” the correlation co-
efficient for gene-to-gene interaction predictions. Specifically, it thresholds the
pair-wise connection between two genes by a number in [0,1]. Thus, the tran-
scriptional correlation becomes a connection strength. The advantage of using
such a methodology is that it preserves the continuous nature of correlation infor-
mation, avoiding information loss due to dichotomization (1 = connected genes,
0 = unconnected genes), as well as sensitivity issues relating to choosing a sta-
tistical threshold. To build networks with WGCNA, we set the soft-thresholding
power β to 8 after visual inspection of network indices, in order to approximate
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the scale-free topology (Figure 3.7). The distributions of the correlation mea-
surements calculated using the three independent methods, ARACNE, CUDA-
MI and WGCNA, is reported for a subset of networks, as representative example
(Figure 3.8). As already observed in Subsection 3.2.1 the distributions of the
correlation measurements relative to each network are non-overlapping also ac-
cording to CUDA-MI and WGCNA algorithms, highlighting that the inferred
networks are heterogeneous between them, in terms of the degree of transcrip-
tional correlations with the gene neighbours, despite the computational method
used to infer them. Moreover, although ARACNE and CUDA-MI algorithms are
both based on MI computation, we observed that the distributions of the MI
measurements substantially differ between them, i.e., they are not overlapping.
This behaviour might be explained not only by the different way they perform
data discretization but also by the Data Processing Inequality (DPI) procedure
that is implemented in ARACNE and not in CUDA-MI algorithm. By remov-
ing putative indirect interactions through the DPI (i.e. according to the DPI
threshold, see Methods, Subsection 2.2.1), the set of gene neighbours of the hub
genes predicted by the two algorithms may differ as well as, consequently, the
MI measurements distributions. For each GRN inferred using ARACNE, CUDA-
MI and WGCNA, we subsquently selected the top 100 neighbors after ranking





Figure 3.7: Network topology for various soft-thresholding power indices.
Left panel, the graph shows the scale-free fit index (y-axis) as a function of the soft-thresholding power (x-axis). Right panel, the mean connectivity degree
(y-axis) is reported as a function of the soft-thresholding power (x-axis).
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Figure 3.8: Distribution of the correlation measurements computed by ARACNE,
CUDA-MI and WGCNA algorithms for a representative subset of GRNs.
The distributions of the correlation measurements computed respectively by ARACNE,
CUDA-MI and WGCNA methods relative to a representative subset of GRNs are re-
ported.
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To assess the robustness of GRNs derived, we evaluated the concordance (i.e.
gene content and predicted pair-wise transcriptional relationships) of the “first
100 network neighbors” inferred using the three independent methods. We ap-
plied the Cohen test on each triplet of networks inferred from each CM-gene.
In total, we performed comparisons for 1,516 triplets. Based on the Cohen’s es-
timated coefficients for agreement, 1,498 networks were found to be concordant
(p-value < 0.05), while 18 were not (p-value > 0.05). Among the set of 1,498 sta-
tistically significant coefficients, 1,124 (75%) triplets showed a “good agreement”
(i.e. with “almost perfect”, “substantial” or “moderate” agreement; Figure 3.9),
while 374 (25%) showed a “bad agreement” (i.e. with “slight” or “fair” agree-
ment; Figure 3.9). Based on this concordance analysis, it emerges that a large
fraction of GRNs share the same set of transcriptionally correlating genes with
respect to the relative hub gene, independently of the method used for GRNi




Figure 3.9: Concordance analysis agreement distribution.
The concordance analysis agreement distribution is reported. On the x-axis the number of
GRNs is reported (Nets); on the y-axis the extent of agreement is reported (Agreement).
Percentages indicate the number of GRNs showing the observed agreement with respect
to the total set of networks (see main text). Green circles group together networks having
a bad agreement, while red triangles group together networks with a good agreement.
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3.3 Mutational annotation for the identification of
cancer-mutated genes and mutated GRNs
3.3.1 Mutational annotation of Cancer Module genes
and enrichment tests
The mutational annotation of CM-genes was performed in order to identify those
genes mutated in breast cancer, which may ultimately affect biological functions
predicted by our GRNi analysis. We focused on somatic mutations annotated
in the COSMIC-Census relative to Breast cancer (238 genes; see Methods, Sub-
section 2.3.1 for details) and TCGA datasets (7136 total mutated genes; whole-
genome sequencing, TCGA[BRCA], CGA Network, 2012. See Methods, Sub-
section 2.3.2). On a total of 1652 CM-genes, 49 were mutated according to
the COSMIC-Census set of mutated genes, while 812 genes were mutated ac-
cording to TCGA dataset (see the computational pipeline in Appendix A, red
section). These mutated genes represent ∼0.2% and ∼4%, respectively, of the
entire genome (∼20.000 genes:http://www.ncbi.nlm.nih.gov/), or ∼3% and
∼49%, respectively, of the full list of CM-genes (1,652 total genes). This means
an enrichment in mutated genes of 10- to 15-fold in CMs with respect to the en-
tire genome. The mutational analysis was intentionally repeated twice using the
COSMIC and TCGA databases, to balance the benefits and limitations of the
two approaches. Indeed, the COSMIC dataset contains mainly experimentally
validated mutations, but since it is a literature-curated database it may be biased
by the number of papers focused on specific sets of cancer genes. In contrast, the
TCGA dataset is not biased by the literature, since it is the result of unsuper-
vised screening by next-generation sequencing analysis; however, this dataset is
likely to contain false positives because many of the mutations reported have not
been experimentally validated. Importantly, 73% (35 out of 49; p=4x10−38) of
mutated CM-genes according to COSMIC, were present also in the TCGA mu-
tational annotation. We next tested the statistical significance of the enrichment
of mutated genes in the set of CM-genes. We generated a set of 1,000 random
gene lists that we annotated for mutations using both COSMIC and TCGA. We
then performed 1,000 runs of proportion tests (with a 99% confidence interval)
to compare the number of mutated genes found in the CMs with respect to the
number of mutated genes in each one of the 1,000 randomly generated gene lists.
The computed p-values were adjusted for multiple comparisons by Benjamini-
Hochberg correction and the relative FDR calculated (see Tables 3.6 and 3.7 for
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the statistical test results relative to the COSMIC-Census and TCGA datasets,
respectively).
Table 3.6: Proportion test results for COSMIC-Census mutational annotation.
























The results of the proportion tests relative to the COSMIC-Census mutational annotation
are reported. For each random gene list, the number of mutated genes and the adjusted
q-value are reported. Each proportion test was performed by comparing the mutated
gene content in each random list versus the number of mutated genes found in the CMs
(i.e. 49). In this table, only the results relative to 23 random gene lists are reported on
the full set of 1000, because, for some of them, the number of mutated genes is equal;
hence, here, “replicated” comparisons (i.e. referring to gene lists with the same content
of mutated genes) are represented once.
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Table 3.7: Proportion test results for TCGA mutational annotation.
























The results of the proportion tests (23 out of 98 comparisons are shown as an example)
relative to the TCGA mutational annotation are reported. Each proportion test was per-
formed by comparing the mutated gene content in each random list versus the number of
mutated genes found in the CMs (i.e. 812). As for the Table 3.6 “replicated” comparisons
(i.e. proportion tests performed on random gene lists having the same content of mutated
genes) are reported once.
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The distribution of the number of mutated genes in the random gene lists was
plotted against the number of mutated genes in CMs for both the COSMIC-
Census and TCGA mutational annotations (see Figure 3.10 A and B, respec-
tively). A Shapiro-Wilk test was performed to check the normality of the mutated
gene content distribution of the random gene lists. For both mutational anno-
tations, COSMIC-Census and TCGA, the Shapiro-Wilk test demonstrated that
the number of mutated genes in the random gene lists was normally distributed
with a p-value < 0.05. In contrast, the number of mutated genes in CM-genes
is significantly higher with respect to the number of mutations in the random
lists (square boxes in Figure 3.10). The statistically significant enrichment of
cancer-related mutated genes in the full set of CM-genes further reinforced their
relevance to breast cancer.
Results 86
Figure 3.10: Distribution of mutated genes after the mutational annotation in ran-
dom gene lists and in CMs.
The distribution of the number of mutated genes in percentage (x-axis) in the 1000 ran-
dom gene lists and in the CMs is reported according to:
A: COSMIC-Census mutational annotation;
B: TCGA [BRCA] (CGA Network, 2012) mutational annotation.
The mutated genes content relative to the 1,000 random gene lists is normally distributed
(red line). The mutated genes content relative to CMs is highlighted by square boxes
outside the distribution.
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3.3.2 Mutational annotation and mutual exclusivity analysis of
GRNs
We extended the mutational annotation to the “top-100” gene neighbors of the
1,516 GRNs inferred by ARACNE (see Subsection 3.2.1 and the computational
pipeline in Appendix A, red section). The mutational annotation and the mutual
exclusivity analysis of the inferred GRNs were performed to: i) place breast can-
cer mutated genes in a network context in order to unveil functional relationships
and regulation among cancer genes; ii) investigate the functional role of mutually
exclusive and low frequently mutated genes in the breast cancer population of pa-
tients in a mechanistic context; iii) to prioritize driver genes in high-throughput
cancer mutation data. Because of the huge amount of genes from the inferred
networks to be annotated for the presence of mutated genes (11,721 total unique
genes), we performed the mutational annotation by using the comprehensive list
of 7,136 mutated genes (with respect to the COSMIC-Census mutational data
on 238 mutated genes; see Subsection 3.3.1) from the TCGA [BRCA] dataset
(CGA Network, 2012 http://www.cbioportal.org/public-portal/; see Meth-
ods, Subsection 2.3.3). For each network we firstly mapped the gene names on
the TCGA database gene symbols removing networks genes not recognized by
the TCGA annotation. A total of 10,936 out of 11,721 networks genes were
recognized as valid gene symbols.The remaining 785 not annotated genes (∼6%)
according to TCGA dataset gene symbols annotation, were part of the not anno-
tated Affymetrix HG-U133A probe sets we included in ARACNE GRNi analysis
(see Methods, Subsection 2.2). The distribution of the mutated genes in the
1,516 GRNs (5,849 out of 10,936 genes;∼53%) is reported in Figure 3.11. We
next investigated the presence of patterns of occurrence of mutated genes in the
GRNs across breast tumors, and, in particular, the presence of mutually exclu-
sive mutated genes. As shown in Figure 3.12 (the EFNA3 network is reported
as an example), the GRNs inferred from CM-genes contain genes mutated at
low and high frequency in breast cancer population (< 1% and ∼37%, respec-
tively). Importantly, some GRNs displayed a clear mutually exclusive mutational
pattern of mutated gene neighbours as from the visual inspection of the muta-
tional profile of breast cancer patients . This, might suggest an oncogenic role of
the GRNs according to the recent observations that genes commonly involved in
the same cancer pathway tend not to be mutated together in the same patient
([200],[201],[202]).
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Figure 3.11: Distribution of mutated genes in the GRNs.
The distribution of the number of mutated genes, reported as a percentage (x-axis), in the






Figure 3.12: Mutual Exclusivity pattern of networks mutated genes.
The Mutual Exclusivity pattern of the EFNA3 mutated network neighbors is reported. The set of patients in which the gene neighbors of the network were
found to be mutated is reported on the x-axis. The list of the mutated genes of the network according to TCGA mutational annotation is reported on the
y-axis. The box highlight the mutually exclusive pattern of the low frequency mutated genes (dark red dots) between them and respect to the high frequency
mutated gene (PIK3CA).
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We then investigated whether the mutually exclusive pattern observed in some
GRNs was statistically significant. To do this, we generated 1,000 random gene
sets of 100 genes each (the same size as our “top-100” gene neighbors) and per-
formed a mutational annotation using the TCGA[BRCA] dataset, as previously
described for the GRNs. The distribution of mutated genes in these random lists
is shown in Figure 3.13. Finally, we checked for the presence of mutually exclu-
sive mutated genes in these random gene lists, and analyzed whether there was a
significant difference in the number of mutually exclusive mutated genes between
the GRNs and the random gene sets. For this analysis, we applied the statisti-
cal proportion test (see Methods, Subsection 2.3.3), running a total of 1,516,000
tests. A schematic representation of the comparisons performed is reported in
Figure 3.14.
Figure 3.13: Distribution of mutated genes in the 1,000 random gene lists.
The distribution of the number of mutated genes, reported as a percentage (x-axis), in the
1,000 random gene lists is reported according to TCGA [BRCA] mutational data (CGA
Network,2012).
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Figure 3.14: Schematic representation of the comparisons performed by the pro-
portion tests.
A schematic representation of the comparisons performed by the proportion tests is re-
ported. CM-Net indicates the GRN inferred using the ARACNE algorithm. “R” indicates
the random gene list and “#1# freq” indicates the presence of one mutated gene of the
network per breast cancer patient.
The results obtained can be summarized as follows:
• for each network (1,516 total GRNs), we found a fraction of statistically
significant proportion tests (i.e., the GRN was significantly enriched in mu-
tually exclusive mutated genes compared with the random lists) and a frac-
tion of not statistically significant proportion tests (i.e. the GRN was not
significantly enriched in mutually exclusive mutated genes). The number
of statistically significant proportion tests range from 992 (i.e., the GRN is
enriched in mutually exclusive mutated genes with respect to 992 random
gene lists while it is not with respect to 8 random lists) to 10 (i.e., the
GRN is enriched in mutually exclusive mutated genes with respect to only
10 random gene lists while it is not with respect to 990 random lists).
• we observed a “negative correlation” between the number of not statisti-
cally significant proportion tests for some GRNS, and the total number
of patients in which at least one gene of the GRN was found to be mu-
tated in a mutually exclusive way (Figure 3.15). Specifically, genes that
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are highly frequently mutated in the population and that are also mutated
in a mutually exclusive way with respect to the other genes in the network
can influence the proportion tests results. When these genes are present in
GRNs they will drive the significance towards them; on the contrary they
will favour the significance of random gene lists when they are represented
in random gene lists instead of in GRNs. Since we observed an increase in
the number of not statistically significant proportion tests as the mutually
exclusive mutated genes were infrequently mutated in the population for
some GRNs, we argued that this might be one possible reason of the lack
of significance of our GRNs. Different normalization procedures exists in
order to control the effect of the frequency of mutation. In our case we
did not normalized according to the frequency of mutation since we were
interested to investigate the role of low frequency mutually exclusive mu-
tated genes with respect to, also, high frequency mutated genes (as for the
case of EFNA3 network, see Figure 3.12) as putative cancer driver genes
playing a role in a network context.
• the statistically significant difference in the number of mutually exclusive
mutated genes between the GRNs and the 1,000 random networks (i.e. the
FDR q-value was < 0.01 after multiple correction on the set of 1,000 ran-
dom gene lists), might be the result of the left-tail effect of the two-tailed
proportion test. Indeed, the statistical significance of the comparisons (q-
value < 0.01), might result from a higher content of mutually exclusive
mutated genes in the random gene lists rather than in the GRN. Accord-
ing to this left-tail effect of the proportion test, there is still a significant
difference in the number of mutually exclusive mutated genes between the
GRN and the random lists, but the enrichment is relative to the random
gene lists instead of the GRNs.
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Figure 3.15: The number of non significant comparisons as a function of the sample
size.
The number of non significant comparisons as a function of the sample size is reported.
As the sample size (i.e. the number of breast cancer patients with at least one gene of
the network mutated) increase, the number of non significant comparisons decrease.
To select the GRNs significantly enriched in mutually exclusive mutated genes
from the proportion tests considering both, the number of statistically signifi-
cant comparisons and the left-tail effect of the two-tailed proportion test on the





-“NSC” represents the fraction of “Non-statistically Significant Comparisons”,
i.e. the number of proportion tests run on GRNs versus random networks, which
did not pass the significance threshold; FDR = 0.01;
-“NF” represents the “Negative Frequencies”, i.e., the number of statistically
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significant comparisons resulting from a higher content of mutually exclusive
mutated genes in random gene lists with respect to the GRNs.
The score ES, was then normalized on the total number of random gene lists
(i.e., 1,000). According to this scoring system, the lower the score (ES), the
higher is the significance of the enrichment of mutually exclusive mutated genes
in the GRNs. The networks were then sorted according to ES and only the
networks with a score < 0.25 were finally considered as significant. Based on
these statistical tests and selection criteria, we identified a core of 50 GRNs that
were significantly enriched in mutually exclusive mutated gene neighbors (see
Table 3.8). Interestingly, this set of networks was unique with respect to the
48 networks prioritized according to the COSMIC-Census mutational annotation
(see Subsection 3.3.1), with the exception of one network MSH2 that was in
common.
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Table 3.8: List of 50 GRNs significantly enriched in mutually exclusive mutated
genes.
GRN MGs SCs NSCs NFs PFs Score
RASA2 50 992 8 0 992 0.008
EFNA3 55 991 9 0 991 0.009
FADS2 49 991 9 0 991 0.009
TXNIP 45 991 9 0 991 0.009
NIPAL3 45 991 9 0 991 0.009
MYBBP1A 46 990 10 0 990 0.01
G3BP1 57 990 10 0 990 0.01
SMARCC1 62 990 10 0 990 0.01
AATF 53 990 10 0 990 0.01
RRP1 46 990 10 0 990 0.01
DDB2 57 989 11 0 989 0.011
OSBPL8 59 987 13 8 979 0.021
FOXC1 61 972 28 8 964 0.036
CDH3 62 971 29 8 963 0.037
SR140 54 968 32 9 959 0.041
ARL4C 58 964 36 9 955 0.045
ITPR2 57 952 48 9 943 0.057
KDM4B 52 947 53 9 938 0.062
IVD 55 928 72 9 919 0.081
DHCR7 52 928 72 9 919 0.081
CAMP 55 928 72 9 919 0.081
ADM 52 920 80 9 911 0.089
PMAIP1 56 920 80 9 911 0.089
SKP2 57 920 80 9 911 0.089
CEBPB 58 909 91 9 900 0.1
GSTP1 58 897 103 9 888 0.112
NPY1R 54 897 103 9 888 0.112
ENO1 58 897 103 9 888 0.112
NDN 61 886 114 10 876 0.124
NQO1 55 886 114 10 876 0.124
SLC7A5 57 886 114 10 876 0.124
HMGCS2 51 871 129 10 861 0.139
PNP 58 856 144 10 846 0.154
PHGDH 56 840 160 10 830 0.17
IL8 59 840 160 10 830 0.17
ANGPTL2 57 823 177 10 813 0.187
PLAU 62 823 177 10 813 0.187
CXCL12 58 823 177 10 813 0.187
LUM 55 823 177 10 813 0.187
ACTN1 65 823 177 10 813 0.187
XPO4 62 823 177 10 813 0.187
KRT15 56 823 177 10 813 0.187
SERPINH1 53 798 202 10 788 0.212
PMP22 58 798 202 10 788 0.212
ASAH1 65 798 202 10 788 0.212
PENK 65 798 202 10 788 0.212
MSH2 51 798 202 10 788 0.212
POLB 58 798 202 10 788 0.212
KCNN4 61 771 229 10 761 0.239
THOP1 51 771 229 10 761 0.239
The list of 50 GRNs significantly enriched in mutually exclusive mutated genes is reported
followed by: the number of Mutated Genes (MGs) according to TCGA mutational an-
notation; the number of Significant Comparisons (SCs), i.e. the number of statistically
significant proportion tests; the number of Non-Significant Comparisons (NSCs), i.e. the
statistically non-significant proportion tests; the Negative Frequencies (NFs), represent-
ing the number of random gene lists enriched in mutually exclusive mutated genes; the
Positive Frequencies (PFs), representing the number of random lists not enriched in mu-
tually exclusive mutated genes compared to the GRNs; the Score calculated as described
in the main text.
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3.4 Identification of higher order
regulatory mechanisms
We performed an in-depth GRN deconvolution analysis to identify putative tran-
scriptional Master Regulator (MR) hub genes for the 48 and 50 networks priori-
tized by the COSMIC-Census mutational annotation and the mutual exclusivity
analysis, respectively (see Subsections 3.3.1 and 3.3.2 and the computational
pipeline in Appendix A, blue section). A hub gene is defined as a highly inter-
connected gene within a complex network, that has a key biological role in the
cell ([203],[204]). In the case of gene expression, the connections with other genes
represent the degree of correlation between expression measurements. Typically,
for GRNs, a hub gene is a transcription factor (TF) or co-factor that is the MR of
expression of neighboring genes, making it highly interconnected. Specifically, the
TF or co-factor is at the top of a of a regulatory hierarchy. Besides TFs, MRs can
also be genes whose expression is critical to the transcriptional activation of mul-
tiple downstream genes (including TFs) involved in cell signaling cascades ([205]).
Since the expression of CM-genes correlates with pathological conditions associ-
ated with breast cancer, we attempted to identify cancer-related mechanisms at
the transcriptional level. For the full list of CM-genes (1516 total genes), we
performed a network inference analysis in which we assumed that each CM-gene
was a hub gene, i.e. a transcriptionally highly interconnected gene (Figure 3.16,
panel ‘a’). From this analysis, we inferred 1,516 GRNs (CM-gene GRNs), how-
ever, we were unable to determine whether a gene was likely to be a real hub or
not. In addition, we observed that for some of these CM-gene GRNs, the hub
genes shared common neighbors supporting the possibility of a higher-order regu-
latory program under the control of a common putative transcriptional MR (Fig-
ure 3.17). To overcome the bias of assuming that all CM-genes were hub genes in
the network inference analysis, and to identify potential MRs of transcriptional
programs, we performed a transcriptional network deconvolution analysis using
the ARACNE algorithm (Figure 3.16, panel ‘b’). In this analysis, we considered
that for each one of the 48 and 50 GRNs (CM-gene GRNs) each gene neighbor
within the network is a hub gene around which to build a new “transcriptional”
network. The MR was then defined as the gene neighbor that occurs most fre-
quently among the new networks (Figure 3.16, panel ‘b’). Once the MR gene
was identified, we finally built a GRN around the MR hub gene. The networks
inferred from the MRs were called MR-gene GRNs (or MR-networks). Using
this strategy, we were able to identify in an unbiased way, the MR of transcrip-
tional mechanisms identified through the network inference analysis performed
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on CM-genes. For some networks inferred from CM-genes as hub genes, the tran-
scriptional MR appeared to be the CM-gene itself, confirming the relevance of
CM-genes in these putative oncogenic networks. In contrast, for other networks
the MR was a neighboring gene of the original network hub. Interestingly, some
GRNs inferred from CM-genes shared a common MR (Figure 3.18), allowing
these networks to be grouped together, representing branches of a higher-order
regulatory mechanism. The full list of MRs for the set of 48 and 50 GRNs is
reported in Table 3.9 and 3.10. We identified 23 and 31 unique MRs for the set of
48 and 50 GRNs respectively, with the exception of the RUNX1T1 gene that was
in common. 14 out of 54 total MR genes are described as transcription factors
in TRANSFAC database (http://www.gene-regulation.com/pub/databases.
html/). They are: ATF6B, CREBL2, E2F4, ESR1, FOXM1, FOXO1, HOXA5,










































(a) GRN inference from CM-gene 
FREQUENCY OF OCCURRENCE 
(b) MR-gene identification and MR-gene network inference 
MR-gene NETWORK 
ARACNE 
Figure 3.16: Identification of higher order regulatory mechanisms.
Schematic representations of the network inference analysis performed on CM-genes (a)
and the network analysis performed for the identification of higher-order regulatory mech-
anisms (b). In panel (a), the network inference analysis performed to build GRNs from
CM-genes (CM-gene GRNs) is shown. Each CM-gene was assumed to be a hub gene to
identify transcriptionally correlating genes, i.e. gene neighbors (Nghb). In panel (b), the
network inference analysis to investigate for the presence of higher-order regulatory mech-
anisms is shown. Each neighboring gene for each GRN inferred from CM-genes (shown in
‘a’) was assumed to be a hub gene; the network was then built around the hub gene based
on gene expression data using the ARACNE algorithm. The master regulator (MR) was
then identified as the gene with the highest frequency of occurrence, as a neighbor gene,
across all networks inferred from the original GRN (shown in ‘a’). Once identified, a new
network composed of genes from the original GRN, was built around the MR gene.
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Figure 3.17: Overlapping neighbors of the ARL4C, NDN and GSTP1 CM-gene
GRNs.
The GRNs inferred from ARL4C, NDN and GSTP1 CM-genes are reported. The gene
neighbors of the networks and the relative hub genes are highlighted in blue, red and green
for ARL4C, NDN and GSTP1, respectively. For each network, the edges connecting the
hub gene with its neighbors are in gray, while the edges connecting the hub genes with





Figure 3.18: FOXO1 gene as Master Regulator (MR) of ARL4C, NDN and GSTP1 CM-gene GRNs.
FOXO1 is a master regulator of the ARL4C, NDN and GSTP1 CM-gene GRNs. FOXO1 expression correlates at a transcriptional level with the expression
of all the genes composing the networks inferred from the CM-genes ARL4C, NDN and GSTP1. FOXO1 therefore represents the transcriptional master
regulator of a higher-order regulatory mechanism. On the left of the figure, the genes of each network are listed. In red are reported the gene neighbours
relative to the ARL4C network, in green those relative to the GSTP1 network, and in blue the gene neighbours relative to the NDN network. Black curved
lines represent pairwise transcriptional correlations inferred by ARACNE algorithm between the CM-gene as hub gene and the relative neighbours listed in






Table 3.9: Master regulators relative to the set of 48 CM-gene GRNs identified through the COSMIC-Census mutational annotation of CM-genes.
Master Regulator (MR) Full gene name CM-gene hub(s)
ACRV1 acrosomal vesicle protein 1 CASC5, HOXD13
AGPAT1 1-acylglycerol-3-phosphate O-acyltransferase 1 EWSR1
CAV1 caveolin 1, caveolae protein, 22kDa GPC3
CCDC9 coiled-coil domain containing 9 FGFR2
CD2 CD2 molecule SOCS1
CD48 CD48 molecule JAK2
CDK1 cyclin-dependent kinase 1 BRCA1
DAZAP1 DAZ associated protein 1 TOP1
DMWD dystrophia myotonica, WD repeat containing BAP1, CDK12, CDKN2A, MYD88, ETVC
DPYSL3 dihydropyrimidinase-like 3 EXT2
EGR1 early growth response 1 JUN
FAM171A1 family with sequence similarity 171, member A1 RET
HSPA8 heat shock 70kDa protein 8 MSH6
KCNMB1 potassium large conductance calcium-activated channel MET
MMP2 matrix metallopeptidase 2 COL1A1
MYO15B myosin XVB pseudogene CDK4
PABPN1 poly(A) binding protein, nuclear 1 PMS1
PSG6 pregnancy specific beta-1-glycoprotein 6 EGFR
RUNX1T1 runt-related transcription factor 1; translocated to, 1 (cyclin D-related) CCND2
TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) BRCA2, BRIP1, BUB1B,
TRBC1 T cell receptor beta constant 1 POU2AF1
TROAP trophinin associated protein (tastin) BLM
UBE2C ubiquitin-conjugating enzyme E2C RECQL4,WHSC1
ZNF160 zinc finger protein 160 APC
Table lists the master regulators relative to the set of 48 CM-gene GRNs identified through the COSMIC-Census mutational annotation of CM-genes, followed





Table 3.10: Master regulators relative to the set of 50 CM-gene GRNs identified through the mutual exclusivity analysis.
Master Regulator (MR) Full gene name CM-gene hub(s)
ACTL6A Actin-Like 6A TXNIP
ASH1L ash1 (absent, small, or homeotic)-like (Drosophila) XPO4
ATF6B activating transcription factor 6 beta NIPAL3
BCL11A B-Cell CLL/Lymphoma 11A (Zinc Finger Protein) PHGDH
CHD3 cadherin 3, type 1, P-cadherin (placental) MYBBP1A
CREBL2 cAMP responsive element binding protein-like 2 ASAH1
E2F4 E2F transcription factor 4, p107/p130-binding THOP1
ELK3 ELK3, ETS-domain protein (SRF accessory protein 2) ITPR2
ESR1 estrogen receptor 1 IVD
FOXM1 forkhead box M1 DHCR7, HMGCS2, NPY1R
FOXO1 forkhead box O1 ARL4C, GSTP1, NDN
GATA3 GATA binding protein 3 IL8, KDM4B, PMAIP1,POLB
HOXA5 homeobox A5 KRT15
IFI16 interferon, gamma-inducible protein 16 ADM
LRPPRC leucine-rich PPR-motif containing MSH2
MAX MYC associated factor X G3BP1
MLXIP MLX interacting protein KCNN4
MYBL2 v-myb myeloblastosis viral oncogene homolog (avian)-like 2 PNP, SLC7A5
NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive RASA2
PRRX1 paired related homeobox 1 PLAU, SERPINH1
PTTG1 pituitary tumor-transforming 1 CAMP
RBMS1 RNA binding motif, single stranded interacting protein 1 OSBPL8
RUNX1T1 runt-related transcription factor 1; translocated to, 1 (cyclin D-related) PENK
SOX10 SRY (sex determining region Y)-box 10 CDH3, FOXC1
TAF6 TAF6 RNA polymerase II, TATA box binding protein (TBP)-associated factor EFNA3
TCF4 transcription factor 4 CXCL12
TCF7L1 transcription factor 7-like 1 (T-cell specific, HMG-box) NQO1
TGFB1I1 transforming growth factor beta 1 induced transcript 1 ACTN1, ANGPTL2
TP53BP1 tumor protein p53 binding protein 1 RRP1
ZFPM2 zinc finger protein, multitype 2 LUM, PMP22
ZNF45 Zinc Finger Protein 45 (A Kruppel-Associated Box (KRAB) Domain FADS2
ZNF302 zinc finger protein 302 SR140
Table lists the master regulators relative to the set of 50 CM-gene GRNs identified through the mutual exclusivity analysis, followed by their full gene name
and relative CM-gene hub(s).
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3.5 Clinical relevance of GRNs
3.5.1 Transcriptional activity of GRNs: the concordance analysis
We then assessed the clinical and pathological relevance of the 48 and 50 sets of
GRNs (CM-gene GRNs) prioritized by the COSMIC-Census mutational annota-
tion and the mutual exclusivity analysis respectively and of the relative MR-gene
GRNs (inferred as described in Section 3.4) to breast cancer (see the computa-
tional pipeline in Appendix A, pink section). We first established a scoring
system to predict the activation/inhibition of the inferred networks in breast
cancer (see Methods, Section 2.4). The transcriptional activity of the networks
was evaluated using an independent microarray gene expression dataset of 997
breast tumors (the Metabric study, Discovery set ([36])). The log2 median cen-
tered gene expression matrix was sorted across breast cancer patients according
to the transcriptional profiles of the CM-gene ‘hub’ or the MR gene, around
which the networks were built. The sorted dataset was then transformed into
a binary matrix assigning +1 to positive gene expression measurements (genes
up-regulated) of the gene neighbors of the network and of the hub gene, and -1
to the negative gene expression measurements (genes down-regulated). From the
binarized data, a Concordance Score (CS) was computed as follows:
CSup = ∀PHup(Ngup −Ngdn)
Where:
-CSup is the network concordance score in the case of up-regulated hubs;
- (Ngup−Ngdn) is the difference between the number of up-regulated genes and
the number of down-regulated genes of the network, computed for each breast
cancer sample (∀PHup) when the hub gene is up-regulated.
or
CSdn = ∀PHdn(Ngdn −Ngup)
Where:
-CSdn is the network concordance score in the case of down-regulated hubs;
-(Ngdn − Ngup) is the difference between the number of down- regulated genes
and the number of up-regulated genes of the network, computed for each breast
cancer sample (∀PHdn) when the hub gene is down-regulated.
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CSdn is the network concordance score in the case of down-regulated hub,
(Ngdn − Ngup) is the difference between the number of down-regulated genes
and the number of up-regulated genes of the network computed for each breast
cancer sample (∀PHdn) when the hub gene is down-regulated. According to the
computed difference ∆, the extent of the concordance was defined as follows:
CSup =

Positive Concordance if ∆up > 0
Negative Concordance if ∆up < 0
Non Concordance if ∆up = 0
CSdn =

Positive Concordance if ∆dn > 0
Negative Concordance if ∆dn < 0
Non Concordance if ∆dn = 0
We then defined three distinct patterns of transcriptional activation/inhibition
of the networks in breast cancer according to the scoring system:
• Absence of transcriptional activation/inhibition of the network (Non Con-
cordance): 50% of the neighbors of the network have the same transcrip-
tional profile with respect to the hub gene, while the remaining 50% of
neighbors have the opposite transcriptional regulation (Figures 3.19 and
3.20 box a).
• Positive transcriptional activation/inhibition (Positive Concordance): >
50% of gene neighbors in the network have the same transcriptional regula-
tion as the hub gene (up-regulated/activated or downregulated/inhibited)
(Figures 3.19 and 3.20 box b).
• Negative transcriptional activation/inhibition (Negative Concordance): >
50% of gene neighbors in the network have the opposite transcriptional
regulation with respect to the hub gene (Figures 3.19 and 3.20 box c).
The gene expression values of the network neighbors plotted with respect to the
computed CSs for the three transcriptional patterns is shown in Figure 3.21. For
the absence of a transcriptional activation/inhibition pattern, the gene expression
profiles of the CM-gene AATF network neighbors (reported as a representative
example) is plotted against the computed CSs. As shown, when half of the neigh-
bors are up-regulated and half are down-regulated, the computed CS is close to
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0. In contrast, in the case of positive transcriptional activation/inhibition (as
displayed by the CM-gene PLAU network), when the majority of the neighbors
have the same direction of gene expression regulation (either up-regulated or
down-regulated) as the hub gene, the CS is greater than 0. Finally, when the
majority of the neighbors of the network have an opposite gene expression regu-
lation compared to the hub gene, (as disaplyed by the CM-gene CEBP network),
the CS is less than 0. The full list of the networks, grouped by transcriptional
activation/inhibition patterns is reported in Table 3.11 for the set of 48 networks
and in Table 3.12 for the set of 50 networks relative to networks inferred from
CM-genes and MR-genes. For subsequent analyses, we focused on the set of
networks with positive and negative transcriptional activation patterns, because
they could indicate activation/inhibition of molecular mechanisms represented by
the networks in breast cancer.
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Figure 3.19: The transcriptional activation of CM-gene GRNs on Metabric cohort
of breast cancer patients.
Hierarchical cluster analysis of the Concordance Scores (CSs) computed on the CM-gene
GRNs inferred from the set of 48 networks resulting from the COSMIC-Census mutational
annotation and from the set of 50 networks resulting from mutual exclusivity analysis.
Columns represent breast cancer patients from the Metabric cohort, while rows represent
the networks scores. The heatmaps refer to the set of 48 CM-gene GRNs (A) and to the
set of 50 CM-gene GRNs (B). The boxes highlight the three transcriptional activation
patterns of the networks resulting from the concordance analysis: box a, the absence of
a transcriptional activation/inhibition; box b, the presence of a positive transcriptional
activation/inhibition pattern; box c, the presence of a negative transcriptional activa-
tion/inhibition pattern.
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Figure 3.20: The transcriptional activation of MR-gene GRNs on Metabric cohort
of breast cancer patients.
Hierarchical cluster analysis of the Concordance Scores (CSs) computed on the MR-gene
GRNs inferred from the set of 48 networks resulting from the COSMIC-Census mutational
annotation and from the set of 50 networks resulting from mutual exclusivity analysis.
Columns represent breast cancer patients from the Metabric cohort, while rows represent
the networks scores. The heatmaps refer to the set of 48 MR-gene GRNs (A) and to the
set of 50 MR-gene GRNs (B). The boxes highlight the three transcriptional activation
patterns of the networks resulting from the concordance analysis: box a, the absence of
a transcriptional activation/inhibition; box b, the presence of a positive transcriptional






Figure 3.21: Transcriptional patterns of CM-gene GRNs: gene expression vs. concordance.
The CM-gene GRN expression profiles plotted against the GRN Concordance Scores (NET SCORE) for three networks representative of the three tran-
scriptional activation patterns: a) the absence of a transcriptional activation pattern (CM-gene AATF network); b) the positive transcriptional activation





Table 3.11: The concordance analysis results relative to the 48 CM-gene and MR-gene networks.
Non Concordance Positive Concordance Negative Concordance
CM-gene GRN
CCND2, ATM, DDX10, HOXD13, CDK12, CDK4, RET, CASC5, ATRX,
THOP1, APC, FGFR2, EGFR, TFRC, EML4, ERBB2, MUC1, BRCA2
CREBBP, KRAS, CBLB, MSN, ETV5, BAP1,
PMS1, EWSR1, MSH6, RECQL4, BLM, JUN,
CDH1, KLF6, MSH2, GPC3, SOCS1, POU2AF1,
NRAS, MYD88, CDKN2A, COL1A1, JAK2, EXT2,
ELF4, MET, BRIP1 BUB1B, WHSC1, BRCA1
MR-gene GRN
ZNF160 APC, CCDC9 FGFR2, TPX2 BUB1B, TROAP BLM, UBE2C WHSC1, TPX2 BRIP1,
ACRV1 CASC5, PABPN1 PMS1, CDK1 BRCA1, PSG6 EGFR, ACRV1 HOXD13, DMWD BAP1,
DAZAP1 TOP1, RUNX1T1 CCND2, DMWD CDK12, MYO15B CDK4, UBE2C RECQL4, TPX2 BRCA2,
AGPAT1 EWSR1, HSPA8 MSH6, MYO15B CDK4, EGR1 JUN, DMWD MYD88, DMWD CDKN2A
KCNMB1 MET CAV1 GPC3, TRBC1 POU2AF1,
CD2 SOCS1, CD48 JAK2,
MMP2 COL1A1, FAM171A1 RET,
DPYSL3 EXT2
The concordance analysis results relative to the set of 48 CM-gene and MR-gene networks are reported. The networks are grouped according to the
transcriptional activation pattern : Non Concordance, Positive Concordance, or Negative Concordance patterns. The CM-gene networks are represented
by their hub gene (i.e. the CM-gene imposed as the hub gene of the network). The MR-gene networks are represented by two gene symbols separated by





Table 3.12: The concordance analysis results relative to the 50 CM-gene and MR-gene networks.
Non Concordance Positive Concordance Negative Concordance
CM-gene GRN
THOP1, XPO4, NIPAL3, ITPR2, IL8, SR140, DDB2, SKP2, PNP,
NQO1, FADS2, RASA2, MYBBP1A, FOXC1, KDM4B, SMARCC1, ENO1, CAMP
KCNN4, RRP1, G3BP1, CDH3, ADM, PENK, CEBPB
EFNA3, POLB, HMGCS2, OSBPL8, ARL4C, GSTP1,
ASAH1, AATF, IVD, NDN, CXCL12, LUM,
PHGDH, KRT15, DHCR7, ACTN1, PLAU, PMP22,
TXNIP, MSH2, PMAIP1, ANGPTL2, SERPINH1
SLC7A5, NPY1R
MR-gene GRN
E2F4 THOP1, ATF6B NIPAL3, FOXO1 GSTP1, FOXO1 NDN, GATA3 IL8, ELK3 ITPR2,
NFAT5 RASA2, MLXIP KCNN4, FOXO1 ARL4C, TGFB1I1 ANGPTL2, CHD3 MYBBP1A, ZNF302 SR140,
ASH1L XPO4, TCF7L1 NQO1, TGFB1I1 ACTN1, TCF4 CXCL12, SOX10 FOXC1, RUNX1T1 PENK
ZNF45 FADS2, PTTG1 CAMP, ZFPM2 LUM, ZFPM2 PMP22,
TAF6 EFNA3, MAX G3BP1, PRRX1 PLAU, PRRX1 SERPINH1,
GATA3 POLB, ESR1 IVD, GATA3 KDM4B, GATA3 PMAIP1,
BCL11A PHGDH, CREBL2 ASAH1, SOX10 CDH3, IFI16 ADM,
TP53BP1 RRP1, FOXM1 DHCR7, RBMS1 OSBPL8
FOXM1 HMGCS2, HOXA5 KRT15,
ACTL6A TXNIP, MYBL2 SLC7A5,
MYBL2 PNP, LRPPRC MSH2,
FOXM1 NPY1R
The concordance analysis results relative to the set of 50 CM-gene and MR-gene networks are reported. The networks are grouped according to the
transcriptional activation pattern : Non Concordance, Positive Concordance, or Negative Concordance patterns. The CM-gene networks are represented
by their hub gene (i.e. the CM-gene imposed as the hub gene of the network). The MR-gene networks are represented by two gene symbols separated by
underscore. The first gene name refers to the MR-gene. The second gene symbol refers to the original CM-gene.
Results 111
3.5.2 Gene set enrichment analysis of transcriptionally active
networks in triple-negative breast cancer (TNBC) patients
Triple-Negative Breast Cancer (TNBC) is an aggressive breast cancer subtype
that lacks the expression of the hormone receptors, ER and PgR, and does not
overexpress Her2/neu. Consequently, these tumors are unresponsive to the cur-
rently available targeted therapies for breast cancer, such as endocrine therapies
(e.g. Tamoxifen) and anti-Her2 agents (e.g. Trastuzumab). Indeed, treatment
options are limited for TNBC and chemotherapy remains the mainstay of treat-
ment ([206]). Although chemotherapy can delay tumor progression in TNBC
patients, it is not curative and the development of chemoresistance, resulting
in disease progression, is common. Therefore, a better understanding of the
mechanisms of chemoresistance in TNBC could help in the identification of novel
molecular targets for the development of more effective breast cancer therapies.
To determine whether the transcriptionally active networks that we identified in
breast cancer (71 positively and 27 negatively concordant networks derived from
the CM-gene and MR-gene GRNs) could be relevant to chemoresistance, we per-
formed an enrichment analysis of these networks in the Hatzis et al.,([190]) cohort
of 152 TNBC patients ([190]). In this cohort, the 152 TNBC patients had received
neoadjuvant taxane-anthracycline chemotherapy (NACT; see Methods, Subsec-
tion 2.1.3.8 and Section 2.5). The response to this treatment varied from a patho-
logic complete response (pCR) with significant improvements in both disease-free
survival and overall survival, to residual invasive disease (RD) with no benefit in
terms of survival rate. Through this enrichment analysis, we aimed to identify
networks “enriched” in chemorefractory tumors, in order to predict their involve-
ment in chemoresistance mechanisms. Our ultimate goal was to identify putative
molecular targets for the development of novel treatment strategies for TNBC.
To identify networks associated with chemoresistance, we performed the Gene
Set Enrichment Analysis (GSEA) and the Gene Set Analysis (GSA) in pCR and
RD patients from the 152 TNBC cohort, using the transcriptionally active GRNs
as gene sets. The GSEA and GSA algorithms are two of many computational
tools, known as Functional Class Scoring (FCS) methods, available to investigate
the transcriptional enrichment of gene sets with respect to different phenotype
conditions. Briefly, the GSEA analysis tests whether the distribution of the ranks
of genes in a gene set differs from an empirical null distribution, using a weighted
Kolmogorov-Smirnov statistical test. The genes in the gene list are ranked by
the strength of association with the phenotype, defined by, for example, the t-
test, signal-to-noise ratio, correlation coefficients, or fold-change etc. Instead, the
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GSA analysis uses the maxmean statistic to determine whether the strongest evi-
dence for a particular gene set is the up-regulation or the down-regulation. Both
methods are optimized to investigate harmonized changes of expression levels of
genes, within a particular gene set, according to a desired condition (phenotype).
For the enrichment analysis, we used the two methods GSEA and GSA, on gene
expression data normalized according to three different normalization methods
(i.e. RMA, MAS5 and MAS5-based normalization reported in Hatzis et al., 2011.
See Methods, Section 2.5). We chose three normalization techniques in order to
control the effect of the normalization methods on the enrichment results, and
two methods for the enrichment analysis to verify the robustness of them. The
rationale behind this choice was that if the active networks represent biologically
relevant transcriptional mechanisms in RD TNBC, we expect to observe the en-
richment, independently of the different theoretical formulations of the method
(i.e. GSEA or GSA) used to perform the enrichment analysis. The statisti-
cal significance of the enrichment of the transcriptionally active networks was
evaluated according to the nominal p-value resulting from the GSEA and GSA
analysis output. We did not consider the FDR q-value to identify the statistically
significantly enriched networks, since our aim was not to select the most enriched
networks (i.e. it was not to perform network selection or to compare networks
between them) from the set of networks used as inputs, but, instead, to evaluate
the enrichment of each network as single mechanisms. The FDR computation,
in fact, considers the distribution of the enrichment scores computed across all
the gene sets ([197]). Moreover, we considered as significantly enriched, those
networks found to be enriched (p-value≤ 0.1) according to at least one normal-
ization method and according to both enrichment analysis algorithms. Using
this approach, we observed the enrichment of 6 transcriptionally active networks
in RD TNCB: TCF4, TGFB1I1, ZFPM2, PRRX1, ELF4, COL1A1 (Table 3.13;
Figure 3.22 and 3.23; Appendix A, orange section). A typical enrichment plot
from the GSEA analysis is shown in Figure 3.22 for the TGFB1I1 transcriptional
network. The gene neighbors of the network were ranked according to the Sig-
nal2Noise (S2N) metric, which is defined as the difference of means of expression
levels of the two phenotype classes (PhLs), RD and pCR, scaled by their stan-
dard deviation. The genes of the TGFB1I1 network were sorted from high S2N
(high association with RD pathological condition) to low S2N (low association
with RD pathological condition) values. A representative set of the core genes
of the enrichment analysis, i.e. the genes that contributed most to the enrich-
ment of the entire TGFB1I1 network are also reported in Figure 3.22, including
the PDGFRB receptor, a putative druggable target gene that functions as a cell
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surface kinase receptor. A more comprehensive list of the GSEA core genes for





Table 3.13: Enrichment results of the transcriptionally active networks in RD TNBC.
Transcriptionally active network in BC (RMA) (MAS5) (MAS5, Hatzis 2011)
NES; p-val NES; p-val NES; p-val
GSEA
TCF4 - - 1.54; 0.074
TGFB1I1 1.43; 0.051 1.54; 0.052 1.63; 0.022
ZFPM2 1.39; 0.072 1.52; 0.061 1.56; 0.023
PRRX1 1.44; 0.021 1.64; 0.031 1.63; 0.011
ELF4 1.53; 0.044 1.72; 0.045 1.80; 0.002
COL1A1 1.46; 0.044 1.54; 0.054 1.61; 0.025
GSA
TCF4 - - 0.60; 0.100
TGFB1I1 0.78; 0.025 0.81; 0.020 0.82; 0.021
ZFPM2 0.96; 0.015 1.05; 0.005 1.03; 0.004
PRRX1 1.27; 0.002 1.24; 0.004 1.24; 0.002
ELF4 0.72; 0.023 0.74; 0.012 0.77; 0.006
COL1A1 1.69; 0.004 1.69; 0.004 1.64; 0.004
The enrichment results of transcriptionally active networks in TNBC patients resistant to neoadjuvant taxane-anthracycline chemotherapy (RD). The
normalized enrichment score (NES) followed by the nominal p-value (p-val) is reported for the GSEA and GSA analyses, relative to the three normalization
methods: RMA, MAS5 and the MAS5-based normalization proposed in Hatzis et al 2011 (MAS5 Hatzis 2011)([190]). Networks with an enrichment p-value
≥ 0.1 are indicated with the “-” symbol. The hub genes TCF4, TGFB1I1, ZFPM2 and PRRX1 are MR-hub genes relative to the original set of 50 GRNs
enriched in mutually exclusive mutated genes. ELF4 and COL1A1 are CM-hub genes from the original set of 48 COSMIC-Census mutated genes.
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Figure 3.22: Enrichment analysis plot for the TGFB1I1 network in RD TNBC tu-
mors.
The GSEA enrichment plot relative to the TGFB1I1 network enrichment analysis is re-
ported. The TGFB1I1 gene neighbors in the network representation were sorted according
to the S2N, from high (high association with RD pathological condition) to low (low as-
sociation with RD pathological condition) values. Red circles and corresponding vertical
black lines in the graph, highlight a subset of core genes that contributed most to the
enrichment of the entire network in RD TNBC. For some of these genes, the Hugo gene






























































Figure 3.23: GSEA plots relative to the enrichment analysis in RD TNBC of the
transcriptionally active networks TCF4, ZFPM2, PRRX1, ELF4 and COL1A1.
The GSEA enrichment plots relative to the TCF4, ZFPM2, PRRX1, ELF4 and
COL1A1 networks enrichment analysis are reported. Red circles highlight the
core genes of the networks that mostly contributed to the Running Enrichment
Score (RES). A representative set of 12 core genes ranked according to the S2N




In this project, we aimed to identify GRNs associated with breast cancer from
microarray gene expression data, in order to predict cancer biomarkers and novel
druggable targets. Initially, we identified oncogenic gene sets whose collective
expression profiles significantly correlated with different clinico-pathological pa-
rameters of breast cancers (e.g., ER status, tumor grade and prognosis). We
then derived cancer gene modules (i.e., CMs) from these gene sets, by identify-
ing those genes that contributed most to the correlation between the gene set
expression profiles and the clinico-pathological parameters. Finally, regulatory
networks were inferred from these CMs by assuming that each CM-gene was a
hub gene around which to build the network. For the network inference analy-
sis, we used a statistically representative gene expression dataset (the Loi et al.,
dataset [194]), in terms of number of tumors screened, which was derived using
the Affymetrix HG-U133A chip. From the full set of 1,652 CM-genes, networks
were inferred on a subset of 1,516 genes that were represented on the Affymetrix
HG-U133A chip. For the remaining 136 genes, network inference was not possible
(these genes are represented on the Affymetrix HG-U133B chip). The inference
analysis was performed by using the ARACNE algorithm along with two other
independent methods for network inference analysis: CUDA-MI and WGCNA.
For each CM-gene from which a network was inferred, we observed a good agree-
ment of the pair-wise transcriptional correlations according to the three methods
supporting the robustness of the inferred networks. To gain insights into the
functional relevance of CM-genes in breast cancer, we performed a mutational
annotation of the full set of CM-genes (1,652 total genes). We identified 49
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and 812 CM-genes mutated according to mutational annotation based on the
COSMIC-Census and TCGA datasets, respectively. The significance of the of
mutated genes in the set of CM genes was statistically verified. We prioritized
the set of 49 mutated genes with respect to the 812 mutated genes for subsequent
analyses, because of its small size and the fact that mutations in the COSMIC-
Census dataset are documented in the literature. We considered networks derived
from 48 CM-mutated genes, instead of the complete set of 49 genes, because for
one gene, network inference analysis was not possible since it is represented on
the Affymetrix HG-U133B chip. The mutational annotation was also performed
on the gene neighbors of the full set of 1,516 networks in order to identify mutated
genes that might impair the function of entire networks. This analysis allowed
us to identify an additional set of 50 networks enriched in mutually exclusive
mutated gene neighbors. The set of 48 networks and the set of 50 networks were
finally considered as potentially functionally relevant networks for subsequent
investigation in breast cancer. Using these two sets of networks, we performed
an additional phase of network inference analysis, aimed at identifying the pu-
tative transcriptional MR-gene of each network. This analysis was performed to
overcome the bias of a priori assuming CM-genes as transcriptional hub genes of
networks. The identification of the MR-genes was performed as follows: for each
CM-gene network, each neighboring gene was assumed to be a hub gene around
which a new network was built using ARACNE. In these new networks, the set
of transcriptionally interacting genes were the genes represented in the original
CM-gene network. The most frequently occurring gene neighbor in the full set
of new networks was considered as the putative transcriptional MR-gene. Once
the MR-gene was identified, a final network was built, in which the MR-gene
was assumed to be the hub gene and the full set of CM-genes in the original net-
work were considered as putative transcriptionally interacting genes. Using this
strategy, we identified MRs that were unique to specific CM-gene networks and
MRs that were in common to different CM-gene networks. This analysis allowed
us not only to identify putative transcriptional MR-genes, but also to group to-
gether CM-networks with common transcriptional regulatory programs that were
under the control of the same MR-gene. By considering the set of 48 and 50 net-
works (i.e. the networks inferred from CM-genes [98 total networks] and the new
networks inferred from MR-genes [76 total networks. CM-gene networks with
the same MR gene were not collapsed to a unique network]), we subsequently
evaluated the transcriptional activity of the entire networks in breast cancer tu-
mors. We defined networks as transcriptionally active if more than half of the
neighboring genes had the same or the opposite transcriptional modulation as
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the corresponding hub gene (positive and negative concordance, respectively). In
contrast, transcriptionally inactive networks were those in which half of the neigh-
boring genes have the same transcriptional modulation as the hub gene, while
the remaining half have the opposite transcriptional regulation. Using this strat-
egy, we were able to further prioritize our set of networks to those most relevant
to breast cancer in terms of transcriptional activity (98 total active networks:
71 positively and 27 negatively concordant networks). The clinical relevance of
our computational predictions, in terms of putative transcriptional mechanisms
deregulated in breast cancer, was assessed by evaluating the correlation between
the expression profiles of transcriptionally active networks and the occurrence
of RD in TNBC patients after neoadjuvant taxane-anthracycline chemotherapy.
Interestingly, we identified six active networks (i.e. TCF4, TGFB1I1, ZFPM2,
PRRX1, ELF4, COL1A1) whose transcriptional profiles correlated with RD in
TNBC patients. These networks represent putative mechanisms responsible for
the chemoresistance in these patients. Moreover, the genes of these networks
could represent candidate biomarkers of therapy response, as well as putative
druggable targets for the development of more effective therapeutic strategies.
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4.2 Cancer Modules (CMs) definition from oncogenic
gene sets: a biased approach
Carcinogenesis is mainly caused by genetic alterations, i.e. somatic mutations in
oncogenes and tumor-suppressor genes ([207],[208],[209],[210]). Oncogenes con-
trol cell proliferation and apoptosis, while tumor-suppressor genes (also called
anti-oncogenes) normally inhibit or “suppress” abnormal cell proliferation and
induce apoptosis of abnormal cells. Genomic alterations (i.e., mutations) in
proto-oncogenes and tumor-suppressor genes, cause such normal genes to be-
come cancer-causing genes. Given the role of these genes in cancer, we iden-
tified modules of genes transcriptionally related to breast cancer (CMs) from
publicly available oncogenic gene sets. An oncogenic gene set is a collection of
genes showing a coordinate gene expression modulation upon the perturbation
of known oncogenes and tumor suppressor genes. Such perturbations are gen-
erally experimentally-induced down-regulation, in the case of tumor-suppressor
genes, or overexpression, in the case of oncogenes, which causes alterations in
the expression of downstream genes in the oncogenic pathway. The induced
perturbations in gene expression and subsequent alteration in the activity of
such genes, recapitulates, in a biased way ([211]), the transcriptional regula-
tory events that are downstream of oncogenes and tumor suppressor genes in
cancer cells. We collected experimentally-derived oncogenic gene sets represen-
tative of the major hallmarks of cancer, such as: i) cell proliferation, apoptosis
and differentiation (i.e., MYC, MYC/TGFA, MYC/E2F1, MYB, TGFB1, SRC,
JAG1/NOTCH, EGFR, KRAS, KRAS/PTEN, BCAT, HRAS, ERBB2, BRCA1,
TERT, E2F1, E2F3, TP53, E1A); ii) EMT (i.e., ZEB1, JAP/-TAZ); iii) angio-
genesis (i.e., VEGF, HIF1A/HIF2A); chromosomal instability (i.e., CIN). GSEA
analysis allowed us to investigate if the genes belonging to these oncogenic gene
sets were also transcriptionally modulated (up-/down-regulated) in breast tu-
mors as the result of inactivation of the normal function of proto-oncogenes and
tumor suppressor genes. We found that the genes belonging to 18 of the original
23 oncogenic gene sets were up-/down-modulated in tumors and also accord-
ing to different pathological conditions that characterize breast cancer: i.e., ER
status, tumor grade and prognosis. Further analysis revealed that genes com-
ing from the full list of significantly enriched oncogenic gene sets identified by
GSEA, clustered into 7 “major” gene modules, the CMs: Grade, Grade/ER,
All, Relapse/Survival/Grade/ER, Survival/Grade/ER, ER, and Survival. These
findings support the notion that the experimentally-derived oncogenic gene sets
recapitulate the activation of oncogenic pathways in breast tumors and also that
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the related genes are transcriptionally modulated according to the pathological
condition of the disease (Figure 3.2). For example, we observed the enrichment
of the genes belonging to the E1A, as well as to the CIN or MYC gene sets, in
different and non-overlapping CMs (Figure 3.3). This result suggests a differ-
ential functional involvement of the genes originating from a common oncogenic
lesion, according to the state of the tumor, thus, helping in the identification
of the molecular determinants of the clinical state of the disease. Importantly,
our predictions (i.e., the CMs) were in silico verified in an independent set of
breast cancer datasets, confirming that the observed enrichment was not cohort-
dependent. Although the selected gene sets represent only a small fraction of
all the cancer-related oncogenic events occurring in a tumor cell, this approach
represents a flexible strategy towards the deconvolution of the altered molecu-
lar mechanisms responsible for the disease and may be easily extended as new
oncogenic gene sets become available.
4.3 Gene Regulatory Networks inference analysis:
identification of cancer-related mechanisms
Network inference from CM-hub-genes
In this project, we applied a semi-unsupervised data-driven approach to re-
verse engineer GRNs, starting from publicly available gene expression microarray
datasets. Data-driven network inference analysis methods can be classified into
two groups: “unsupervised” and “supervised”. Unsupervised methods infer func-
tional relationships between genes directly from the data. The unsupervised re-
construction of regulatory networks from “genome-wide” expression data is com-
putationally intensive because of the high-dimensional space of transcriptional
data (i.e. it considers the full set of genes expressed in a cell under a particular
condition). Moreover, the biological interpretation of the predicted functional
relationships between genes is often unfeasible because of the huge amount of
inferred interactions. In order to reduce the complexity of the analysis and to
simplify the biological interpretation of data, alternative “supervised” methods
have been proposed for GRNi. These methods consist of inferring GRNs from a
set of genes whose regulatory interactions are already known; this set of genes is
used as the training set. Although this approach reduces the complexity of the in-
ference analysis, it is biased towards well characterized genes, which are weighted
in the analysis more than less studied genes. In addition, for the vast majority of
the human genes the regulatory interactions are still unknown. To overcome the
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limitations of the unsupervised and supervised methods for GRNi, we adopted a
semi-unsupervised network inference approach. Specifically, networks were built
starting from the CMs that we identified using published gene sets, representing
known oncogenic stimuli; i.e., the GRNi analysis started from a set of cancer-
relevant genes (CM-genes) that we used as hub genes around which functional
relationships were predicted among genes found correlating with the hub gene ex-
pression profile (i.e. the gene neighbors). These CM-genes worked as “routers”
to guide the inference of regulatory interactions in the multidimensional tran-
scriptional space, in an unsupervised way using high-throughput expression data.
Regulatory network inference at a global expression level in mammalian cellular
contexts (i.e. considering the full set of expressed genes in a human or mouse pri-
mary cell) is a complex task because of the complexity of the regulatory programs
characterizing such living organisms, at high end of the evolutionary ladder. In-
deed, the majority of algorithms were developed to infer GRNs in simpler model
organisms ([168],[170],[212]). Nevertheless, several algorithms have been devel-
oped to infer regulatory mechanisms from the full set of gene expression data
in mammalians ([131],[133],[193],[213],[214]). These algorithms, however, suffer
from a number of limitations. The first limitation concerns the inference analysis
from static expression data for the vast majority of them. Cells, in fact, are adap-
tive systems with dynamic properties and “static measurements” of expression
levels do not incorporate temporal, spatial and conditional information except
indirectly. The modeling of regulatory networks that take into consideration the
dynamic properties of cellular systems (i.e. the evolution of cellular systems over
the time), requires time-series gene expression data. The time-related changes
of expression levels allow the inference of causal relationships between biological
molecules and of more accurate regulatory mechanisms. In particular, time-series
expression data might be useful to gain insights into the transcriptional programs
that govern the cellular behavior of highly perturbed and highly evolving living
systems like cancer cells. Unfortunately, with the exception of model organ-
isms and cell lines systems, the generation of expression profiles at different time
points directly from human cancer tissues is unfeasible because of ethical rea-
sons and because individuals with cancer quickly undergo surgical resection or
pharmacological treatments. Thus, it is not possible to monitor changes in gene
expression levels over several time points directly from tumor biopsies. Static
expression profiles from cancer tissues before treatment are, therefore, the only
source of data from which to infer regulatory probabilistic mechanisms. In this
project, GRNi analysis was performed using primarily the ARACNE algorithm
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([133]). This algorithm was preferred because of its literature documented relia-
bility as a “genome-wide” network inference algorithm in the mammalian context
([131]), consisting in the experimentally validated subset of gene-to-gene interac-
tions. In addition, from a theoretical perspective, the ARACNE algorithm infers
transcriptional interactions also from non-linearly dependent variables (genes)
through the MI measure, extending the possible pair-wise associations with re-
spect to the correlation-based methods, such as those used in the clustering,
which instead infer interactions only from linearly-dependent variables. Finally,
the ARACNE algorithm implements the DPI procedure that allows the removal
of putative indirect interactions. Although the ARACNE algorithm infers reliable
(i.e. experimentally-proved) pair-wise interactions and despite the fact that we
performed 1,000 bootstrap replications to prove the statistical significance of the
transcriptional correlations, the ability of reverse engineering methods, includ-
ing ARACNE, to infer realistic gene-to-gene associations from microarray gene
expression data faces two limitations. The first limitation concerns the impact
of measurement noise, especially for genes expressed at very low levels, which
affects the reliability of the predictions. The second limitation concerns the di-
mensionality curse phenomena (i.e. the number of genes is higher than samples)
that prevents to accurately recover the pair-wise gene interactions from their ex-
pression level. Two possible strategies to verify the reproducibility and hence the
robustness of the inferred interactions are: i) to perform the network inference
analysis using one or more independent dataset of expression profiles, i.e. the
validation datasets; ii) to perform network inference analysis on the same dataset,
but using different network inference methods. In our case, the first strategy was
unfeasible because gene expression datasets with the same or comparable num-
ber of expression profiles were not available (327 breast tumor transcriptional
profiles). Thus, we applied the second strategy under the assumption that if
an ARACNE-predicted pair-wise interaction is statistically robust (i.e. it does
not represent a false positive finding, but instead a true finding), it will also be
inferred using alternative algorithms, based on alternative measures to score the
gene-to-gene transcriptional correlation. We therefore performed GRNi analyses
using the CUDA-MI ([192]) and the WGCNA ([193]) algorithms. CUDA-MI algo-
rithm implements the MI computation through the use of the B-spline functions,
while WGCNA builds weighted gene co-expression networks by “soft threshold-
ing” the Pearson correlation coefficient for gene-to-gene interaction predictions.
We chose these two alternative algorithms because in the first case, although
the correlation is estimated through the MI measure, data discretization is per-
formed using B-spline functions instead of the ARACNE adaptive partitioning,
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while in the second case, the correlation is measured using a totally different
measure. Notably, using the Cohen test to compare the networks inferred from
each CM-gene using the three methods, we observed that for the vast majority of
ARACNE-inferred networks (i.e. 75% of the 1,498 statistically significant Cohen
tests, from a total of 1,516 networks), the pair-wise transcriptional interactions
were the same as those inferred using the two alternative methods. The agree-
ment we observed between the three algorithms, reinforced the relevance of the
inferred transcriptional networks to breast cancer.
4.4 Mutational annotation of CM-genes and the
mutual exclusivity analysis
4.4.1 Mutational annotation of CM-genes
Cancers arise mainly as the result of the acquisition of a number of somatic
genomic alterations, such as point mutations, copy number alterations, epige-
netic changes and karyotypic rearrangements, which confer a selective advantage
characterized by uncontrolled cell proliferation with respect to normal cells and
escape from apoptotic control ([215],[216]). Recent advances in massively par-
allel, high-throughput sequencing of DNA (exome and whole genome sequenc-
ing) has allowed a comprehensive characterization of DNA somatic mutations
through the sequencing of a large number of tumor samples, and provided an
unprecedented opportunity to gain biological insights to the origin and evolution
of cancer. Much of the available mutational data (and genomic data in general)
comes from a handful of large international collaborations: The Cancer Genome
Atlas (TCGA, NCI and NHGRI), The Catalogue of Somatic Mutations in Cancer
(COSMIC, UK Cancer Genome Project) and the more general Cancer Genome
Consortium (ICGC) that allows access to both TCGA and COSMIC data. The
aim of such collaborative efforts is to comprehensively understand the molecular
basis of cancer, not only at mutational level, but more generally at a genomic
level; gene expression data, methylation data and other genomic data are also
available. To better characterize the functional role of CM-genes previously pre-
dicted to be associated at the gene expression level (GSEA analysis) to breast
cancer, we performed a mutational annotation of the CM-genes representing the
hub genes around which the networks were built. This analysis allowed us, not
only to gain insights into the involvement of CM-genes in cancer, but also to
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reduce the set of 1,516 networks to those most biologically relevant. The muta-
tional annotation was primarily performed (on the full set of 1,652 CM-genes)
using the Cosmic Cancer Gene Census ([217]) dataset relative to breast cancer,
because this collection of mutated genes has been causally implicated in cancer.
According to this analysis, 49 CM-genes appeared to be mutated. We also per-
formed the mutational annotation by using TCGA mutational data relative to
breast cancer. This analysis was performed to overcome the bias of the muta-
tional annotation performed according to a subset of well-characterized mutated
genes. Many mutated genes, in fact, still lack biological validation, but might
nevertheless be equally involved in breast cancer. TCGA data allows an unbiased
whole-genome mutational annotation. According to TCGA mutational annota-
tion, 812 CM-genes appeared to be mutated in breast cancer. Importantly, for
both mutational annotations, we observed a statistically significant enrichment
of mutated genes in CM-genes with respect to the empirical null distribution we
generated from a collection of 1,000 random gene lists (p-value< 0.001). This
significant enrichment suggests that the CM-genes might be involved in breast
cancer, not only at the gene expression level, but also at the mutational level.
Moreover, this finding indicates that the strategy we used for evaluating the
enrichment of oncogenic gene sets in breast cancer PhLs, might be relevant to
select putative key cancer-related genes. Undoubtedly, further investigations are
needed to clarify the relationship between the presence of the mutational event
in CM-genes and their transcriptional association with the disease. Although we
subsequently focused our attention on the networks derived from the smaller set
of 48-CM-mutated genes (for one of the set of 49 genes, network inference was not
possible), the set of 812 TCGA mutated genes might contain novel, biologically
uncharacterized mutated genes, which could have an important role in cancer.
4.4.2 Mutual Exclusivity analysis
Cancer genomes contain “driver” mutations and “passenger” mutations. The
former are causative of the tumor, while the latter are neutral mutations that oc-
cur randomly, during cell division, without functional consequences. Large-scale
cancer genomic projects, like the TCGA (http://cancergenome.nih.gov/) and
ICGC (https://dcc.icgc.org/), with their high-resolution view of molecular
defects, at the DNA level, in different types of tumors, and whole-genome se-
quencing that allows the analysis of more than 20,000 protein-coding genes, offer
an unprecedented opportunity to determine which mutations are drivers and
which mutations are passengers. According to a large fraction of sequencing
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projects, the mutational profile, for most cancer types, consists of a small num-
ber of genes altered in a high percentage of tumors, the so-called “mountains”
and a large faction of genes altered infrequently in the population (< 1%), the
so-called “hills” ([218]). High frequency mutations in the population (i.e. the
mountains), such as mutations in the TP53, MYC, KRAS, ATM, APC, EGFR,
PIK3CA, BRAF, JAK2, and FGFR2 genes, confer a selective growth advantage
to cancer cells. Although the role of these high frequency mutations as drivers in
cancer has been extensively demonstrated through genome sequencing of a large
number of individuals and experimental validation, the role of low frequency mu-
tations (i.e. the “hills”), as drivers, is still not fully characterized. The main
reason for this, is that their low frequency of occurrence in the population, re-
sembles the frequency expected for neutral passenger mutations. One possibility
for elucidating the role of low frequency mutations in individuals and to address
inter-tumor heterogeneity, is to investigate the function of these infrequently mu-
tated genes in a pathway-context. Indeed, it is well-known that different gene
mutations can target the same pathway ([219],[220]). Moreover, the presence of
a single mutated gene is sufficient to perturb the entire pathway ([220], [201]),
such that the mutation of key genes belonging to the same pathway exhibit a
mutually exclusive behavior. In this project, we inferred networks of transcrip-
tionally correlating genes from CM-genes, predicted to be associated with breast
cancer at the transcriptional level. Hence, we have network tools (i.e. pathway
tools) to investigate for the presence and to predict the role of low frequency
mutations in individual breast cancer patients. From the mutational annota-
tion of the gene neighbors of each network (TCGA[BRCA] mutational data), we
observed that some genes were mutated with a frequency of < 1% in the popu-
lation, i.e. low frequency mutations or “hills”, while others were mutated with
a frequency of ∼37%, i.e. high frequency mutations genes or “mountains”, as
expected. Moreover, we observed a mutually exclusive behavior of a fraction of
mutated gene neighbors of the inferred networks (Figure 3.11). For a subset of
50 networks, out of the total set of 1,516 networks, the enrichment of mutually
exclusive mutated genes was statistically significant. Interestingly, among the
set of mutually exclusive mutated genes, we observed that, not only high fre-
quency mutated genes (e.g. PIK3CA) exhibited a mutually exclusive mutational
behavior, but also low frequency mutated genes. This result suggests that the
presence of a mutational event in these latter genes might confer the same selec-
tive advantage as known high frequency driver mutations in the population. To
further assess the robustness of the mutually exclusive relationships of genes, we
plan to benchmark our in silico predictions by applying computational methods
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based on different mathematical and statistical frameworks like those reported
in: [200],[221],[222],[223].
Discussion 128
4.5 Identification of putative Transcriptional Master
Regulators
The network inference analysis to identify cancer-related mechanisms was primar-
ily performed by assuming that each CM-gene was the hub gene of the network.
This assumption derived from the observed transcriptional regulation of CM-
genes in breast cancer gene expression profiles, according to the pathological state
of the disease, thus sustaining their centrality as cancer-related genes. Despite the
biological rationale behind this assumption, the transcriptional centrality of such
CM-genes as regulators of transcriptional programs required additional investi-
gation. For this reason, we performed an additional network inference analysis
in order to assess the role of these CM-genes as transcriptional hubs, and to
identify the putative transcriptional MRs at the top of the transcriptional reg-
ulation hierarchy. The inference analysis was performed by assuming iteratively
each gene neighbor of each CM-gene network (i.e. from the set of 48 GRNs iden-
tified through the COSMIC-Census mutational annotation and from the set of
50 GRNs significantly enriched of mutually exclusive mutated genes), as the hub
gene for a new network. Then, the most frequently occurring gene neighbor, i.e.
the most highly interconnected gene in the new networks was considered to be
the putative transcriptional MR-gene. For a set of CM-gene networks (i.e., 78%
on 98 total CM-gene networks), the MR-gene was different with respect to the
CM-gene, i.e. it was a neighbor from the original CM-gene hub network. Among
this group, for a subset of CM-gene networks, the putative inferred MR-gene was
the same, meaning that we were able to group together CM-gene networks repre-
senting sub-mechanisms of a global regulatory transcriptional network. Notably,
for a set of CM-gene networks (i.e., 22% on 98 total networks), the putative MR-
gene was confirmed as the CM-gene. This observation confirmed the centrality
and the putative transcriptional relevance of the CM-genes, as well as the validity
of the approach used to identify cancer-relevant genes. Although the identifica-
tion of the MR-genes was limited to the set of the gene neighbors composing
the initial CM-gene network, our approach has the advantage of simplifying the
search space of candidate MRs, which would otherwise be infeasible considering
the full transcriptome of a cell. Using this approach, we have intermediate levels
of regulation, among which to investigate for the presence of MRs.
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4.6 Clinical relevance of breast cancer-related
networks
TNBC is a subtype of breast cancer characterized by the lack of the ER, the PgR
and Her2 ([206]). Drugs like Tamoxifen or Trastuzumab, which are routinely used
in clinic as pharmacological treatments for ER-, PgR- or Her2-positive breast can-
cers cannot be used to treat TNBC. In addition, TNBCs are clinically charac-
terized by high malignancy, high risk of the local recurrence, poor prognosis (i.e.
poor disease-free survival), and poor cancer-specific survival ([224],[225]). Molec-
ularly, they are characterized by high proliferation and mitotic rates. The risk of
recurrence in TNBC is higher in the 3-5 years after diagnosis with respect to ER-
positive breast cancers ([226],[227]). Few therapeutic strategies are available for
TNBC and chemotherapy is the only effective treatment for TNBC patients after
surgery ([228]). Several studies have shown that TNBCs are much more sensitive
to adjuvant or neoadjuvant chemotherapy than other subtypes of breast cancer
([229]). pCR to neoadjuvant chemotherapy (mainly anthracyclines alone or in
combination with taxanes) correlates with a better prognosis in responsive TNBC
patients, with an overall survival similar to that of the non-TNBCs. Despite the
therapeutic benefits achieved in TNBC patients showing a pCR to neoadjuvant
chemotherapy, accounting for approximately 30% of TNBCs, there is a fraction of
TNBC patients who arae resistant to neoadjuvant chemotherapy. These patients
present RD after neoadjuvant chemotherapy and are characterized by high rates
of metastatic recurrence (because of the presence of viable cancer cells in breast
or in lymph nodes), and overall poor clinical outcome ([227],[230]). Thus, new
treatments are urgently needed to treat TNBCs resistant to chemotherapy. To
achieve this, it is crucial to elucidate the molecular mechanisms responsible for
chemoresistance, in order to molecularly sensitize cancer cells to pharmacological
treatments in a targeted way. In this project, we inferred gene networks repre-
sentative of putative breast cancer-related mechanisms. The case of unresponsive
RD TNBC patients represented a good opportunity to evaluate the clinical rel-
evance of our predictions, i.e. to “translate” our findings to the clinic to meet
an unmet clinical need. The clinical relevance of the inferred cancer mechanisms
was assessed by investigating the transcriptional profiles of the breast cancer ac-
tive networks (GSEA analysis) in RD TNBCs. Active networks were defined as
mechanisms in which the vast majority of neighboring genes had the same or the
opposite transcriptional regulation with respect to the hub gene around which
the network was built (i.e., the CM-gene or MR-gene), as assessed by the con-
cordance analysis. The importance of defining the transcriptional activity of a
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network lies in the possibility to pharmacologically revert the cancer-associated
transcriptional profile of an entire mechanism to a non-cancer profile. More
specifically, in the case of RD TNBC, to identify alternative drug targets for
overcoming mechanisms of chemoresistance. From the initial full set of active
networks, we identified a small subset of 6 networks (TCF4, TGFB1I1, ZFPM2,
PRRX1, ELF4, COL1A1) transcriptionally regulated (up-/down-modulated) in
RD TNBCs with respect to pCR TNBCs. These networks represent putative
mechanisms associated with chemoresistance, and although further investigation
is needed to define their precise role in RD TNBC, evidence in literature sup-
ports the functional involvement of at least some of these networks in the RD
TNBC biology. For example, PDGFRB is one of the core genes of the TGFB1I1
network that contributed most to the enrichment of this network in RD TNBCs
(i.e. it highly correlated at the transcriptional level with the RD pathological
condition with respect to the pCR condition; see Figure 3.21). Notably, it has
been recently demonstrated that PDGFR signaling contributes to TGFB-induced
EMT in oncogenic mammary epithelial cells, and, consequently, to the metastatic
potential of these cells ([231]). Moreover, the vast majority of the enriched core
genes in the TGFB1I1 network are involved in remodeling of the extracellular
matrix (COL6A3, COL3A1, COL5A1, COL5A2, LOXL1, MMP2, PCOLCE),
supporting the involvement of the TGFB1I1 network as a whole in the EMT
process in highly metastatic TNBCs. These genes represent, also, a fraction of
the enriched core genes of the remaining 5 networks (Figure 3.22), i.e. they are
in common between all the 6 networks, suggesting a cooperative involvement of
all the 6 networks in the EMT process as branches of a more global molecular
mechanism and offering multiple putative alternatives to pharmacologically tar-
get the entire EMT process. Using our strategy, we identified putative molecular
mechanisms that, at the transcriptional level, might provide predictive biomark-
ers of resistance to currently available therapies for TNBC. In contrast to typical
biomarker studies that screen for aberrant expression of single genes in tumors
to derive standalone tumor markers, our approach has the advantage that we
first defined the association of well-known cancer mechanisms (i.e. proliferation,
apoptosis, angiogenesis, tissue invasion and metastasis mechanisms) with specific
pathological conditions and then derived biomarkers involved in these mecha-
nisms. As reported in [79], there are approximately 150,000 papers documenting
the identification of thousands of biomarkers, however, only ∼100 of them have
been validated and approved for clinical practice. There are many reasons that
account for this failure in translation to the clinic. One main reason concerns
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the lack of an in-depth knowledge on the molecular mechanisms involved in dis-
ease. In this project, we developed a computational pipeline to infer molecular
mechanisms functionally related to breast cancer that might be used, not only
as sources of novel cancer biomarkers, but also of new druggable targets.
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4.6.1 Ongoing work and future plans
Experimental validation of the transcriptionally regulated active
networks in RD TNBCs
To determine the biological relevance of the in silico predicted networks that
transcriptionally correlate with RD TNBC, we are now performing RNA inter-
ference (RNAi) experiments on the hub genes of the networks. Specifically we
firstly selected a panel of basal-like breast cancer cell lines expressing the hub
genes: TCF4, TGFB1I1, ZFPM2, PRRX1, ELF4, and COL1A1. The expression
of them was assessed through the quantitative real-time RT-PCR (RT-qPCR).
By using the short hairpin RNAs (shRNAs) we are now perturbing the expres-
sion of the hub genes. We expect to observe a gene expression modulation of
the gene neighbours of the entire network upon the loss-of-function of the hub
gene, if the statistically inferred dependencies, biologically reflect molecular and
biochemical mechanisms of gene expression regulation acting in breast cancer
cells. We are using the high-throughput OpenArray technology to investigate the
changes in the mRNA levels of the gene neighbours of each candidate network
upon interference with the expression of the hub gene.
Computational analysis
We will build CM and MR-GRNs from breast cancer TCGA RNA-Seq expres-
sion data in order to confirm the gene expression interactions predicted by using
Affymetrix expression data. We will perform an in-depth in silico molecular
characterization of the networks that we predicted to correlate with RD TNBC
expression profiles through the integration of multi-level large “-omics” data in
order to gain insights into the molecular mechanisms that might govern the tran-
scriptional state of them. In particular, we will annotate the genes of the net-
works for the presence of targets of known TFs through the integration of publicly
available ChIP-Seq data on breast cancer. We will, also, annotate the genes, for
the presence of predicted targets of miRNA that might control the expression
levels of them as well as for the presence of breast cancer related patterns of
DNA methylation that, together with miRNA, might represent mechanisms of
epigenetic gene expression regulation of the networks associated with RD clinical
condition in TNBCs. TCGA methylation data and miRNA expression data as
well as Metabric miRNA expression profiles will be used to investigate for the
presence of epigenetic mechanism of gene expression regulation. We will also
annotate the genes of the networks for the presence of protein-protein interac-
tions, taking advantage of recently generated proteomic profiling data ([232]),
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to investigate for the presence of physical interactions that might give rise to
molecular events responsible for the resistance to the neoadjuvant pharmaco-
logical treatment. Finally, we will interrogate databases of drugs and bioactive
molecules (Mantra 2.0 https://http://mantra.tigem.it/, Connectivity Map
2, https://www.broadinstitute.org/cmap/) in order to in silico predict pu-
tative molecules (agents) able to target the genes of the networks associated
with RD pathological condition thus representing candidate alternative pharma-
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Enrichment analysis in RD TNBC (Hatzis et al., 152 pts): 








71 positively concordant GRNs 
27 negatively concordant GRNs 
Figure A.1: Computational pipeline used to identify transcriptional breast cancer
networks.
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The computational pipeline used to infer breast cancer relevant
transcriptional networks from microarray gene expression data.
Green section: to identify groups of genes (gene modules) whose expression
correlate with clinical-pathological features of breast cancer disease, we per-
formed the Gene Set Enrichment Analysis (GSEA) of 23 oncogenic gene sets
on microarray gene expression profiles relative to 5 cohorts of breast cancer pa-
tients (“Discovery set”) for a total of 1,019 patients. From the GSEA, 18 out of
23 oncogenic gene sets (the “core set”) resulted significantly enriched in breast
tumours according to the following clinical-pathological variables (Phenotype
Labels, PhLs): the tumor grade, the ER status, the survival and the relapse. We
then performed the cluster analysis of the 1,652 genes, composing the 18 enriched
oncogenic gene sets, in order to cluster together the core genes according to the
relative PhLs enrichment. We identified 15 total groups of genes (i.e. clusters)
we called “Cancer gene Modules” (CMs). Of the full set of CMs 7 were “major”
CMs (1,516 total genes), i.e. they represented clusters with a higher content of
genes with respect to the other clusters. We further validated the enrichment
of the 7 CMs by performing GSEA on an independent set of microarray gene
expression profiles relative to 4 cohorts of breast cancer patients (“Validation
set”, 916 total patients). The clinical-pathological variables we considered were
the same we used for the GSEA analysis performed on the “Discovery set”, i.e.
he tumor grade, the ER status, the survival and the relapse. We finally validated
6 out of 7 CMs.
Black section: to identify breast cancer relevant mechanisms at gene expression
level, we performed the GRNs inference analysis using ARACNE algorithm on
the full set of 1,516 genes composing the 7 CMs. We assumed each gene of the
full set of 1,516 genes to be the “hub” gene of the network. We inferred 1,516
total networks (CM-GRNs). We also performed the network inference analysis
by using two independent algorithms with respect to ARACNE, i.e. CUDA-MI
and WGCNA, to assess the in silico reliability of the predicted networks. We
performed the Cohen test in order to evaluate the statistical significance of the
overlap of the neighbours of each network inferred by using the three algorithms.
1,498 networks on 1,516 total GRNs were found to be statistically significantly
concordant of which, 1,124 showed good agreement and 374 bad agreement. 18
networks were found to be not statistically significantly concordant.
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Red section: we performed the mutational annotation (COSMIC-Census and
TCGA, CGA Network 2012, mutational data) of the full set of 1,652 genes com-
posing the 15 total CMs to further assess their association with breast cancer
disease not only at transcriptional level. We found 49 mutated genes according
to the COSMIC-Census mutational annotation and 812 according to the TCGA
annotation. We also performed the mutational annotation of the gene neigh-
bours of the 1,516 networks inferred by ARACNE in order to investigate their
relevance in breast cancer disease as oncogenic mechanisms. We identified 50
GRNs significantly enriched in mutually exclusive mutated gene neighbours. We
then considered the set of 50 GRNs and 48 GRNs (98 total CM-GRNs) we pri-
oritized through the mutual exclusivity analysis and the mutational annotation
for further investigation. We reduced the set of 49 GRNs to 48 GRNs because
for one hub gene the network inference analysis by ARACNE was not possible.
Blue section: we then performed an in-depth GRN deconvolution analysis to
identify putative transcriptional Master Regulator (MR) hub genes for the set
of 48 and 50 CM-GRNs. For 44 out of 50 GRNs and for 32 out of 48 GRNs
we identified a putative MR hub gene different from the CM gene we previously
assumed to be the hub gene of the transcriptional network. New networks were
then inferred considering each MR-gene as the hub gene of the GRN.
Pink section: we performed the concordance analysis (i.e. we characterized
the transcriptional regulation of the gene neighbours of each GRN with respect
to the hub gene) in order to characterize the transcriptional activity of the set
of 94 GRNs (44 MR-GRNs and 50 CM-GRNs) and of the set of 80 GRNs (32
MR-GRNs and 48 CM-GRNs) in breast tumours. The concordance analysis was
performed on Metabric cohort of patients (Discovery set, 997 patients). For the
set of 50 CM-GRNs we found 23 Non Concordant GRNs, 20 Positively Concor-
dant GRNs and 7 Negatively Concordant GRNs; For the set of 44 MR-GRNs
we found 23 Non Concordant GRNs, 15 Positively Concordant GRNs and 6
Negatively Concordant GRNs; For the set of 48 CM-GRNs we found 21 Non
Concordant GRNs, 21 Positively Concordant GRNs and 6 Negatively Concor-
dant GRNs and for the set of 32 MR-GRNs we found 9 Non Concordant GRNs,
15 Positively Concordant GRNs and 8 Negatively Concordant GRNs.
Orange section: we predicted the clinical relevance of our findings by investi-
gating the transcriptional correlation of the full set of 71 Positively Concordant
networks (relative to the 50 CM-GRNs, 44 MR-GRNs and to the 48 CM-GRNs
and 32 MR-GRNs) and 27 Negatively concordant networks (relative to the 50
CM-GRNs, 44 MR-GRNs and to the 48 CM-GRNs and 32 MR-GRNs) with
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the expression profiles of 152 TNBC with Residual Disease (RD) pathological
condition after neoadjuvant taxane-anthracycline chemotherapy. We identified 6
enriched GRNs: TCF4, TGFB1I1, ZFPM2, PRRX1, ELF4 and COL1A1 repre-
senting putative mechanisms involved, at transcriptional level, in the metastatic
process of RD TNBC tumours. The first four networks were inferred from the
MR gene (MR-GRNs) while the last two were inferred from CM-genes (CM-
GRNs). The 6 GRNs represent our final candidate set of breast cancer related
mechanisms for the experimental validation of their biological relevance.
Appendix B
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Table B.1: A representative list of 42 core genes (GSEA analysis) of the TCF4 network enriched in RD TNBC.
Gene Symbol Description
TCF4 transcription factor 4
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2
FSTL1 follistatin-like 1
SPARC secreted protein, acidic, cysteine-rich (osteonectin)
FAP fibroblast activation protein, alpha
CFH complement factor H
PCOLCE procollagen C-endopeptidase enhancer
MXRA5 matrix-remodelling associated 5
DPT dermatopontin
FILIP1L filamin A interacting protein 1-like
HEG1 HEG homolog 1 (zebrafish)
CAV1 caveolin 1, caveolae protein, 22kDa
ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif, 5
OLFML2B olfactomedin-like 2B
A2M alpha-2-macroglobulin
MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1)
CILP cartilage intermediate layer protein, nucleotide pyrophosphohydrolase
CFI complement factor I
COL15A1 collagen, type XV, alpha 1
ITGBL1 integrin, beta-like 1 (with EGF-like repeat domains)
SPARCL1 SPARC-like 1 (hevin)
EFEMP2 EGF-containing fibulin-like extracellular matrix protein 2
NDN necdin homolog (mouse)
ZCCHC24 zinc finger, CCHC domain containing 24
IGF1 insulin-like growth factor 1 (somatomedin C)
GPR124 G protein-coupled receptor 124
SFRP4 secreted frizzled-related protein 4
COL6A3 collagen, type VI, alpha 3
CDH5 cadherin 5, type 2 (vascular endothelium)
LDB2 LIM domain binding 2
SERPINF1 serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1
NID1 nidogen 1
HTRA1 HtrA serine peptidase 1
GNG11 guanine nucleotide binding protein (G protein), gamma 11
SLIT2 slit homolog 2 (Drosophila)
LAMB1 laminin, beta 1
ZFPM2 zinc finger protein, multitype 2
MEIS2 Meis homeobox 2
PTRF polymerase I and transcript release factor
DCN decorin
IGFBP6 insulin-like growth factor binding protein 6
A representative list of 42 core genes (GSEA analysis) of the TCF4 network enriched in RD TNBC is reported. The HUGO Gene Symbol is reported,

































Table B.2: A representative list of 42 core genes (GSEA analysis) of the TGFB1I1 network enriched in RD TNBC.
Gene Symbol Description
TGFB1I1 transforming growth factor beta 1 induced transcript 1
PDGFRB platelet-derived growth factor receptor, beta polypeptide
COL3A1 collagen, type III, alpha 1
COL5A1 collagen, type V, alpha 1
LOXL1 lysyl oxidase-like 1
COL5A2 collagen, type V, alpha 2
FAP fibroblast activation protein, alpha
AEBP1 AE binding protein 1
CNN1 calponin 1, basic, smooth muscle
MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)
LRRC32 leucine rich repeat containing 32
FHOD3 formin homology 2 domain containing 3
PCOLCE procollagen C-endopeptidase enhancer
BGN biglycan
COL6A3 collagen, type VI, alpha 3
NID1 nidogen 1
COL16A1 collagen, type XVI, alpha 1
HEG1 HEG homolog 1 (zebrafish)
RCN3 reticulocalbin 3, EF-hand calcium binding domain
SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1
SFRP4 secreted frizzled-related protein 4
THY1 Thy-1 cell surface antigen
TAGLN transgelin
COL1A1 collagen, type I, alpha 1
GPR124 G protein-coupled receptor 124
PTRF polymerase I and transcript release factor
HTRA1 HtrA serine peptidase 1
OLFML2B olfactomedin-like 2B
SPARC secreted protein, acidic, cysteine-rich (osteonectin)
MYL9 myosin, light chain 9, regulatory
SERPINF1 serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1
DKK3 dickkopf homolog 3 (Xenopus laevis)
FSTL1 follistatin-like 1
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2
LAMB1 laminin, beta 1
FILIP1L filamin A interacting protein 1-like
MXRA8 matrix-remodelling associated 8
ZFPM2 zinc finger protein, multitype 2
SYNPO synaptopodin
MXRA5 matrix-remodelling associated 5
ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide)
A representative list of 42 core genes (GSEA analysis) of the TGFB1I1 network enriched in RD TNBC is reported. The HUGO Gene Symbol is reported,

































Table B.3: A representative list of 42 core genes (GSEA analysis) of the ZFPM2 network enriched in RD TNBC.
Gene Symbol Description
ZFPM2 zinc finger protein, multitype 2
COX7A1 cytochrome c oxidase subunit VIIa polypeptide 1 (muscle)
POSTN periostin, osteoblast specific factor
COL3A1 collagen, type III, alpha 1
TAGLN transgelin
LOXL1 lysyl oxidase-like 1
COL10A1 collagen, type X, alpha 1
LRRC15 leucine rich repeat containing 15
FAP fibroblast activation protein, alpha
CFH complement factor H
PCOLCE procollagen C-endopeptidase enhancer
DPT dermatopontin
COL1A1 c ollagen, type I, alpha 1
COMP cartilage oligomeric matrix protein
AEBP1 AE binding protein 1
WISP1 WNT1 inducible signaling pathway protein 1
RCN3 reticulocalbin 3, EF-hand calcium binding domain
FBN1 fibrillin 1
MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)
THY1 Thy-1 cell surface antigen
COL16A1 collagen, type XVI, alpha 1
VCAN versican
SFRP4 secreted frizzled-related protein 4
COL6A3 collagen, type VI, alpha 3
NOX4 NADPH oxidase 4
COL5A2 collagen, type V, alpha 2
BGN biglycan





SNAI2 snail homolog 2 (Drosophila)
GNG11 guanine nucleotide binding protein (G protein), gamma 11
INHBA inhibin, beta A
ODZ3 odz, odd Oz/ten-m homolog 3 (Drosophila)
COL11A1 collagen, type XI, alpha 1
SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1
CNN1 calponin 1, basic, smooth muscle
COL5A1 collagen, type V, alpha 1
DCN decorin
COL1A2 collagen, type I, alpha 2
A representative list of 42 core genes (GSEA analysis) of the ZFPM2 network enriched in RD TNBC is reported. The HUGO Gene Symbol is reported,

































Table B.4: A representative list of 42 core genes (GSEA analysis) of the PRRX1 network enriched in RD TNBC.
Gene Symbol Description
PRRX1 paired related homeobox 1
POSTN periostin, osteoblast specific factor
COL3A1 collagen, type III, alpha 1
MMP11 matrix metallopeptidase 11 (stromelysin 3)
SPARC secreted protein, acidic, cysteine-rich (osteonectin)
TAGLN transgelin
LOXL1 lysyl oxidase-like 1
COL10A1 collagen, type X, alpha 1
LRRC15 leucine rich repeat containing 15
FAP fibroblast activation protein, alpha
PCOLCE procollagen C-endopeptidase enhancer
MYL9 myosin, light chain 9, regulatory
COL1A1 collagen, type I, alpha 1
GREM1 gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis)
AEBP1 AE binding protein 1
WISP1 WNT1 inducible signaling pathway protein 1
UNC5B unc-5 homolog B (C. elegans)
OLFML2B olfactomedin-like 2B
FBN1 fibrillin 1
MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)
FN1 fibronectin 1
LRRC32 leucine rich repeat containing 32
THY1 Thy-1 cell surface antigen
VCAN versican
COL6A3 collagen, type VI, alpha 3
NOX4 NADPH oxidase 4






HTRA1 HtrA serine peptidase 1
TIMP3 TIMP metallopeptidase inhibitor 3
INHBA inhibin, beta A
MMP13 matrix metallopeptidase 13 (collagenase 3)
SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1
WNT2 wingless-type MMTV integration site family member 2
COL11A1 collagen, type XI, alpha 1
PTRF polymerase I and transcript release factor
COL5A1 collagen, type V, alpha 1
COL1A2 collagen, type I, alpha 2
A representative list of 42 core genes (GSEA analysis) of the PRRX1 network enriched in RD TNBC is reported. The HUGO Gene Symbol is reported,

































Table B.5: A representative list of 42 core genes (GSEA analysis) of the ELF4 network enriched in RD TNBC.
Gene Symbol Description
ELF4 E74-like factor 4
ARHGAP25 Rho GTPase activating protein 25
PLEKHO2 pleckstrin homology domain containing, family O member 2
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2
LOXL1 lysyl oxidase-like 1
SERPING1 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1
IL15RA interleukin 15 receptor, alpha
C1S complement component 1, s subcomponent
CCR1 chemokine (C-C motif) receptor 1
PCOLCE procollagen C-endopeptidase enhancer
ADCY7 adenylate cyclase 7
SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
GFPT2 glutamine-fructose-6-phosphate transaminase 2
GREM1 gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis)
TCIRG1 T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3
ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide)
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit)
COL6A2 collagen, type VI, alpha 2
OLFML2B olfactomedin-like 2B
THY1 Thy-1 cell surface antigen
HSPG2 heparan sulfate proteoglycan 2
SLC7A4 solute carrier family 7 (cationic amino acid transporter, y+ system), member 4
CHST11 carbohydrate (chondroitin 4) sulfotransferase 11
COL6A3 collagen, type VI, alpha 3
CD97 CD97 molecule
CD74 CD74 molecule, major histocompatibility complex, class II invariant chain




ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa; similar to Actin-related protein 2/3 complex subunit 1B (ARP2/3 complex 41 kDa subunit) (p41-ARC)
SERPINF1 serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1
IL4R interleukin 4 receptor
LEPRE1 leucine proline-enriched proteoglycan (leprecan) 1
C3AR1 complement component 3a receptor 1
ADAP2 ArfGAP with dual PH domains 2
INHBA inhibin, beta A
XBP1 X-box binding protein 1
ANGPTL2 angiopoietin-like 2
BIN2 bridging integrator 2
COL5A1 collagen, type V, alpha 1
TGFBI transforming growth factor, beta-induced, 68kDa
EGFL6 EGF-like-domain, multiple 6
A representative list of 42 core genes (GSEA analysis) of the ELF4 network enriched in RD TNBC is reported. The HUGO Gene Symbol is reported,

































Table B.6: A representative list of 42 core genes (GSEA analysis) of the COL1A1 network enriched in RD TNBC.
Gene Symbol Description
COL1A1 collagen, type I, alpha 1
COL3A1 collagen, type III, alpha 1
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2
MMP11 matrix metallopeptidase 11 (stromelysin 3)
FSTL1 follistatin-like 1
SPARC secreted protein, acidic, cysteine-rich (osteonectin)
LOXL1 lysyl oxidase-like 1
DKK3 dickkopf homolog 3 (Xenopus laevis)
COL10A1 collagen, type X, alpha 1
LRRC15 leucine rich repeat containing 15
FAP fibroblast activation protein, alpha
MXRA8 matrix-remodelling associated 8
PCOLCE procollagen C-endopeptidase enhancer
PDGFRB platelet-derived growth factor receptor, beta polypeptide
ADAM12 ADAM metallopeptidase domain 12
MXRA5 matrix-remodelling associated 5
MYL9 myosin, light chain 9, regulatory
HEG1 HEG homolog 1 (zebrafish)
GREM1 gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis)
AEBP1 AE binding protein 1
COL6A2 collagen, type VI, alpha 2
UNC5B unc-5 homolog B (C. elegans)
WISP1 WNT1 inducible signaling pathway protein 1
OLFML2B olfactomedin-like 2B
MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)
LRRC32 leucine rich repeat containing 32
THY1 Thy-1 cell surface antigen
COL16A1 collagen, type XVI, alpha 1
VCAN versican
COL6A3 collagen, type VI, alpha 3




HTRA1 HtrA serine peptidase 1
INHBA inhibin, beta A
SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1
CTSK cathepsin K
NBL1 neuroblastoma, suppression of tumorigenicity 1
PTRF polymerase I and transcript release factor
COL5A1 collagen, type V, alpha 1
A representative list of 42 core genes (GSEA analysis) of the COL1A1 network enriched in RD TNBC is reported. The HUGO Gene Symbol is reported,
followed by the full gene name (i.e. Description). Only 42 genes are reported for simplicity.
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